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Abstract
Cells respond to external and internal stimulimostlywith changes in transcription of target genes. Gene expres-
sion is mediated by transcription factors, central nodes in highly regulated signalling networks. In multiple sig-
nalling pathways, different stimuli converge on the same transcription factor, yet induce different cell fates. Re-
cently, the dynamics of transcription factors have been identified to play a key role in converting the received
trigger into the appropriate response. It is proposed that the same transcription factor induces different gene
expression programs purely depending on its dynamics.
One example of particular interest is the transcription factor p53. Under physiological conditions, p53 levels
are kept low by a tightly regulated network. Upon stress, p53 levels increase and show a pulsatile or sustained
behaviour, dependingon the type and severity of the stress. Interestingly, itwas proposed that p53dynamics dic-
tate which downstream gene expression programs are initiated. However, many questions remain open, such
as whether the dynamics are sufficient to drive differential gene expression, or whether stress-induced post-
translational modifications of p53 and other interacting factors play a role alongside p53 dynamics. Moreover,
it is still unknown, how p53 dynamics are eventually translated into a specific target gene expression programs.
The p53 signalling and regulatory network is both, highly complex and dynamic. Understanding this network
requires targeted dissection using specific and precisemethods. To address these requirements, I employed op-
togenetic methods, as light possesses unmatched spatial and temporal resolution. In contrast to chemical per-
turbation methods, light as a trigger is non-invasive and has a superior specificity. Here, I used optogenetics to
reconstitute various p53 dynamics, by controlling the levels and localization of p53, and I investigated the out-
come of thesemanipulations in the absence of upstream stress.
Specifically, I achieved light-mediated control of endogenousp53 levels and its activity. TheE3ubiquitin ligase
Mdm2isknowntobe themain regulatorofp53 levels. I coulddemonstrate that thep53-Mdm2inhibitorypeptide
(PMI) inhibits p53 degradation in vivo, and that its effect on p53 levels is localisation-dependent, and only occurs
when PMI is present in the nucleus. To control the localization of PMI with light I used a light-inducible nuclear
export system (LEXY). LEXY is a versatile protein tag that harbours an engineered AsLOV2 domain exposing a
nuclear export sequence (NES) uponblue light illumination, leading to rapidnuclear export of the taggedamino
acid sequence, and re-import into the nucleus once the cells are not subjected to blue light anymore. By fusing
PMI to LEXY, I could obtain light-mediated control over localisation of PMI-LEXY and thus degradation of p53,
resulting in elevated p53 levels. Additionally, expression of the p53 target gene p21 was increased, showing that
not only p53 protein levels are increased, but also that p53 is transcriptionally active.
In a second approach, I used LEXY to control the localization of an exogenously expressed p53 with light. I
could show that I can repeatedly accumulate p53 tagged with LEXY in and out of the nucleus, effectively gener-
ating p53 pulses akin to those obtained under certain stress conditions. I generated a stable cell line expressing
p53-LEXYunder an inducible promoter, allowing robust expression of p53-LEXY. p53-LEXY is transcriptionally ac-
tive, and can induce transcriptionofmultiple p53 target genes in theabsenceof stress. Moreover, p53-LEXY could
induce the terminal cell fate senescence. However, prolonged blue light exposure and application ofmore com-
plex illumination patterns resulted in impaired translocation and cellular stress. Reduction of the light intensity
to prevent phototoxicity corresponded to losing the ability to control p53-LEXY with light. Inducing genotoxic
stress to stimulate p53 activity increased the expression of some p53 target genes in the stable cell line, yet re-
vealed high variability between biological replicates, questioning the utility of this cell line.
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Zusammenfassung
Zellen reagieren auf externe und interne Reize zumeist mit der Anpassung der Transkription von Genen. Gen-
expression wird von Transkriptionsfaktoren gesteuert, zentralen Knoten in hoch regulierten Signalnetzwerken.
In vielen Signalwegen laufen verschiedene Reize in einem Transkriptionsfaktor zusammen, induzieren jedoch
unterschiedliche Zellschicksale. Die Dynamiken von Transkriptionsfaktoren scheinen dabei eine Schlüsselrolle
dabei zu spielen,wie einReiz indie angemesseneReaktionumgewandeltwird. Eswurdepostuliert, dass einund
derselbe Transkriptionsfaktor basierend auf der Dynamik seiner Aktivierung unterschiedliche Genexpressions-
Programme induzieren kann.
Ein Beispiel von besonderem Interesse ist der Transkriptionsfaktor p53. Unter physiologischen Bedingungen
werden p53 Proteinmengen durch ein eng reguliertes Netzwerk sehr niedrig gehalten. In Reaktion zu Stress
erhöhen sich die p53 Proteinmengen und zeigen pulsende oder ununterbrochene Aktivierung, abhängig von
der Art und der Schwere des Stresses. Interessanterweise wurde postuliert, dass p53 Dynamiken die stressin-
duziertenGenexpressions-Programmediktieren. VielenFragenbleiben jedochnochungeklärt,wie zumBeispiel
obdieDynamikenallein ausreichen sind, umdifferentielleGenexpressionherzurufen, oder ob zusätzlich zuden
DynamikenstressinduzierteposttranslationaleModifikationanp53oderanderen interagierendenFaktoreneine
Rollespielen. Außerdemistesnoch immerunbekannt,wirp53Dynamiken letztendlich inspezifischeGenexpressions-
Programmedekodiert werden.
Das p53 Signal- und Regulationsnetzwerk ist sowohl hochkomplex als auch äußerst dynamisch. Umdas Net-
zwerk verstehen zu können bedarf es gezielter Analysemittels spezifischer und präziser Methoden. Um diesen
Vorgabengerechtzuwerden,habe ichoptogenetischeMethodenverwendet,daLichteineunübertroffeneräum-
licheundzeitlicheAuflösung innehat. ImGegensatzzuchemischenPerturbationen istLichtnicht-invasivundhat
eine überlegene Spezifität. Hier habe ich optogenetischeMethoden genutzt, um verschiedene p53 Dynamiken
durch die Kontrolle der Proteinmengen und der Lokalisierung von p53 nachzustellen. Außerdem habe ich die
Folgen dieser appliziertenDynamiken in der Abwesenheit von Stress untersucht.
Genauergenommen,habe ich licht-basierteKontrolleüberProteinmengenundAktivität vonendogenemp53
erzielt. Die E3 Ubiquitin Ligase Mdm2 ist der Hauptregulator von p53 Proteinmengen. Ich konnte zeigen, dass
das p53-Mdm2 inhibierendes Peptid (PMI) den Abbau von p53 in vivo verhindert, und das die Effekte auf die p53
Proteinmengen abhängig von demOrt der PMI-Expremieung ist, und nur auftritt wenn PMI im Zellkern ist. Um
dieLokalisierungdesPMIPeptidsmittels Licht zukontrollierennutzte ichdas “light-induciblenuclear export sys-
tem” (LEXY, für lichtinduzierbares Kernexportsystem). LEXY ist ein vielseitig einsetzbares Protein-Tag, welches
aus einer optimierten AsLOV2 Domäne besteht, die in Reaktion auf blaues Licht ein Kernexportsignal (NES, für
nuclear export sequence)offenlegt,was zueinemschnellenExportdesanLEXYangehängtenProteins führt, und
zu einemReimport in denNukleus, sobald das Licht ausgeschaltet wird. Durch das Anhängen von LEXY an PMI
konnte ich licht-basierte Kontrolle über die Lokalisierung von PMI-LEXY und dadurch den Abbau von p53 erre-
ichen, was zu erhöhten p53 Proteinmengen geführt hat. Außerdemwurde die Expression von dem p53 Zielgen
p21 erhöht; das demonstriert das nicht nur p53 Proteinmengen erhöht wurden, sondern das p53 Transkription
induzieren kann.
In einemzweitenAnsatz hab ich diemittels LEXYdie Lokalisierung von exogen exprimierten p53mittels Licht
kontrolliert. Ich konnte p53 mit angehängtem LEXY wiederholt im Nukleus und im Cytosol akkumulieren, ein
Verhalten das ähnlich dem Pulsieren von p53 als Reaktion auf verschiedene Stressbedingungen ist. Ich habe
eine stabile Zelllinie kreiert, welche zuverlässige p53-LEXY Expression mittels eines induzierbaren Promotoren
ermöglicht. Dabei ist p53-LEXY transktipionell aktivundkanndieTranskriptionmehrererp53Zielgene inderAb-
wesenheit vonStress induzieren. Außerdemkonntep53-LEXYdas terminaleZellschicksal Seneszenz induzieren.
Allerdingshatdie langeBelichtungszeitmittelsblauemLichtunddieApplizierungvonkomplexerenLichtMustern
in vermindert Translokation und zellulärem Stress resultiert. Die Reduzierung der Lichtintensität zur Vermei-
dung von Phototoxizität resultierte in dem Verlust der Kontrolle über p53-LEXY mittels Licht. Das Induzieren
vii
von genotoxischem Stress um die Aktivität von p53 zu stimulieren erhöhte die Expression von einigen p53 Ziel-
genen in der stabilen Zelllinie, hat aber auch die hohe Variabilität zwischen biologischen Replikaten offenbart,
die die denNutzen dieser Zelllinie infrage stellt.
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1 Introduction
1.1 The transcription factor p53 and its regulation
Every cell is permanently exposed to a myriad of stress signals, ranging from mild changes in its environment
to irreparable DNA damage. Sensing and evaluation of these stress signals is detrimental to maintain cellular
homeostasis, and complicated signalling networks have evolved to enable cells to cope with different kind of
stresses in the appropriatemanner.
A key proteinwithin this network is the transcription factor p53. Also labelled ’guardian of the genome’ (Lane,
1992) or ’cellular gatekeeper’ (Levine, 1997), p53 integrates various stress signals into the most appropriate cel-
lular response by regulating transcription of specific genes. Due to its significance to uphold genomic integrity,
the regulation of p53 itself is carried out by a sophisticated network (Figure 1.1). Discovered in 1979 (Linzer and
Levine, 1979), itwasfirstmisidentifiedasanoncogene, until its tumour suppressor functionwerediscovered (Fin-
lay et al., 1989). Not only mutated inmost of human cancers (Vogelstein et al., 2000), inactivation of p53 is also
associatedwith apoorpatient prognosis (Olivier et al., 2010), highlighting its significance inoverseeing cell cycle
progression.
Figure 1.1: The intricacies of p53 regulation
p53 is the central nodeof a complex, stress sensingnetwork. Blue lines represent stimuli receiveddirectly byp53.
Red lines indicate transcriptional targets of p53. Grey lines represent the pathway interactions downstream of
p53.
Adapted from (Kastenhuber and Lowe, 2017).
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As a transcription factor, inherently p53’s most vital function is the induction of a specific set of target genes.
To this day, more than 3500 target genes in a broad functional spectrum have been discovered to be stimulated
in response to various stress situations (Fischer, 2017), showcasing the significant influence p53 has on a cell’s
transcriptome (Figure 1.1). This is further underlined by the fact that the vast majority of pathogenic mutations
of p53 occur within the DNA-binding Domain (DBD). Yet recently there has been a lot of attention on the non-
transcriptional functions of p53.
In the following, I will give an overviewover the tumour suppressor p53 and its role in orchestrating cell fate in
response to internal and external stress signals by inducing transcription of subsets of target genes. I will discuss
howcells control p53 levels andhighlight someof the recentfindingsof p53’s non-transcriptional functions. Iwill
set a particular focus on p53 dynamics, as these are themain focus of this study.
1.1.1 The structure of p53
TheTP53 geneon the short armof chromosome 17 encodes humanp53. The gene spans 20 kb in total, yet canon-
ical p53 consists of 393 amino acids. The gene displays a conservation in vertebrates, yet onlyminor resemblance
to invertebrates (May and May, 1999). p53 contains 6 major functional domains, and distortion of its structural
characteristics is a common way to disrupt p53 folding and oligomerization and thus function in human carci-
noma (Muller and Vousden, 2013).
At theN-terminus, there are two intrinsically disorderedN-terminal transactivation domains (TADs), respon-
sible for controlling transcriptional activity of p53 (Figure 1.2). Initially considered as one domain, the discovery
of independent functions of TAD1 (1 - 42) and TAD2(43 - 63) has led to the appreciation of two distinct functional
units. Next, a proline-rich region (PRD) (63 - 97), containing several Src homology 3 (SH3)-domain binding sites,
a commonmotif in cell signalling proteins (Ren et al., 1993).
Figure 1.2: Functional domains of p53 and key sites of post-translationalmodification
p53 consists of 6major functional subunits and 3 localization sequences. The twoN-terminal transactivation do-
mainsAD (AD1 andAD2)domains are involved in protein-protein interaction, followedby aproline-rich domain.
The core of p53 consists of the DNA-binding domain (DBD). Then, there is bipartite NLS, consisting of two sepa-
ratestretches. Togetherwith theNES locatedwithin the tetramerizationdomain (here: oligomerizationdomain)
itmaintains localization of p53. The C-terminus contains a basic domain (BD). A number of key residues for post
translationalmodifications are shown. Abbreviation: S: Serine; T: Tyrosine, K: Lysine; E: Glutamatic Acids.
Adapted fromBrock (2009).
The central core of p53(100-300) inhabits a structuredDNA-binding domain (DBD), which bindingmotif con-
sists of RRRCWWGYYY (R = A, G;W = A,T; Y = C,T) separated by a variable spacer (El-Deiry et al., 1992;Wei et al.,
2006). This DBD contains the six most common mutations occurring in cancer (Brosh and Rotter, 2009), and a
number of other amino acid residues commonly mutated in tumor cells resulting in deficient DNA interaction
properties (Kastenhuber and Lowe, 2017). In addition,mutations that handicap theDNAbinding properties can
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resolve in dominant negative effects even if only one copy is affected, since a singlemutated subunit canprevent
p53 tetramer complex formation, which is crucial for interaction with the transcription machinery (Muller and
Vousden, 2013).
The DBD is followed by a bipartite nuclear localization sequence (NLS) consisting of two basic amino acid
groups, Lys-Arg (K305, R306) and Lys-Lys-Lys (K319, K320, K321), separated by a spacer of 12 amino acid residues
leading to a nuclear localisation in unstressed conditions (Liang and Clarke, 1999). The tetramerization domain,
necessary to from homo-oligomers essential for p53 to become transcriptional active are located upstream of
the secondNLS stretch (325-356). Locatedwithin the tetramerization domain is a nuclear export sequence (NES)
(M340, L344, L348, L350), which is blocked once p53 forms a tetramer (Stommel et al., 1999). Finally, a basic,
lysine-richdomainat theC-terminus (363-393) comprisingan important site for post-translationalmodifications
and regulation of p53 function (Joerger and Fersht, 2008).
Thehumanp53geneexpresses at least 12different isoformsdue toalternativeRNAsplicing, alternative trans-
lation initiation and alternative promoter usage (Khoury and Bourdon, 2011). These isoforms, composed of dis-
tinctdomaincomposition,havebeendemonstratedtohavediverse functions, suchas interferingwith thecanon-
ical transcription ability of p53 (Bourdon et al., 2005). p53 isoform expression is commonly missregulated in
tumours (Takahashi et al., 2013) and non-carcinogenic pathologies such as premature ageing (Muhlinen et al.,
2018).
1.1.2 Regulation of p53 byMdm2andMdmX
Given the significance of an appropriate p53 function as a central signalling node involved in the stress response
pathway, it is not surprising that the regulation of p53 consists of a complex network to fine-tune the p53 lev-
els and its activation to achieve the appropriate stress response. This is accomplished by a range of protein-
interacting partners and an array of post-translationalmodifications (PTM), onmore than 36 amino acids of p53
(Kruse andGu, 2008).
Under physiological conditions, p53 levels are kept low. The amount of p53 protein is rather determined by
the rate of its degradation, than the production rate. In unstressed conditions, protein half-life time is very short,
ranging from5 to 30minutes, yet dramatically increased inupon stress or in transformedcells (Rogel et al., 1985).
Themain regulators of both, p53 activity and protein levels are the oncogeneMdm2 and its homologMdmX
(alsoknownasMdm4) (Figure 1.3). Amplificationormissregulationofeitherof the twoMDMgenes is a feature in
many tumours, especially in tumours lacking p53mutation (Momand et al., 1992; Shibagaki et al., 1995; Ito et al.,
2010). Both bind a putative helix formed by residues 18-26 of the p53 TAD1 (Kussie et al., 1996) and inhibit p53’s
ability to regulate the induction of target genes, rendering it transcriptional inactive (Chen et al., 1995; Shvarts
et al., 1996). The key difference betweenMdm2 andMdmX is the E3 ubiquitin ligase activity towards p53Mdm2
possesses once it homo-oliogmerizes (Haupt et al., 1997; Fang et al., 2000; Cheng et al., 2011).
On binding, Mdm2 either monoubiquitinate p53, which exposes the nuclear export sequence and leads to
translocation into the cytoplasmorpolyubiquitinatesp53, leading toproteasomaldegradationofp53 (Figure 1.3)
(Tao and Levine, 1999; Lohrum et al., 2001; Li et al., 2003; Carter et al., 2007). The Mdm2-mediated ubiquitina-
tion occursmainly at the six carboxy terminal lysines (K370, K372, K373, K381 and K386) (Rodriguez et al., 2000).
Mdm2 can form heterooliomgers with MdmX which are proposed to make p53 degradation more efficient by
stabilizingMdm2 (Badciong andHaas, 2002). Mdm2 is an unstable protein, due to autoubiquitination or ubiq-
uitinaition by other E3 ligases (Fang et al., 2000; Itahana et al., 2007). Eventhough the importance of Mdm2 in
degradation can not be overstated, cells of MDM2-deficient mice are able to degrade p53, yet slower compared
toMdm2 expressing cells (Ringshausen et al., 2006).
The relationship between theMdmhomologs and p53 is not unidirectional. While p53-induced transcription
ofMdmXhasonlybeendemonstrated recently, andonlyoccurringunder certain conditions (Phillipsetal., 2010),
the control of Mdm2 expression by p53 is a central feature and has been established already over 25 years ago
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Mdm2
p53 degrada�on
Figure 1.3:MDM2 is themain regulator of p53 protein levels
Levels of p53 are controlled mainly by the ubiquitin E3 ligase, which binds p53’s N-terminus and subsequently
ubiquinates p53’ C-terminus, rendering it for degradation. MDM2 is also a transcriptional target of p53, creating
a negative feedback loop.
Adapted fromWilliams and Farzaneh (2012).
(BarakandOren, 1992;Perryetal., 1993). This interplay results inaautoregulatory feedback loop regulatingboth,
the activity of p53 and the expression ofMdm2 under unstressed conditions (Wu et al., 1993).
1.1.3 Stabilisation of p53
Themain task of p53 is maintaining genomic integrity of the cell and various stress conditions lead to the inter-
ruption of the negative feedback loop that keep p53 levelsminimal and thus result in the rapid accumulation of
p53 protein levels. For a long time it was hypotised, that only unusual and acute stress results in the rise of p53
levels. Recent studies suggest that also under normal growth and development, p53 activation occurs and plays
an essential role beyond its classic trades, for example in regulation ofmetabolism, antioxidation, development
and aging (reviewed inBerkers et al. (2013)). Yet, albeit upstreamactivators of p53 aremanifold andbe triggered
bydistinct stress signals, our understandingof p53’s activationandorchestrationof cellular fatehasbeen shaped
by the investigations on both, single strand and double strand breaks upon genotoxic stress, and these are the
processes I want to focus on here.
The classicmodel of p53describes a three stepprocess,which ismainly controlleddue toPTMs. Underunchal-
lenged conditions, p53 is rapidly turnover. Upon stress, N-terminal phosphorylation leads to stabilization of the
short-lived p53, and thus accumulation in the nucleus. Next, p53 forms a homotetrameric complex (Friedman
et al., 1993), which is an essential step for binding to DNA and recognizing p53’s binding motif (Davison et al.,
1998). In this state, p53 transcribes genes like MDM2 or PirH2, which are associated with p53-turnover and cell
survival (Leng et al., 2003). Partial acetylation of p53 causes the recruitment of cofactors and expression of genes
like p21 and GADD45, genes associated to cell cycle arrest and DNA repair. Finally, p53 is further acetylated, be-
coming fully active and transcribing genes responsible for irreversible apoptosis like BAX or PUMA (Kruse and
Gu, 2009).
While modification and interaction of Mdm2 is a common mechanism, as illustrated for example by the tu-
mour suppressor p14ARF which binds Mdm2, thereby inhibiting Mdm2 functions towards p53 and thus aug-
menting p53 levels and activity (Kamijo et al., 1998), themajority ofmechanisms interrupting the negative feed
back loopkeepingp53 levels lowareaimedatp53directly. Ingeneral, humanp53 isahotspot forpost-translational
modifications, andwhile by now, the vastmajority of thesemodificationsmight be discovered, the arising com-
plexity is still puzzling. The function of these individual adjustments often seem to be interchangeable ormutu-
ally exclusive (for example, acetylationandubiquinationbothoccur on lysine-residues). AnumberofPTM’shave
been associated to various outcomes and are often highly context specific and even reversible, as shown by the
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deubiquitinating enzymeHAUSP, which prevents both, p53 andMDM2, from degradation by removing already
bound ubiqutin (Li et al., 2002, 2004).
Phosphorylation is a key mechanism of regulating p53, and phosphorylation sites are concentrated at the N-
terminal transactivationdomains. Phosphorylationat theN-terminus is highly redundant, andas a single kinase
phosphorylates various sites, a single site is also phosphorylated by various kinases (Kruse andGu, 2009).
Genetic lesions caused by irradiation or genotoxic chemicals is a threat to DNA, as the inheritance of genetic
information is essential and a key process in life, so it is not surprising that the corruption of the genetic code
results in activation of the "guardian of the genome".
Persistent single strand breaks (SSB), lead to the rapid activation of ATR (Ataxia telangiectasia and Rad3 re-
lated), a serine/threonine-protein kinase, which phosphorylates several sites in p53, most notably S15 (Tibbetts
et al., 1999). Similarly, in the presence of double-strandbreaks (DSB), the serine/threonine-protein kinase ataxia
telangiectasiamutated (ATM) associates with site of genetic lesion , undergoes autophosphorylation and phos-
phorylates p53 at several sites, including S15 (Canman et al., 1998; Bakkenist and Kastan, 2003).
Phosphoryation of S15 upon genotoxic stress sensed by ATM/ATR is a key step in p53 stabilisation, since it acts
as a nucleation event and is precursor for phosphorylation at T18 and S20 (Saito et al., 2002). Phosphorylation
at these sites impedesMdm2/MdmXbinding to theN-terminus of p53 andpromoting p53’s longevity, but it also
facilitates theassociationof theatranscriptional coactivatorcomplexp300/CBP(CREBbindingprotein) (Lambert
et al., 1998; FinlanandHupp, 2004). Asdescribedhere, for anumberof PTMsofp53 it is hard toevaluatewhether
they result in either the stabilisation of p53 or a potential change in target gene expression, or both. p300/CBP is
a histone acetyltransferases (HAT), which acetylates lysine residues within the DBD and the C-terminal domain
of p53, thereby preventing the ubiquination of p53 by Mdm2 and further stabilize p53 (Ogryzko et al., 1996; Ito
et al., 2002). Phosphorylation of other N-terminal serine residues further fine tune the affinity between p53’s
TAD1 and p300/CBP (Teufel et al., 2009). In contrast, S376 and S378 are constitutively phosphorylated, and at
least S376becomesdephosphorylateduponstress creatingabindingmotif for 14-3-3proteinsand increaseDNA-
binding affinity (Waterman et al., 1998). In general, the pattern of phosporylation are not necessarily caused by
stress, but are dynamic throughout the cell cycle with specific patterns for each stage (Buschmann et al., 2000).
As mentioned above, acetylation is another key modification p53 undergoes in becoming stable and for the
recruitment of cofactors. While phosphorylation is rather associated to increase p53 longevity, acetylation is
thought to fine tune the transcriptional response. p53 was the first non-histon protein substrate shown to be
regulated by acetylation (Gu andRoeder, 1997). Acetylation by p300/CBP at the very same lysine residuesMdm2
targets for ubiquination is supposed to prolong p53 protein life (Ito et al., 2002). This implies, the importance of
the lysineswithin C-terminus in regulating p53 turnover, yet studieswith cells derived frommice lacking these 6
lysine residues show no impairment in p53 turnover and regulation of cell fate compared to p53wt mice (Krum-
mel et al., 2005). This is a commonphenomenon,modifications, which have beendemonstrated to occur in vitro
and regulate p53 function in cell culture experiments havenoor onlyminor implication in vivoor inmousemodel
studies.
Acetyltransferases like p300/CBP, and other cofactors attracted by acetylations like Kat5 and hMof are able to
modify histones in the vicinity of p53 target genes and hencemaking the chromatinmore accessible (Goodman
and Smolik, 2000). p300/CBP also acetylates K164, a lysine within the DBD. In this case, acetylation is associ-
atedwith growth arrest, senescence and apoptosis (Tang et al., 2008). Kat5 and hMof also acetylate p53 itself on
K120, which one of the few sites of modification conserved throughout all species. The acetylation of this lysine
is suggested tobe a key switch for transcriptionof apoptotic genes (Tang et al., 2006; Sykes et al., 2006). As phos-
phorylations, pattern of acetylations are highly dynamic, histone deacetylase complexes (HDAC) like HDAC1 or
Sirt1 can deacetylate lysines in p53 (Luo et al., 2000, 2001; Vaziri et al., 2001).
Even though a number of transcriptional coactivators have been reported to bind p53, there is only evidence
of a few proteins which are then recruited to the promoter of p53 target genes (Kruse andGu, 2009)
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1.1.4 Transcriptionally independent functions of p53
p53-controlled transactivation of target genes is an essential feature of the stress response pathway, although
some effects of p53 may be independent of transcription. Originally it was thought that export of p53 to the
cytosol was only an indirect way to prevent nuclear accumulation and thus transcription. Observation of p53-
dependent apoptosis in the absence of p53-induced transcription and the transcriptionally inactive p53mutant’s
ability to induce apoptosis in Hela cells suggested p53’s transcriptionally independent role in apoptosis (Caelles
et al., 1994; Haupt et al., 1995) .
Pioneering studies lay the groundwork of our understanding of the mechanism behind p53’s cytosolic func-
tion. Once in the cytoplasm, p53 colocalises to the mitochondria and interacts with anti-apoptotic proteins like
B-cell lymphoma-extra large (Bcl-xL), and B-cell lymphoma-extra (Bcl 2). This interaction diminishes their anti-
apoptotic functions, andcausesoligomerizationofproapoptotic factorsBcl-2homologousantagonistkiller (Bak)
and Bcl-2-associated X protein (Bax), both also transcriptional targets of p53 (Mihara et al., 2003; Chipuk et al.,
2004). The oligomerization causes the formation of pores at themitochondrial outer membrane, a hallmark of
mitochondria mediated apoptosis, resulting in the release of cytochrome C and other apoptotic activators into
the cytosol (Mihara et al., 2003; Chipuk et al., 2004). Alternatively, by interacting with Mcl1, p53 disrupts the
induced myeloid leukemia cell differentiation protein (Mcl1)-Bak complex, causing the release of Bak and ren-
dering it active (Leu et al., 2004).
In some cell types, there is a soluble Bcl-xL fraction within the cytosol. Cytosolic p53 bound to free diffusing
Bcl-xL is inactive. In the emergence of stress, nuclear p53 transcribes p53 upregulated modulator of apoptosis
(Puma), which subsequently binds the soluble Bcl-xL, releasing p53 to activate Bax and causing disruption of the
mitochondrialmembrane in the above described fashion (Chipuk et al., 2005).
Next to apoptosis, cytosolic p53 was identified as a contributor to mitochondrial dysfunction in the mouse
heart, leadingto increasedriskofheart failureby inhibitingtheautophagyofdysfunctionalmitochondria (Hoshino
et al., 2013), highlighting oncemore the broad range of potential, context dependent influence of the tumor su-
pressor p53.
1.2 Thedynamic nature of cell signalling
Many cell signallingpathways are akin in their topology. Multiple upstreamsignallingnodes converge in a single
transcription factor, that triggers expression of different subsets of genes, often linked to a distinct physiological
output. Given that a transcription factor can be activated by numerous stimuli and induce a context dependent
gene expression, the questions arises how a certain stimuli is encoded into cellular signal, and subsequently de-
coded in to transcriptional program.
The technical advance inmethods on the single cell level have yieldednew insights, highlighting thedramatic
variations of response of cells treated with the same stimulus (Cohen et al., 2008; Lee et al., 2009). Processes
formerly overlooked due towrongly chosen time points could be observed due to the advent of newfluorescent
probes, enabling scientists to visualize temporal highly dynamic cellular processes, showcasing the dynamic na-
ture of cell signalling. Particularly in immune- and stress-related pathways, multiple signalling pathways have
beendemonstrated to behighly dynamic, particular transcription factors exhibit spatio-temporal patterns of ac-
tivity.
Currently, there is a lot of focus on trying to reveal how cells encode the extracellular stimulus the signalling
web and execute decisionmaking. First approaches considered cell signalling as a boolean network. In contrast
to the simplified text book view on any given signalling pathway, the actual in vivo composition of a pathway is
dependent on cell type and its current state. A intracellular logical gate takes cellular properties like presence of
interaction partners or post-translational modification of pathway proteins into account, and triggers a certain
output. While this approach yielded some success, it has not led to a comprehensive and more general under-
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standing of cell signalling (Saez-Rodriguez et al., 2009).
Similar to analogous signal transmission, the signal-is-information paradigmpostulates that the signal itself
carries all necessary information to execute the desired outcome. When cells receive stimuli, either intra- or ex-
tracellular, the features of the stimulus is encoded into a intracellular signal, usually the activation of a transcrip-
tion factor. Features of the signal comprise amplitude, frequency, rate of increase, thresholds or the area under
the curve, meaning the total accumulated activated signal. These features are then decoded into a specific re-
sponse (Figure 1.4).
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Figure 1.4: Signal as information - A theory of dynamic signal processing
Internal and external stimuli with unique features are encoded into a signal, usually the activity kinetics of a
transcription factor. Then, this temporal profile is decoded into the appropriate response.
Adapted from (Behar andHoffmann, 2010).
Recent studies demonstrated that the intracellular signal is indeed able to convey both identity and quantity
of an upstream trigger, and a link between the activation dynamics of a transcription factor and the en- and de-
coding into a specific response. The formation of these temporal dynamics has been described in several cases
(Hoffmann et al., 2002; Batchelor et al., 2008), and specific temporal dynamics have also been linked to distinct
cellular outcomes (Marshall, 1995; Purvis et al., 2012; Zambrano et al., 2016; Wilson et al., 2017). While the un-
derstanding of how stimuli are encoded into intracellular signals has improved a lot, less evidence is presented
for the decoding of the signal.
Here, I want to give a brief overview of the recent discoveries of transcription factor dynamics in eukaryotes.
There, I will focus on three well studied cell signalling pathways in mammalian cells, namely the extracellular
signal-regulated kinase (Erk) pathway, theNFκ-beta pathway andnuclear factor of activated T cells (Nfat) path-
way, followed by a summary of studies about the yeast transcription factor Msn2. Finally, I will focus on the dy-
namic nature of p53.
1.2.1 Examples of transcription factor dynamics
1.2.1.1 The Erk pathway
The Erk pathway is a mitogen-activated protein kinase (MAPK) family pathway. It is among the first signalling
pathways, forwhich the counter-intuitive behaviour of triggering twoopposing outcomesby the same transcrip-
tion factor has been reported. Treatedwithnerve growth factor (NGF), rat neuronal precursors start to differenti-
ate, yet applying epidermal growth factor (EGF) causes rapid proliferation (Gotoh et al., 1990;Nguyenet al., 1993;
Traverse et al., 1992). In particular, NGF triggers sustained Erk activation, while EGF only results in a short, tran-
sient response (Figure 1.5). This observation of distinct activation patterns of Erk by the two different ligands led
to the first postulation of dynamics contributing to cellular decisionmaking (Marshall, 1995).
Thefirst clueof the formationof thesedistinct pulseswere reportedbySasagawaand colleagues,whousedan
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Figure 1.5: Different stimuli trigger dis-
tinct temporal behaviours
A | Dynamics of Erk activation in re-
sponse to either EGF or NGF. EGF treat-
ment causes a transient activation, NGF a
sustained activation.
B | Activation of NF κ-beta via TNFα
causes an oscillatory response, LPS stim-
ulation triggers sustained activation.
C | Yeast transcription factor Msn2 re-
sponds to glucose starvationby a series of
bursts, whose length and frequency de-
pend on the severity of starvation. Ox-
idative stress causes a sustainedMsn2 re-
sponse, the amplitude correlates with its
intensity.
Adapted from (Purvis and Lahav, 2013).
elaboratemodel topredictpotential factorsshapingErkdynamicsandsubsequentlyverify them invivo (Sasagawa
et al., 2005). They provided evidence for a different feedbackmechanism, depending on the upstreamactivator.
Activation of the Erk pathway by bothNGF and EGF, eventually converge on either Ras or Ras-proximate-1 (Rap1)
upstream of Erk, and the temporal properties of Erk activation is partly determined by which of the two small
GTPases becomes active. OnlyNGF treatment causes a full activation of Rap1, blocking the negative feedback on
Erk through Son of Sevenless (SOS)and thus generating a sustained Erk activation. Addition of EGF yields only
minor activation of Rap1 and consequently only transient activation of Erk. Additionally, only NGF activation is
sustained upon receptor activation, further contributing to sustained activation of Erk (Sasagawa et al., 2005).
This behaviour here implies that distinct temporal patterns of transcription factor are shaped by distinct topolo-
gies of the individual signalling pathway and these topologies are determined by the growth factor context. This
is further supported by the discovery of a positive feedback loop for NGF stimulation, yet not in the response to
EFG treatment, exemplifying the signal encoding based on the duration of activation (Santos et al., 2007).
Recent observation have demonstrated more elaborate dynamics, like long term oscillations in single cells,
stochastic Erk activation pulses linked to proliferation and intercellular propagating waves in vivo (Albeck et al.,
2013; Aoki et al., 2013; Hiratsuka et al., 2015). The importance of the correct execution of the signal decoding is
highlighted by the observation, that well-known oncogenic mutations in the Erk pathway are altering the dy-
namics properties of the signal transmission (Bugaj et al., 2018).
While the growth factor context shapes Erk activation and triggers distinct cell fates, the elicited profile of
immediate-early gene (IEG)mRNAexpression, a set of geneswhich is transcribedwithinminutes upon a certain
stimulus, is surprisinglyakin (Murphyetal., 2002). Oneof these IEG is c-Fos,upongrowthfactor stimulation, c-Fos
is transcribed rapidly. Due to the rapid production, it occurs independent of the duration of upstreamactivation.
Thehalf life timeofnewlyproducedc-fos isbetween30and45minutes. Yet,whenphosphorylatedonC-terminus
by prolonged Erk activation, c-fos undergoes a transformational change and exposes the DEF domain. The DEF
domain can locally concentrates active Erk and sense small changes in Erk levels (Murphy et al., 2002, 2004).
Deletion of the DEF domain disables their sensory functions. Additionally, DEF domains are present inmultiple
of the IEGs, leading to the hypothesis that this is a general mechanism of Erk signalling, to fine tune nuclear
presence of activated Erk and protect it for degradation (Murphy et al., 2002;Murphy and Blenis, 2006). The IEG
might act as a first response to a certain stimulus, sense the duration of Erk activation and control the onset of
transcription of other genes.
ByusinganelegantapproachcombiningoptogeneticsandbiochemicalactivationofErk,Wilsonandcolleagues
could show that, eventhough the transcriptional onset of IEGs are similar, their protein synthesis are subject to
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another layer of regulation (Wilson et al., 2017). They show a band pass filter like behaviour for IEGs, where re-
peated pulsatile activation triggers transcription of IEGsmore efficiently than sustained activation. Further they
present evidence for a different regulation of post-transcription processes for distinct upstream activation (Wil-
sonetal., 2017). Theypurposea two layerdecoding for IEGs, afirst layer,whichallowsslowaccumulationof target
gene transcript level in the presence of repeated transient Erk activation, and second layer of post transcription
control, where timing of translation can be fine tuned in response to distinct combinations of input signals (Wil-
son et al., 2017).
1.2.1.2 Nfκ-beta
Another example is theNFκ-beta pathway, carrying a key role in regulating the immune response. NFκ-beta is
continuously translocatedbetweenthecytosolandthenucleus, yetactivationbyupstreamligandscauses itspro-
longed retentionwithin the nucleus, enabling gene expression of target genes. Treatmentwith tumour necrosis
factor-α (TNFα) generates an oscillatory behaviour (Hoffmann et al., 2002;Nelson et al., 2004), but adding bac-
terial polysaccharides triggers a more gradual, sustained period of nuclear NF κ-beta (Figure 1.5) (Covert et al.,
2005; Lee et al., 2009). The shapeof the response ismainly determinedby the expressionandactivationof IκBα,
both, a transcriptional target and negative regulator of NF κ-beta. Pulsatile activation results in the expression
of inflammatory response genes, prolonged activation triggers comparable expression of these genes, yet addi-
tionally induce cytokine secretion andgenes related to the adaptive immune response (Werner et al., 2005). The
NFκ-beta pathway can encodeup to 8different TNF concentrations, and even short stimulation for 1minute can
trigger the full apoptotic outcome (Lee et al., 2016; Tudelska et al., 2017).
Using microfluidics, Tay and colleagues could demonstrate a dosage-dependent fraction of cells responding
to the stimulus. This response seems to be a digital process, as activated cells induce transcription of IEGs, inde-
pendent of the signal intensity. However, transcription of late genes require a prolonged nuclear presence of NF
κ-beta, which is only triggered at high concentrations of TNFα stimulation (Tay et al., 2010). Whether the early
genes contribute to shaping the late transcriptional response as seen in the Erk pathway remains to be deter-
mined. Apparently, the noise itself is able to contribute to robust signalling. Intrinsic and extrinsic noise enables
entrainment, a process of two interacting oscillators eventually assuming the same period, allowing amplifica-
tion of oscillations and thus transcriptional efficiency (Kellogg and Tay, 2015).
ZambranoandcolleaguesdemonstrateddifferentNFκ-beta targetgenescanexhibitdistinctdynamics insyn-
chronized populations, and different NF κ-beta dynamics are decoded into expression of distinct, functionally
related gene subsets (Zambrano et al., 2016). This finding could be supported in an elegant study combining live
microscopyandsingle-cellRNAsequencing (Laneetal., 2017). By tracing thenuclearabundanceoffluorescently-
labelledNFκ-beta inmacrophage-like cells treatedwith bacterial lipopolysaccharide, they identified three sub-
populationwithdifferent temporaldynamics,highlightingagaintheheterogeneityof theresponse. Thevariabil-
ity in cellular behaviour towards infectious agentsmightbedesired, sinceheterogeneity is abasis of the immune
system. The three different dynamics are correlated to differential gene expression, enabling various response
to an infection in a population of immune cells (Lane et al., 2017).
1.2.1.3 NFAT
Calcium levels control a wide range of biological functions, the spatio-temporal patterns of Ca2+ are thought to
be a key determinant of cellular outcome (Negulescu et al., 1994; Dolmetsch et al., 1997; Berridge et al., 2003).
Depending on the frequency and amplitude of Ca2+ oscillations, one of three distinct signalling nodes becomes
activated, among themNFAT (Dolmetsch et al., 1997). Apparently, calcium oscillations can already partly be de-
coded at the level of activation of a specific transcriptional regulator.
NFAT is transcription factor that resides phosporylated in the cytoplasm, once stimulated by an increase in
Ca2+ NFAT becomes rapidly dephosphorylated by a calcium-dependent phosphatase and can be translocated
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into the nucleus (Klee et al., 1998). The translocation of NFAT proceeds slow, likewise the re-phosphorylation in
the cytoplasm, once the stimulus is turned off. This rate limiting step is crucial in decoding Calcium oscillations
frequency, as only oscillatory stimuli cause an accumulation of dephosphorylated NFAT in the cytosol, and thus
in the nucleus. The cytosolic pool of active, not yet translocated NFAT molecules acts as a working memory of
calcium activation (Tomida et al., 2003).
The NFAT family consists of five isoforms, named NFAT1 - NFAT5 (Müller and Rao, 2010). Especially NFAT1,
NFAT2 and NFAT4 are important regulators in many immune cells (Macian, 2005). Interestingly, Yissacher et
al could demonstrate, that NFAT1 and NFAT4 have a diverse dynamic response to a static calcium stimulus (Yis-
sacharetal.,2013).WhileNFAT1displaysaslow, sustainedresponsewiththeamplitudecorrelatingtothestrength
of the stimulus, NFAT4 responds in fast, fixed amplitude bursts in stimulus dependent frequency. The authors
hypothesize that this duality in response enables fine tuning of expression of genes transcribed by both, yet did
not investigatewhether a subset of genes is exclusively transcribedbyoneof the isoforms.Whether isoformcon-
tribute to dynamic variability in other pathways has not been elucidated yet. Sub-cellular Ca2+ profiles shape the
different temporal profiles of NFAT1 and NFAT4 (Kar and Parekh, 2015). NFAT1 reacts solely to cytoplasmic Ca2+
while NFAT4 requires both cytoplasmic and nuclear Ca2+ to remain nuclear (Kar and Parekh, 2015).
For more than 30 years, it has been postulated that calcium dependent transcription factors decode stimuli
based on the frequency of Ca2+ oscillations (Berridge andGalione, 1988; Dolmetsch et al., 1997). New technolog-
ical development enabled Hannanta-anan and Chow to revisit this model. Using an optogenetic approach they
could elegantly manipulate both the frequency and duty cycle independently. The duty cycle is the fraction of
a single period, in which the signal is active. In contrast to the previous model, they identified the duty cycle of
the calcium oscillations to be the key parameter to fine tuneNFAT activation (Hannanta-anan and Chow, 2016).
These results are consistent with the previously described working memory of calcium signalling, and makes
NFAT an integrator of calcium load (Tomida et al., 2003; Hannanta-anan and Chow, 2016).
1.2.1.4 Msn2
Msn2 is a stress sensing transcription factor in yeast, that remainswithin the cytoplasmand is phosphorylated in
its inactive form. Upon stress, Msn2 is rapidly dephosphorylated, which causes the translocation in the nucleus
(Görner et al., 1998). It could be demonstrated, that the identity, certain trigger can be encoded in the temporal
profile ofMsn2 (Figure 1.5). While glucose starvation causes a oscillatory response ofMsn2, oxidative stress trig-
gered a sustained activation (Hao andO’shea, 2012). Interestingly, also the intensity of the trigger is conveyed in
the signal. The severity of glucose limitation correlates to the length of thefirst oscillatory burst, anddetermines
the number of following, weaker bursts (Hao and O’shea, 2012). On the other hand, increase in oxidative stress
causes a higher amplitude and prolonged activation (Hao andO’shea, 2012) Pioneeringwork in signal decoding
at the cis-promoter level has been done by Hansen and O’Shea. By pharmacological controlling the phospho-
rylation state of Msn2, thus its localisation, Hansen and O’Shea were able to control the transcriptional activity
in a high temporal resolution (Hansen and O’shea, 2013). Combined with the time-lapse microscopy and high-
throughput microfluidics, they could demonstrate that multiple gene expression programs can be encoded in
the dynamics of a single transcription factor. Dependent on theMsn2 activation kinetics and the resulting gene
expression pattern of individual promoters, they could identify two distinct key features of a promoter, namely
amplitude thresholds andpromoter activation time-scales and could predict gene expression accordingly. Addi-
tionally, they report thedependencyof promoter activation time-scale onnucleosome remodelling (Hansenand
O’shea, 2013). In a second study, they thoroughly analysed the cis -promoter elements of distinct Msn2-target
gene threshold and activation kinetics, and could develop a simple model that can predict promoter behaviour
on just three parameters, the number of Msn2-binding-sites, the localization of the TATA box, and the nucleo-
some organization of the promoter (Hansen andO’Shea, 2015).
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1.2.2 p53 dynamics, causes and consequences
Onereason thedynamicsofp53 receiveda lotattentionwithin the lastdecadeare theclinicalpotential of abetter
understandingofp53signallingcouldyield, as it isassumedtobemutated in50%ofall cancers, andmutations in
the p53 pathway occur in virtual all cancers (Vogelstein et al., 2000). Mutation causing aberrant dynamics of p53
response can result in undesired cellular outcomes. A single nucleotidemorphism (SNP) in theMDM2promoter
hasbeen reported,which leads toelevatedprotein levels and thus strongernegative feedbackonp53 (Bondetal.,
2004). Another MDM2 SNP transforms the physiological oscillatory response to γ-radiation into a sustained
response (Hu et al., 2007b). However, it studies to evaluate the effect of this SNP have been contradictory (Bond
et al., 2006; Petenkaya et al., 2006; Campbell et al., 2006).
Bar-Or and colleagueswere the first to described the dynamic nature of p53-activation in cultured cancer cells
in response to DNA-damage caused by γ-radiation as dampened oscillations when assessing p53 levels with
Western Blot (Bar-Or et al., 2000). Examination on the single cell level using a fluorescently-tagged p53 later
revealed the same height and duration of these pulses, independent of the intensity of the applied γ-radiation
(Lahav et al., 2004; Geva-Zatorsky et al., 2006). Varying pulse numbers and lack of synchronization between sin-
gle cells led to themiss classification as dampened oscillations at the population level.
These oscillations have also been observed in vivo in a transgenicmouse line expressing a luciferase driven by
a p53-responsive promoter. When irradiated with γ-irradiation, p53 dependent oscillations of luciferase were
monitored in the intestinal tissue. The shape of these oscillationswas coherentwith those seen in cultured cells.
Interestingly, the response toDNAdamagewas tissue specific, hinting to cell-type specific, distinct composition
of the p53 network (Hamstra et al., 2006). One possible cause of differential p53 dynamics in response to geno-
toxic stressamongdifferent tissuesandcell typesdespitehavingcomparablep53abundance,hasbeen identified
as the activity of the kinase ATM the cell-specific efficiency inDNA repair (Stewart-Ornstein and Lahav, 2017). By
comparing the response of 12 tumour cell lines DNA damage in individual cells, they found that, even though
all cell lines response by activating p53, the dynamics varied strongly. Interestingly, also the type of dynamical
response differs among cell lines. In some cell lines, p53 responded dose-independent, in others, the response
was rather dose-responsive.
Oscillations depend on recurrent production a degradation, and initially it was assumed that Mdm2was suf-
ficient to shape a pulsatile p53 response to γ-irradiation. Collecting quantitative data in a high temporal res-
olution, Batchelor et al could demonstrate that the p53-MDM2 feedback loop is not sufficient for creating the
observed oscillations (Batchelor et al., 2008). They could identify a second negative feedback loop required for
the pulsatile behaviour. By doing quantitative population and single-cell analysis ofmultiple proteins in the p53
signallingpathway, andusingmodelling theypredicted that ratherpulses ofupstreamproteins that senseDNA-
damage and initiate p53 activation shape the dynamic response of p53. The phosphataseWip1was identified as
the centralmediator of this second feedback loop. Wip1 phosphorylates both, ATM and Chk2, both activators of
p53 to suppress activation. On theotherhand,Wip1 is a transcriptional target ofp53. Itwashypnotised, thatDNA
damage is evaluated by ATM, and if not repaired yet, further pulses are triggered.
Originally, p53 pulses have been thought to occur only in stress-conditions. Yet, it could be demonstrated that
unstressed cells exhibit transient, spontaneous p53 pulses (Loewer et al., 2010). The correlation of the p53 pulses
to cell-cycle stages with increased risk of DNA damage, suggesting that these are caused by spontaneous DNA
damage. In contrast to pulses caused by radiation or drugs, the transient activation of p53 in non-stressed cells
did not result in expression of p21, or trigger an arrest of the cell cycle. It was further demonstrated, that the
p53’s acetylation of K373 and K382 differ between non-stressed and stressed conditions, complete acetylation
only occurred in stressed conditions, andwas almost not present in unstressed conditions.
Batchelor and colleagueswere able to show that distinct stresses causedifferent dynamics of p53withdistinct
features (Figure 1.6) (Batcheloretal., 2011).Whilep53activationcausedbyneocarzinostatin (NCS), aDSBcausing
drug, triggers pulses with a fixed length and amplitude, UV-radiation causes long, sustained activation. In the
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latter case, the level of activation is dosage dependent. Continuation of the non-oscillatory, sustained activation
of p53 is linked to permanent cell cycle arrest or apoptosis (Chen et al., 2013). The distinct activation patterns
betweenmild DNA damage (NCS treatment or γ-radiation) andmore severe stress (UV radiation) correlates to
the activation of different subset of target genes in response to the respective stress input (Zhao et al., 2000).
Whether thedynamical behaviourofp53activationactually causes expressionof a specific subsetof targetgenes
and hence trigger a distinct cellular effect, or whether they are just the byproduct caused by the activation via
different upstreampathways remains elusive.
A B
Figure 1.6: Identityand intensityofupstreamtriggeraredecoded inp53dynamicsanddeterminecellularout-
come
A| Activationduetoγ-radiationcausesanoscillatory response,whichfrequency isdependentonradiation inten-
sity, while p53 activity is sustained uponUV-radiation. Amplitude is depending on the amount of UV-radiation.
B | Temporal profiles of p53 activity are associated to distinct subsets of target genes, triggering defined pheno-
types.
Adapted from (Purvis and Lahav, 2013).
To examine the tie between the p53 activation pattern and the expression of target gene subsets eventually
leading to distinct phenotypic outcome, Purvis and colleagues used nutlin3, a small molecule which binds to
Mdm2, inhibiting degradation of p53 to shape the p53 response (Purvis et al., 2012). Theywere able to transform
thepulsatile responsecausedbyγ-radiation, intoasustained responsebyaddingnutlin3. Bydoingso, theycould
drive cells treated with γ-radiation into senescence, a phenotype caused by UV-radiation. Furthermore, it could
be demonstrated that in response to the chemotherapeutic drug cisplatin cell fate is rather determined by the
kinetics of p53 accumulation than overall p53 abundance (Paek et al., 2016).
The formation of the different shapes of p53 activation have been investigated thoroughly, and can be de-
scribed fully by negative feedback loops (Lahav et al., 2004; Batchelor et al., 2008). Since distinct p53 behaviour
was linkedtodifferentcellularoutcomes (Batcheloretal., 2011;Purvisetal., 2012), it seems likely that thedynam-
ical nature of p53 encodes information, most notably the severity of stress, which is then decoded at promoter
level, to execute the desired phenotypic outcome.
Toanswer thisquestion,Hafner etal carriedoutanextensive study, using time-courseChIP-seqmeasurements
andRNA sequencing and correlated nucleosomebinding tomRNAexpression (Hafner et al., 2017). Several sub-
sets of gene expressionpatterns hadbeen identified,whichhadbeenobservedbefore andare causedby the sta-
bility of the single mRNAs (Melanson et al., 2011; Porter et al., 2016). Surprisingly, Hafner and colleagues could
not determine differences of p53-binding to the promoter of the distinct gene subsets, rather they observed uni-
form occupancy of p53-promoters (Hafner et al., 2017).
As fascinating and insightful these studies revealing the impact of p53 dynamic have been, they relied on
rather indirect andharshmethods tomanipulate p53. Studies relying onγ radiation as a trigger of p53 activation
often neglect that such treatment causes a plenty of feedback, yet not limited to p53 response. In absence of p53,
γ radiation can still trigger cell cycle arrest or apoptosis (Halacli et al., 2013). Similarly, UV irradiation can induce
transcription of p53 target gene p21 independent of p53 (Haapajärvi et al., 1999). In addition, drugs to manipu-
late p53 levels bear side effects influencing the cellular response. Nutlin 3, used to interferewithMDM2’s control
of p53 levels, also disturbs MDM2 activity next to p53 regulation, for example regulating DNA repair (Alt et al.,
2005; Bouska et al., 2008; Conradt et al., 2013; Carrillo et al., 2015). Additionally, Cisplatin treatment induces a
wide range of signalling pathways besides p53 (Dasari and Tchounwou, 2014).
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Addressing these experimental limitations require amore specific anddirect approach, to enable precise per-
turbationof thep53network in theabsenceofupstreamstress signals. Onlyso, causeandeffect canbeentangled.
1.3 Optogenetics
The advent of fluorescent probes and high resolution live-cell imaging empowered scientists to observe cellular
processes at a unprecedented spatial and temporal resolution (Toettcher et al., 2011). The observation of protein
levels and localization demonstrated how dynamic processes are within cells. Yet, as methods for observation
dynamic processes led to a newappreciation ofmolecular processes, the abilities to quantitatively describe their
mechanisms lagged behind. Classical genetic perturbation (knockdown, overexpression) enabled thorough in-
terrogation on which proteins contribute to a given phenotype, but are less powerful in explaining underlying
mechanisms. Additionally, genetic perturbation are slow and/or irreversible, giving cells enough time to adapt
to the perturbed status and thus are more likely to impair rather than adjust the spatio-temporal features of a
network.
Chemical perturbationmethods like small molecules take effect on a shorter timespan, but lack reversibility
unless applied in amore complicated experimental setup. Smallmolecules lack spatial control, and the number
of highly specific small molecules is limited, as these often exhibit undesired off-target effects and thus require
extensive engineering (Bishop et al., 2000).
To fully comprehend the dynamic nature of a network in a quantitative manner, perturbation methods are
required that grant selective inhibition or activation of targeted nodes within the network. Optogenetics em-
ploys light-responsive proteins (photoreceptor) that offer a potential revolutionary new approach to overcome
aforementioned limitations. The key featuresmaking sensory photoreceptors so versatile encompass the use of
light to trigger cellular events, that offers an unmatched spatial and temporal resolution (Ziegler and Möglich,
2015). Light is an inert trigger, penetrating tissue up to a certain wavelength dependent depth (Weissleder and
Ntziachristos, 2003). Irradiationwith light in the visible spectrumdoes commonly cause no adverse side effects,
unlessapplied inhigh intensitiesor foraprolongedperiod. Additionally, photoreceptorsoperate reversibility, en-
abling repeated and permanent control. As photoreceptors are genetically encoded, they can be combinedwith
awide range of available and established genetic tools, allowing cell types or tissues specific expression and de-
fined subcellular localization (Ziegler andMöglich, 2015). The combination of these features enabled scientists
to actively perturb cellular systems and quantitatively interrogate dynamic processes at a previous unthinkable
resolution (Toettcher et al., 2013; Hannanta-anan and Chow, 2016;Wilson et al., 2017).
Nobel laureate Francis H Crick envisioned already in 1999 the possibility to use light to control cellular pro-
cesses (Crick, 1999), and shortly after, Crick’s vision came to life. In 2005, Deisseroth and colleagueswere the first
to express the microbial, light-gated channelrhodopsin-2 from Chlamydomonas reinhardtii in mammalian neu-
rons, and apply blue light pulses to control cell depolarization in a millisecond time scale (Boyden et al., 2005).
In the same year, Gottschalk and colleagues demonstrated the exiting in vivo possibilities optogenetics offers,
when expressing the same channelrhodopsin-2 in C. elegans to trigger rapid behavioural changes (Nagel et al.,
2005). Shortly after, the term optogenetics was established (Deisseroth et al., 2006). Initially almost exclusively
used to control neuron polarisation via light-gated ion channels and light-driven ion pumps, the development
of optogenetic tools to control a broad range of non-neuronal, intracellular processes have made optogenetics
more accessible andwidely used (Möglich et al., 2009a; Levskaya et al., 2009;Mills et al., 2011).
In thefollowing, Iwant togiveabriefoverviewoverphotoreceptors, specifically theLight-oxygen-voltage(LOV)
domains. A particular focus is on the LOV domain used in this thesis, the AsLOV2 domain. I will review key steps
in the history of optogenetic usage of this domain and show examples and strategies of its employment in non-
neuronal optogenetics. Lastly, I will present theway theAsLOV2domainwas used to enable light controlled pro-
tein translocation.
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1.3.1 Photoreceptors
Light is an essential carrier of information, and species of all kingdoms of life employ genetically encoded pho-
torecepors to integrate light sensing on themolecular level (Briggs and Spudich, 2005). Light-dependent infor-
mation encompass awide range of biological functions, ranging fromphototaxis and phototrophism over circa-
dian clockmaintenance to visual detection in higher organisms.
As cellular membranes are virtually transparent to light, most photoreceptors are soluble and thus cytoplas-
matic. Characteristic absorption profiles span the solar spectrum fromnear UV (350 nm) to far red (750 nm) and
matches the light they are usually exposedwith. In general, photoreceptor possess twoprincipal functions: First,
aphotosensorymodule,whichabsorbs light, andsecondly theeffectormodule thatutilizes theenergyharvested
by photosensorymodule to exert biological activity. Since neither the polypeptide backbone nor the amino acid
sidechainsabsorb light in thevisible spectra, photosensorsuseorganic, nonproteinogenicmolecules calledchro-
mophore within their photosensory module. Thus, the absorption spectra is based on the chromophore. The
chromophores are partly unsaturated, and contain a conjugatedpi electron systemallowing electron delocaliza-
tion upon photon absorption. The size of the conjugated pi system determines the extent of electron delocal-
ization and the absorption spectrum. The energy absorbed by the chromophore is then conveyed to the protein
causing a transformational change from the so called dark stage to the active lit state and triggering the effector
module to exert its function.
Each photoreceptor can revert back from its active state to the inactive, dark state, yet themechanism of this
reversion varies between the different photoreceptor types. Recovery can occur spontaneously with half lives
ranging from seconds andminutes (for some LOV domains (Salomon et al., 2000)) up to hours or even days (for
UVR8 (ultraviolet-B receptor), (Heijde and Ulm, 2013). Other photoreceptors like phytochromes, cyanobacteri-
ochromesandmany rhodopsinsarephotochronic, the lit state canbe reversedbyexposurewith lightof adefined
wavelength (Sharrock andQuail, 1989; Ziegler andMöglich, 2015).
Based on the type and photochemistry of the chromophore, photoreceptors can be classified in several ma-
jor groups: rhodopsins, LOV domains, BLUF proteins (blue-light sensors utilizing flavin adenine dinucleotide),
cryptochromes, phytochromes, and Xanthopsins (Figure 1.7) (Möglich et al., 2010).
Figure 1.7: Excitation spectra of different photoreceptor families
Adapted fromZiegler andMöglich (2015).
Rhodopsins, further classified in two subgroups, microbial rhodopsins and G protein coupled rhodopsins use
a retinal chromophore for photon absorption (Spudich and Bogomolni, 1984). The photoactivity of xanthopsins,
also called photoactive yellow proteins (PYP), is based on the chromophore p-coumaric acid (Kort et al., 1996).
Phytochromes and cyanobacteriochromes employ bilin-derivatives as chromophores, such as phytochromobilin
or phycoviolobilin and phycocyanobilin, respectively (van der Horst and Hellingwerf, 2004). Upon photon ab-
sorption, these chromophores undergo cis-trans isomerization, causing the transition into the active lit state
(van der Horst and Hellingwerf, 2004). In contrast, cryptochromes, LOV domains and BLUF proteins exhibit a
more diverse photochemistry, based on flavin nucleotides (van der Horst and Hellingwerf, 2004). An exception
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is theArabidopsis thalianaUVR8protein, aphotoreceptor independentofanexternallyproducedcofactor. UVR8
is dimeric and exhibits pyramid shaped formation. Here, the tryptophan sidechains at the binding interfaces of
the dimer-dimer act as a photon absorber and initiates reversible disruption of the dimer-dimer interface and
thus the separation of the dimers (Christie et al., 2012;Wu et al., 2012).
1.3.2 LOVdomains
The fist LOV domain was identified within the Arabidobsis thaliana gene non-phototropic hypocotyl (nph), being
responsible for phototropism and thus subsequently renamed Phototropin 1 (Huala et al., 1997; Salomon et al.,
2000). Since thefirstdiscovery, theyhavebeenshowntoexist inalgal, fungal, bacterial, protist andplant species,
were theymediate the reaction uponblue light absoption (Crosson et al., 2003). In a recent computational anal-
ysis across 42million open reading frames discovered around 6700 LOV domains (Glantz et al., 2016). As a pho-
tosensory domain, LOV2 domains can trigger a diver set of effector domains, for instance , DNA or RNA bind-
ing, metabolic function or cell signalling (Crosson et al., 2003). Yet, many of the in situ suggested LOV domains,
havenotbeen tested in thewet lab, andare associated toeffector domainswithunknown functions(Glantz et al.,
2016). This promises a wide of range of new biological activity controllable by blue light, as recently highlighted
by the identification of a new LOV domain allowing light controlledmembrane association (Glantz et al., 2018).
In general, LOVdomains consist of one ormore sensor domain(s), responsible for absorbing blue light and ex-
erting action on the effector domain, commonlymediatedby aα-helical linker connecting the twoparts (Harper
et al., 2003). Structurally, LOVdomains are part of the Period-ARNT-Singleminded (PAS) domain family, a group
of proteins that act as sensors for among others oxygen, redox potential and light (Taylor and Zhulin, 1999). LOV
domains associate non-covalently with either a flavin based cofactor, either flavin mononucleotide (FMN) or
flavin-adenine dinucleotide(FAD) (Salomon et al., 2000;Möglich et al., 2010).
The core of the LOV domains is constituted by a set of 110 amino acids that form the PAS defining fold of a
central, 5-stranded anti-parallel β-sheet and a helical face, that bind the chromophore (Zoltowski and Gardner,
2010). Blue light absorption triggers a covalent thioether bond between the conserved cysteine residues of the
PAS core and the cofactor (Salomonet al., 2001; Crosson andMoffat, 2002). The formed covalent adduct conveys
a transformation change spreading throughout the LOV domain due to rearrangement of several non-covalent
bonds, usually hydrogenbonds (CrossonandMoffat, 2002; Fedorov et al., 2003;Harper et al., 2003). These struc-
tural rearrangements are passed on to the effector domain, typically by relaxation of formerly inflexible struc-
tures (Harper et al., 2003, 2004).
Oneof theoptogeneticworkhorses is themonomeric, LOVdomainAsLOV2domainderived fromphototrophin
1 of the common oat Avena sativa (Harper et al., 2003). In contrast to other members of the LOV domain family,
AsLOV2 is a non-associating photoreceptor, meaning formation of the lit signalling state is not accompanied by
Jα
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illumina�on
dark
Figure 1.8: Blue light-induced exposure of the C-terminal Jα-helix ofAsLOV2
Upon blue photon absorption, the Flaviomononucleotide chromophore triggers a structural rearrangement
causinga transformational change throughout theAsLOV2and leads to theexposureof formerlybound Jα-helix.
Adapted fromZayner et al. (2012).
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adjustmentsof theoligomeric state (ZieglerandMöglich,2015). ThePAScoreconsistsof fourα-helicespacked to
bothsidesof fourantiparallelβ-sheets (Möglichetal., 2009b). OntheN-andC-terminus thereare twoadditional
helices, the Aα and the Jα (Harper et al., 2003). In the inactive dark state, the C-terminal Jα is tightly packed
within the PAS core, masking hydrophobic residues of the central β-sheet (Halavaty and Moffat, 2007). Once
the chromophore FMN absorb photons (Peak of absorbance at 447 nm), a structural rearrangement occurs and
triggers an unfolding of both, the Aα and the Jα (Halavaty andMoffat, 2007; Zayner et al., 2012) (Figure 1.8). In
nature, this conformational change triggers the activation of the kinase domain of phototropin 1 (Harper et al.,
2004).
The recovery to the inactive dark state occurs spontaneously and is caused by a base-catalysed mechanism
leading an disruption of covalent linkage between the cysteine in the active center of theAsLOV2domain and its
chromophore (Alexandre et al., 2007). With a photocycle lasting around 80 s theAsLOV2belongs to the group of
fast cycling LOV domains (Pudasaini et al., 2015). Yet it is important to note, that LOV domains exhibit rather an
equilibrium of caged and an uncaged state rather than a finite defined state (Harper et al., 2003; Halavaty and
Moffat, 2007). This equilibrium is shifted towards the caged state in the dark, and vice versa to the active state
uponbluephotonabsorption (Yaoet al., 2008). While this dynamicequilibrium is already saturatedatmoderate
light intensities in LOV domains with a slower photocycle, fast cycling LOV domains exhibit a higher sensitivity
to light and increased dynamic range in the equilibrium (Pudasaini and Zoltowski, 2013). Over the years, various
mutations have been described to shift the equilibrium towards aremore desired state, and alter the photocycle
kinetics allowingfine tuning activation kinetics tofit a particular need (Stricklandet al., 2010; Zayner et al., 2013;
Diensthuber et al., 2014).
1.3.3 Light-dependent allostery usingAsLOVdomains in non-neuronal optogenetics
The majority of optogenetic tools based on LOV domains can be classified in employing two different strate-
gies (Figure 1.9). The first strategy makes use of the key feature of associating LOV domains, the change of the
oligomeric state due to the structural change upon blue light illumination. This group can be further subdivided
in either blue light responsive homo- or heterodimerization, as well as photoactivatable dissociation of previ-
ously associated proteins. The second strategy is based on the light-dependent allostery, meaning a signal acti-
vated due to a transformational change of a single LOV domain upon light illumination.
Figure 1.9: Overviewof different optogenetic strategies employedusing theAsLOV2
Adapted fromHoffmann et al. (2018).
TheAsLOV2 domain is a prime example for a photoreceptor utilized in light-dependent allostery. Here, scien-
tist make use of the light induced unwinding and exposure of the initially caged AsLOV2 Jα helix. The modular
architecture of photoreceptor, with a clear separationbetween the light absorptionmodule and the signal trans-
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mittingmodule allows for a high degree of customization and the design of a single component tool, with both
the AsLOV2 and the effector domain in one construct.
Asmost cellular processes depend on protein-protein interaction, the possible application are extensive. Yet,
thedevelopmentof such tools is not trivial, as the residual activity in thedarkdue to theexistingequilibrium lim-
its thepotential dynamic rangeofaoptogenetic tool. Additionally, it requires substantial engineering toposition
both parts to guarantee a light controlled activation.
The first successful use of theAsLOV2was carried our by Strickland et al., by fusing the E. coli transcription fac-
tor trp repressor (TrpR) to theAsLOV2creatinga light-activatibleDNAbindingprotein called LOV-TAP (Strickland
et al., 2008). The characteristic N-terminal helix of TrpP needs to associate with the protein core to trigger DNA
binding. Yet, arranging the AsLOV2 domain N-terminal to the TrpR created a chimeric helix composed of the
AsLOV2domain C-terminal Jαhelix and theN-terminal-helix of TrpR. This chimeric helix is bound to theAsLOV2
domain in thedark, uponphotoactivation it disassociates andbinds theTrpP core to triggerDNAbinding (Strick-
land et al., 2008). Eventhough the performance of this systemwas rather week, it served as proof of concept for
further development. Additionally, it could be further improved by the introduction a range ofmutationswithin
the chimeric helix to enhance its stability and binding to the core of the AsLOV2 (Strickland et al., 2010).
Shortly after, a strategy to control the function of protein of interest was presented, that aims at introduc-
ing the AsLOV2 is introduced in an allosteric surface in proximity to the active center of the protein (Lee et al.,
2008). Statistical coupling analysis was used to evaluate sites as potential localization of the AsLOV2 to enable
light-dependent control of disruption of the required allosteric surface (Lee et al., 2008). While the chimeric
protein designed in this study showed only mild activation, it was a ground breaking approach. This approach
was later revised, and several proteins of three different classes were successfully engineered to be controllable
by light, due to insertion of the AsLOV2 in computationally determined protein loops close to the active site
(Dagliyanetal., 2016). Due to the closeproximityof theAsLOV2N-andC-Terminus, the insertion inprotein loops
barely causesa loss in function. Uponphotoactivation, thedistancebetweenthetermini increasesdrasticallyand
causes local disorder close to the active center and thus a loss of function (Dagliyan et al., 2016). This approach
established a new subcategory of tools that trigger light induced disorder. Until then, AsLOV2were widely used
for creating a sterical hindrance, which can be turned on and off by light, and by photocaging of small peptides
in the Jα-helix.
1.3.3.1 Sterical hindrance of accessibility C-terminal attachedprotein
Steric hindrance is a more simplistic approach introduced by Hahn and coworkers in 2009 (Wu et al., 2009).
Rather then creating a complex chimeric fusion protein, they attached the AsLOV2 N-terminally to a protein of
interest, namely theRac1 smallGTPaseandmadeuse transformational change theAsLOV2undergoesupon light
illumination (Wu et al., 2009). In the dark state, the Jα helix is tightly associated to the core of the LOV domain,
thus the C-terminally attached protein is located in close proximity to the LOV domain, and hardly accessible to
the cellular environment. The fusion protein called photoactivatble Rac1 (PA-Rac1) enabled remote control of
motility in fibroblasts expressing PA-Rac1 (Wuet al., 2009). As this perturbationwas highly specific, it permitted
a better understating of the crosstalk between Rac1 and Rho signalling, both regulators of cell migration (Wu
et al., 2009).
Trivial as this strategymay have appeared, difficulties in transferring this approach to control activity of even
closely relatedGTPases surprisingly failed (Winkleretal., 2014). Further structural investigationof theRac1-LOV2
interface and its light induced transition revealed a serendipitously calciumbinding site introduced in the inter-
face, that appears to be essential for the light-dependent function (Winkler et al., 2014).
Nevertheless, this rather straightforward approach of fusing the AsLOV2 N-terminal to a protein of interest
was successfully applied to various proteins. Scientist used this approach to engineer a photoactivated caspase 7
to trigger apoptosis (Mills et al., 2011), mediate activity of a Ca 2+ channel (Pham et al., 2011) or potassium chan-
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nel (Cosentino et al., 2015), maintain optical control of mDia, a formin inducing the assembly of nuclear actin
network (Baarlink et al., 2013), generate amean to regulate local peptide ligand concentration by light (Schmidt
et al., 2014), ascertain control of light induced post-translational control function by intein-mediated protein
splicing (Wong et al., 2015; Jones et al., 2016) or enable the investigation of the unmodified cargo carriermyosin
V1 (French et al., 2017).
The apparent limitation of this approach is the dependency of a small spatial proximity of theAsLOV2 and the
effector domain to theproteinof interest. Efforts in implementing short truncations oneither the target proteins
N-terminusor theAsLOV2 (Baarlink et al., 2013) and introducing linkers, the roomfor improvement remains lim-
ited. An approach to bypass this limitation is the introduction of theAsLOV2 into inter-domain linkers of the tar-
get proteins, as suggest in two studies successfully controlling caspase 3 (Smart et al., 2017) and pyruvate kinase
M2(Gehrig et al., 2017). Yet, this approach affordsmore complex engineering and optimisation.
1.3.3.2 Photocaging of peptides in the Jαhelix
An alternative strategy is peptide photocaging. Rather than fusing a effector domain C-terminal to the Jα helix
and controlling accessibility by due to sterical shielding, a short peptide with a defined biological function at-
tached to the Jα helix C-terminus (Figure 1.10). As the crystal structure of the AsLOV2 hints to the possibility to
bury small peptides in its core in the dark state, it was proposed that by exchanging parts of the C-terminus of
the Jαhelix by a peptidewith abiological function, one can exert this function in response to light, given that the
light responsive transformational change is not abolished due to truncation (Halavaty andMoffat, 2007). Intro-
duction of peptide epitope should lead to a limited accessibility in the dark state, due to its size.
Figure 1.10: Peptide photocagingwithin the C-terminal Jαhelix ofAsLOV2
Sequence chimera of a peptide and the Jα helix can be exposed in a light-dependent fashion. Crucial for pho-
toactivity are both residues crucial for helical folding (blue), residues for peptide function (purple) or both(red).
Non-relevant residues can bemutated to fine-tune either peptide activity or photocaging.
Adapted from Lungu et al. (2012).
Strickland et al created the first optogenetic employing this strategy to enable fine tuned optical control of
protein localisation within mammalian cells (Strickland et al., 2012). In an approach labelled tuneable, light-
controlled interactingprotein tags (TULIPs), thepeptideknowntobindhighly specific toengineeredPDC (ePDC)
was fused to theC-Terminusof the Jα ina serial truncationupto the isoleucineatposition539, as this site is crucial
for dark-state recovery (Harper et al., 2004; Strickland et al., 2012). Both the high affinity and specificity of ePDC
is dramatically increased due to directed evolution (Huang et al., 2008). EPDZ can be fused to any protein of
interest, to enable light controlled associationwith theAsLOV2. Thus, by defining the localization of theAsLOV2
with localization tags, in this case amembrane bindingmotif, the protein of interest fused to ePDZ can recruited
to themembrane in upon blue light photo absorption (Strickland et al., 2012). This systemhas also been used to
modulate kinesin- and dynein dependent transport of organelles (Van Bergeijk et al., 2015), yet its use is limited
due to the comparably low dynamic range.
In close analogy, Hahn and colleagues presented two optogenetic tools based on the same principle (Lungu
et al., 2012). Yet, instead of choosing peptide candidates due to their exceptional high affinity and specificity,
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the screened for peptide sequences, which resemble the endogenous Jα helix to limit alteration of its sequence.
Using this approach, they could demonstrate light controlled heterodimerisation of AsLOV2-SsrA chimera and
any protein of interest fused to the bacterial SspB(Lungu et al., 2012). Eventhough the induction of SsrA-SspBr
showed a low dynamic range, it could later be a dramatically improved by a combination of computer aided de-
sign and phage display selection, leading to widespread use of the then called improved light-induced dimer
(iLID) system(Guntas et al., 2015).
Both, TULIPs and iLID feature peptide-protein interaction originated in bacterial organisms,making themor-
thogonal tools and limiting unwanted effects on the host system. Yet, manipulation of endogenous proteins is
somewhat restricted, unless the protein domains are introduced in the endogenous gene locus, which is labo-
rious and error prone. Thus, to exert function on endogenous proteins, several approaches using short peptides
exhibiting a biological function have been used to create chimeric peptide-Jα proteins. This approach has been
demonstrated successfully in light-dependent recruitment of endogenous vinculin (Lungu et al., 2012), peroxi-
somal trafficiking (Spiltoir et al., 2015), induction of apoptosis (Mart et al., 2016), controlling endogenous kinase
activity (Yi et al., 2014) and protein degradation (Renicke et al., 2013; Bonger et al., 2013; Sun et al., 2017).
Important tonote, that there is an inherent tradeoffbetween truncations too longandcompromising theheli-
cal structure Jαhelix and thus the ability to photocage an epitope, and a too short truncations, allowing peptide-
protein interaction in both, dark and lit state.
1.3.4 LINuS and LEXY,moving proteins in and out of the nucleus
Many signalling pathways eventually converge in the nucleus tomediate transcription or epigenetic regulation.
To enable eucaryotic cells to respond rapidly to internal and external trigger, signallingmolecules exerting a nu-
clear functionareoftenalreadypreproduced,butkept indifferent compartments,mostly thecytosol. Uponstim-
ulation, localization sequenceswithin the signalling protein become either accessible or blocked, leading to the
mediated translocation into the nucleus. Thus, controlling nuclear localization is a common mean to mediate
protein activity and grants a more rapid response than starting production upon stimulation (Purvis and Lahav,
2013; Di Ventura and Kuhlman, 2016).
In general, while proteins smaller than 40 kD can passively diffuse into the via nuclear pores, larger proteins
dependentonactivesupportof transport receptorswhentranslocating inoroutof thenucleus (Mohretal.,2009).
Karyopherins are themost commongroupof proteins regulating transport of protein cargo, generally bybinding
to short, linear localization sequences within the cargo protein (Chook and Süel, 2011). Importin-α is themajor
import receptor and recognizes NLS sequences, while NES sequences are bound by the nuclear export receptor
CRM1(chromosomeregionmaintenance 1, exportin1) (HuttenandKehlenbach,2007). Noteworthy,NLSandNES
motifsofdifferentaffinitiesexits,whichexhibitawiderangeof transportefficiencies (KutayandGüttinger,2005;
Hodel et al., 2006).
As nuclear translocation is at the center of many biological pathways, many tools to take control over local-
ization of proteins have been developed. While several chemical methods to control nuclear translocation have
been developed (Klemm et al., 1997; Kudo et al., 1999; Bayle et al., 2006; Kakar et al., 2007; Haruki et al., 2008),
they either are irreversible, have slow kinetics and high background or potential side effects, rendering them
suboptimal for mimicking a highly dynamic and reversible process. Efforts in combining chemical and light ap-
proaches tomediate translocation improved translocation speed and reducedbackgrounddrastically, yet lacked
reversibility (Watai et al., 2001; Engelke et al., 2014).
Thefirst fully reversible tools tocontrolnucleo-cytoplasmic translocationwerebuildusingthetwo-component
PyhB/PIF (PythochonB/Pythochrome interacting factor)system (Yang et al., 2013; Beyer et al., 2015). Illuminated
with red light, the two components associate rapidly, and remain in a bound state until irradiated with infra-
red light (Ni et al., 1999; Zhu et al., 2000). The tools based on the PhyB/PIF system enable fast and reversible
translocation (Yang et al., 2013; Beyer et al., 2015), yet demands amore elaborate experimental set up. Due to its
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two-component nature, titration of both components is necessary to ensure the right ratio of expression. Addi-
tionally, PhyB requires the addition of its chromophore phycocyanobilin (PCB), and illuminationwith UV light is
necessary to reverse nuclear translocation.
Toaddress the limitationsof theexisting tools, twosingle-component systemsbasedontheAsLOV2havebeen
developed (Niopek et al., 2014, 2016). Both are small, versatile protein tags, that expose engineered localiza-
tion sequence photocaged in the AsLOV2 J-α helix in response to blue light (Niopek et al., 2014, 2016). LINuS
(light-induciblenuclear localizationsignals)exposesanengineeredNLS, triggering rapidphotoactivatednuclear
translocationof any taggedprotein (Niopek et al., 2014), vice versa, LEXY (light-inducible nuclear export system)
causes fast cytoplasmic translocation (Niopek et al., 2016) (Figure 1.11). Once deactivated, both systems rapidly
recover to the pre-illuminated state (Niopek et al., 2014, 2016).
LINuS
NES
(cons�tu�ve) NLS
(caged)
LINuS
NES
(caged)
NLS
(cons�tu�ve)
LINuS
NES
(cons�tu�ve) NLS(exposed)
LEXY
NLS
(cons�tu�ve)
NES
(exposed)
Light
Dark
Dark
Light
Figure 1.11: LINuS and LEXY - small tags to gain photoactive, reversible control of protein import or export
LINuS or LEXY expose an engineered NLS or NES upon blue light absorption, triggering rapid translocation of
fused protein of interest. In the absence of light, both recover to the initial dark state.
Adapted fromHoffmann et al. (2018).
LINuS and LEXY have been demonstrate to robustly translocate a wide range of proteins when fused either
to their N- or C-terminus (Niopek et al., 2014, 2016). Several different LINuS and LEXY version exposing local-
ization sequences exhibiting different translocation efficiencies allowing precise fine-tuning of localization of
cargo proteins (Niopek et al., 2014). Moreover, two almost identical systems, LINX and LANS have been devel-
oped independently, furtherhighlighting the robustnessof this approach inawide rangeofproteinandcell lines
(Yumerefendi et al., 2015, 2016).
1.4 Aimof this study
Many signalling pathways resemble each other in their structure. Multiple inputs converge into a single, central
node, commonlya transcription factor. Growingevidence supports thenotion that transcription factors integrate
information frommultiple upstream stimuli and execute the appropriate response by turning on specific gene
expression programs.
The tumour suppressor p53 exhibits distinct activation dynamics. p53 dynamics are defined as the shape of
the curve characterizing how the levels, activity, modification state or localization of p53 changes over time. The
curve encodes information in features such as amplitude or frequency.
p53 dynamics are determinedby the stress triggering these dynamics. For instance, in response toγ-radiation
p53 levels show pulses of fixed amplitude and period whose number is determined by the intensity of the γ-
radiation. Different p53 temporal patterns are linked to different cellular fates. While it has been established
which factors determine p53 dynamics, our understanding of themechanisms at play that decode these dynam-
ics into specific gene expression programs and subsequent cell fates remains limited.
In this study, I aimed at deepening our understanding of the role of p53 dynamics in dictatingwhich genes are
expressed using state-of-the-art optogenetic tools tomanipulate either p53 levels or localization inmammalian
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cells. In this set-up dynamics can be studied in the absence of an upstream stress.
To control protein levels of endogenous p53 I investigated several approaches that ultimately aimed at pre-
venting inactivationanddegradationofp53bytheE3ubiquitin ligaseMdm2. Light-mediated inhibitionofdegra-
dationwould allow fine-tuning of p53 levels, and thus enable application of p53 dynamics.
To control the localisation of exogenously expressed p53 I employed the optogenetic tools LINuS and LEXY.
Cytosolic sequestration of transcription factors is a commonmechanism to keep these signallingmolecules dor-
mant, while active nuclear translocation allows rapid response to external stimuli. Due to the velocity of import
and export, active translocation of p53would allow application of p53 dynamics of high temporal resolution.
Once the methodology to control p53 dynamics is established, I plan to apply distinct p53 dynamics and test
if they lead to the expression of different p53 target genes and consequently to different cellular fate. Precise
application of p53 dynamics should enable us to understand the regulatory mechanisms involved in decoding
these dynamics into specific transcriptional responses.

2 Material andMethods
2.1 Plasmid generation
All plasmids were constructed using traditional restriction enzyme cloning, in some cloning steps also type IIS
restriction enzymes were used. Restriction enzymes were obtained fromNew England Biolabs (NEB). Oligonu-
cleotides were obtained from Sigma-Aldrich. Polymerase chain reaction amplification (PCR) was carried out us-
ing Phusion Flash High Fidelity Master Mix (Thermo Fischer Scientific, F548S) according to the manufacturer’s
protocol. PCR products were visualized in a 1% Agarose gel and subsequently purified with the Qiagen Gel Ex-
tractionKit (Qiagen, 28704). Restrictions digestswere carried out at 37°C for 1 hour. ThePCRpurification kit (Qia-
gen, 28104)was used to purify the digested PCRproduct. Ligationwas carried outwith T4 Ligase (NEB,M0202S)
according tomanufacturer’s suggestions. The ligation product was transformed in One Shot™TOP10 Chemically
CompetentE. coli (ThermoFischer ScientificC404010). Then, bacterial cellswere cellswere selectedonLysogeny
Broth (LB) agar plates, containing either 100 µg ml-1 ampicillin or 50 µg ml-1 kanamycin. Single Colonies were
amplified in liquid LB cultures containing the respective antibiotic. The plasmidDNA extractionwas carried out
using the Qiagen PlasmidMiniprep Kit (Qiagen, 27104) or the PlasmidMaxi kits (Qiagen, 12162). Isolated DNA
was verified by Sanger sequencing, carried out byGATCBiotech. A list of constructs used in this study is provided
in the appendix.
2.2 Cell culture and cell lines
2.2.1 Cell culture and cell lines
The human non-small cell lung carcinoma cell line H1299 was kindly provided by Prof. Alexander Loewer, TU
Darmstadt. The human colon carcinoma cell line HCT116 p53 +/+ was kindly provided by Prof. ThomasHofmann,
UniMainz. H1299 cells andMCF7 cellswere cultured inRPMI 1640Medium(ThermoFischerScientific, A1049101)
supplementedwith 10%fetal calf serum (FCS, Biochrome, S0115) and 100Uml -1 penicillin and 100µgml-1 strep-
tomycin (PenStrep, ThermoFischer, 15140-122). HCT116 cellsweremaintained inDulbeccos phenol red-freeDul-
becco’sModifiedEagleMedium(ThermoFischer, 31053)supplementedwith10%FCS,2mML-glutamine(Thermo
Fischer,25030-024) and 1% PenStrep. All cell lines were cultured at 37°C and 5% CO2 in a humidified tissue cul-
ture incubator.
2.2.2 Transient transfections
Cells were seeded in 6-well plates (Corning, CLS3335) at densities of 200000 (for H1299), 300000 (HCT116) and
300000 (MCF7-p53-Venus) cell per well for experiments lasting 24 hours post transfection. For longer experi-
ments, cell densities were reduced by 50% per 24 h to prevent overgrowth. The next day, transfection was per-
formedwith Lipofectamin 2000 (Invitrogen, 11668019) according to themanufactures protocol. Following DNA
and Lipofecatmin amounts were used:
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Cell Line Stuffer DNA Construct DNA Lipofectamin
H1299 900 ng 100 ng 2 µl
HCT116 2250 ng 250 ng 4,8 µl
MCF7 1750 ng 250 ng 3 µl
MCF7-p53-Venus 1750 ng 250 ng 3 µl
Ingeneral, pcDNA3.1(+)wasusedasa stuffer. Formicroscopeexperiments 10%of cells,DNAandLipofectamin
used in 6-well plates were used in µ-Slide 8Well (Ibidi, 80826).
2.2.3 Generation of themonoclonal stable cell LinesH1299-p53-LEXY
To generate a stable cell line expressing p53-LEXY under an inducible promoter, cMyc_tetR-KRAB (kind gift from
Ben Kachel, Grimm lab) was cloned in pcDNATM 6\TR yielding pcDNA6_TR-KRAB. Subsequently, the minimal
CMV\Tet2 promoterwas amplified frompcDNATM5\FRT\TO and ligatedwith p53-LEXY and cloned in a pcDNA3.1
(+) Zeonot carrying its CMVpromoter yielding FRT_p53_Lexy. Selective antibiotic concentrationwasdetermined
according to themanufacturer’s protocol.
To generateH1299 cells stably expressing tetR_Krab, H1299 cells were transfectedwith pcDNA6_TR-KRAB. 48
hours after transfection, cellswereexposed tomedia supplementedwith0.03%Blasticidin. For thenext 12days,
media was exchanged every 3 days. Then, the cells were trypsinized and counted. Subsequently, cells were di-
luted to 0.5 cells per 200 µl respectively, and seeded in 4 96-well plates each inmedia containing 0.03% Blasti-
cidin. 5days later, all of the96-wellplateswereanalysed for single colonies.Wells containingsingle colonieswere
transferred in to 6-well plates, and subsequently in T25 well flasks. Then, the 65 clones were seeded in 96-well
plates induplicates and transfectedwithFRT_p53_Lexy. 24hpost transfection, cellswere supplementedwith 100
ng/ml doxycyclin, controls were left untreated. After 24 hours, cells were analysedwith themicroscope.
The samemethodologywas carried out generatingH1299_TR stably expressing FRT_p53_LEXY. The selection
media was supplemented with 0.03 % Blasticidin and 0.05 % Zeocin. To evaluate successful integration, ex-
panded clones were either treated with Doxycyclin or left untreated. The induction was verified with a micro-
scope.
2.3 Western blot
If not mentioned otherwise, cells were seeded into 6 well plates and transfected or induced with the respective
constructs or the indicated doxycyclin concentration. In case of an optogenetic experiment, cells were illumi-
nated with the respective illumination device, and the indicated illumination timings. Cells were exposed to
light either for 24 or 48 hours. Controls were kept in the dark. Then, cells were collected into ice-cold lysis buffer
(20 mM Tris-HCL pH 7.4, 1% Triton X.100, 10% glycerol, 150 mM NaCl, 1% phenylmethylsulfonyl fluoride, 1%
Benzonase (Novagen, 70664) and 1 CompleteMini Protease Inhibitor tablet (Roche, 11 836 153 001). Protein con-
centration was measured by a Bradford assay and adjusted to 1 µg\ml. 15 µg were loaded followed by protein
separation by SDS–PAGE. Proteins were then transferred onto a polyvinylidene difluoride membrane and the
membranewas blocked using 5%BSA in PBS-T. Primary antibodieswere diluted in 5%BSA in PBS-T and applied
for 1 h to detect p53 (Santa Cruz, sc-126, diluted 1:1000) or p21 (BD Pharmigen, 556430, diluted 1:666) and beta-
actin (Abcam, ab8226, diluted 1:1000), followedby incubationwitha secondarygoat anti-mouse IgG(H+L)-PRP0
(Dianova, 115-035-003) for 45 min. Chemiluminescence was detected using the SuperSignal West Pico Chemi-
luminescent Substrate (Thermo Scientific) and the ChemoCam Imager (Intas). Quantitative analysis of protein
expression levels was carried out bymeasuring the intensity of the respective bands using the ImageJ Gels pack-
age. Target gene levels were first normalized to beta-actin levels of the respective sample, then to an indicated
control.
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2.4 Blue light illumination devices
2.4.1 Activationwithin the cell incubator
Blue light exposurewas carried out using a custommade LED stand positionedwithin the cell culture incubator.
Clear bottomwell plates were positioned on a small plexiglass table standing above a LED array consisting of 6
LEDs (LED-TECH, Cree XP-E D5-15, wavelength 458 nm). The distance between LEDs and the table was approxi-
mately 20 cm.
Blue light intensitywasmeasured using a LightMeter (LI-COR, LI-250A). Initially, intensitywas ~20µmolm-2s
-1. In experiments after chapter 2.3.7., light intensity was reduced to ~15 µmolm-2s -1.
The LEDs were were powered by a power supply (Manson, HCS-3102). A notebook connected to the power
supplywasusedtoautomaticallycontrol light intensityand illuminationregimes (Mansonsoftware,Version0.9).
In afirst optimisation step, thenotebookwasexchangedbyaRaspberryPi runninga self-writtenPython script
to control the power supplies settings. Using theRaspberry Pi allowed application ofmore complex illumination
patterns, due to lack ofmaximal number of computer commands.
Ina secondoptimisationstep, theLEDsof the incubatorarraywereexchangedbynewLEDshavinganemission
peak at awavelength of 488 nm (LED-TECH, CREE-XP E2).
2.4.2 LED-devices for automatedmicroscopy
To track localisation during imaging, LEDs were embedded in the lids of well-plates. LEDs were cooled with at-
tached cooling bodies, to prevent overheating. The LEDs were powered by a power supply (Manson, HCS-3102).
Activation state and voltage (controls LED intensity) were controlled with a Raspberry Pi running a self-written
Python script. Emptywells were filledwith PBS, to prevent evaporation ofmedia.
2.5 Microscopy and Imaging
2.5.1 Leica SP5
Confocal laser scanningmicroscopy was carried out on a Leica Sp5 confocal microscope. Initially, cells were acti-
vated with the 458 nm laser at 80 % intensity, then I switched to the 488 nm laser at 80 % intensity to prevent
doxycyclin degradation. mCherrywas imagedusing the 561 nm laser. In general, the 561 nm laserwas used to fo-
cus cells, to prevent premature translocation processes. Themicroscope was equipped with a incubation cham-
ber for long term imaging. For experiments with living cells, the chamber was preheated to 37 °C and set to 5%
CO2. Activation and imaging was done using the 20X objective (NA = 0.7). For translocation experiments, cells
were activated for 5 seconds every 30 seconds. mCherry images were taken prior to each blue light illumination.
20000H1299 or 40000HCT116 cells were seeded in ibidiµ-slide 8wells (ibidi, 8226).
2.5.2 Lionheart
Experiments using the self-built LEDdeviceswere carriedout on theBiotek Lionheart using theproprietaryGen5
software. mCherry was imaged using the texas red filter cube. Images were taken using 20x objective using the
laser-based autofocus. LED power was set to 10 and exposure time to 1600 ms. The software package for auto-
mated imagingwas used for long term imaging. A self written Python scriptwas used tomatch each time points
images and stitch them together to receive one image file.
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2.5.3 ImageAnalysis
Images were taken with the indicated microscopes. Image analysis was performed in FiJi (version 1.51). In gen-
eral, prior to further analysis, backgroundwas subtracted on raw data.
2.5.3.1 Quantification of nuclear/cytoplasmic ratio
For each cell, a region of interest was drawn in the cytosol and the nucleus. Mean intensity was measured, and
nuclear fluorescencewas normalized to cytosolic fluorescence.
2.5.3.2 Quantification of relative nuclear intensity
A region of interest was drawn in the nucleus of each cell and themean intensity wasmeasured using Fiji. Next,
each cell was tracked in every slide through a given time series, and normalized to the initial intensity. Then, the
mean of relative nuclear intensity was calculated for each time point.
2.6 Quantitative analysis ofmRNA transcript levels by qPCR
2.6.1 Primer design and validation
qPCR primer were designed by first accessing the DNA sequence of the desired gene sequence and its mRNA
transcript on pubmed. Either forward or reverse primer has to span an exon-exon junction to prevent amplifica-
tion of genomic DNA. The amplicon size and the melting temperature was selected to be as similar as possible
throughout all designed primers. Primer3 was used to verify absence of secondary structures of designed Oli-
gos. Each primer pair was validated by serial cDNA dilution. cDNA was diluted in 1:10, 1:100, 1:1000, 1:10000
and 1:100000, while primer concentration was kept constant. In general, primers were designed and validated
according toMIQE guidelines (Bustin et al., 2009)
2.6.2 cDNAgeneration
RNA was isolated using the Qiagen RNeasy Kit (Qiagen, 74104) following the manufacturers protocol. The RT
was carried out with the RevertAid First Strand cDNA Syntesis Kit (ThermoFischer, K1621). RT was carried out in
PCR tubes, 1 µl of random primer were added to 1 µg template RNA diluted in 11 µl nuclease free H20. This mix
was then incubatedat 65 °C for 5minutes, followedby2minutes of incubationon ice. Then8µl of themastermix
containing 4µl RT-buffer, 2µl dNTPMix(10 nM), 1µl RiboLock and 1µl reverse transcriptasewas added. Negative
controls were carried out lacking the reverse transcriptase. Mixes were incubated at RT for 5 minutes, followed
by 1 hour at 42 °C and 70 °C for 5minutes. cDNAwas stored -20 °.
2.6.3 qPCR
qPCR was carried out on either the Applied Biosystems StepOne™Real-Time PCR System (96-well plates) or the
Biorad CFX384™Touch Real-Time PCR Detection System (384-well plate format) using SYBR™GreenMaster Mix
(Applied Biosystems, 4309155). Each reactionwas done in a 10µl volume and consisted of 5µl SYBR™GreenMas-
terMix, 0.2µl of both forward and reverse primer (10µM)and0.6 nuclease freeH20µl and4µl of cDNA (1:1000).
Plateswere spun down for 5minutes at 300 rpm, and the following protocol was applied: Initial 95 °C for 10min-
utes followed by 40 cycles of 15 seconds at 95 °C and 30 seconds at 60 °C. After the amplification reaction was
finished, amelting curve analysis was carried out. Temperature was ramped up from 60 °C to 90 °C by 0.5 °C per
minute to verify proper and consistent dissociation of the primer.
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2.6.4 Data analysis
Differential gene expression was calculated by the 2 -∆∆ CT method (Livak and Schmittgen, 2001). Target levels
werefirst normalized to internal levels of beta actin andRpl0 then to a indicated control. Datawas automatically
analysed by a self-written python script.
2.7 Crystal violet staining
After respective treatment, cellswere trypsinised and counted. 100 cells per 6well platewere seeded andplaced
in the incubator for 10 days. Then, cells were washed two times with cold 1xPBS and subsequentyl fixed with
ice-cold 100%methanol for 10minutes. After fixation, cells were incubated in 0.5% crystal violet solution (500
mg crystal violet, 25mlmethanol, 75ml destWater) for 10minutes. Next, cellswashed repeatedly, until no dye is
coming off. Then, single colonieswere counted by eye using a cell counter, and images on a tabletopmicroscope
were taken.
2.8 Single cell laser-tag
2.8.1 Cell Tagging
One day before the experiment, the cells were seeded on 35mmglass bottomdishes with a grid (ibidi, 81166) or
8-well plastic bottom chambers with an engraved grid (ibidi, 80826-G500). Cell were incubated in 0.04 mg/ml
biotin-4-fluorescein (B4F) (SigmaAldrich, B9431-5MG) dissolved inmediumand subsequently illuminated. The
region of interest was imaged using the 473 nm laser at the confocal microscope and the laser intensity set to
100% for 30 seconds. The focal plane was set near the top membrane of the cell. After illumination, the cells
werewashed 5 timeswithwarmPBS to remove unbound B4F and resupplementedwithmedium.
2.8.2 Fluorescent cell labelling
The cells were tagged with B4F as described in chapter 4.8.1 and subsequently incubated in 0.05 mg/ml Alexa-
488-Strepatavidin (Thermo Fisher, S11223) for 15 min at 37 °C and 5% CO2 to stain tagged cells. The cells were
thenwashed again 5 timeswithwarmPBS before imaging.
2.8.3 Selective detachment of non-activated cells
The regionof interestwas taggedasdescribed in in 4.8.1. Then cellswere rinsedoncewithwarmPBSand treated
with 1:1 diluted 0.05% Trypsin-EDTA. Dilution was done in PBS. Cells were incubated in the incubator for 8min-
utes. Then, untagged cells were detached by gently shaking the dish in a circular motion. The remaining cells
werewashed twice very gently withmediumbefore imaging.

3 Results
Due to complexity of the network regulating p53 and its high sensitivity towards stress, experimentally investi-
gating p53 can be challenging. To overcome limitations of indirect or harsh experimental set ups, we set out to
use optogenetic approaches to allow precise perturbation of p53 in the absence of upstream stress or unspecific
activation. Both approaches aim at deciphering how p53 transcription dynamics are decoded into a specific gen
transcription program, and thus the intended phenotype. In section 2.1, I describe optogenetic approaches to
control endogenous levels of p53 by aiming at blocking Mdm2 binding to p53, thus impeding p53 degradation.
In section2.2 and2.3 I explainhow Iuseoptogenetic tools to control nucleocytoplasmic translocation as ameans
of controlling p53 transcriptional activity. To this end, I employed two different strategies, first I used LINuS to
control import of p53 (section 2.2), then LEXY, to manipulate export of p53 (section 2.3). For data obtained by
others, their names are indicated in the respective figure legends and in corresponding paragraphs.
3.1 Light-mediatedmanipulation of endogenous p53 levels
3.1.1 Photocaging theMIPpeptide in theAsLOV2domain
3.1.1.1 Preliminarywork by others
Prior to the start of this work, several students working in our lab tried to achieve light-meditated control of p53
degradation as a means to control its levels, using different strategies. While p53’s activity is mainly controlled
by Mdm2 and MdmX, p53 protein levels are regulated only by Mdm2, which binds to a motif present in p53’s
N-terminal TAD and subsequently ubiquitinates lysine residues on the p53’s C-terminus, ultimately causing the
degradation of p53 (Wu et al., 1993; Haupt et al., 1997). Controlled interruption of this feedback, should allow
adjustable fine-tuning of p53 levels.
As overexpression of Mdm2, a phenomenon commonly observed in cancerous cells, abolishes p53’s ability to
induce cell cycle arrest or apoptosis in cells (Chen et al., 1996), reducingMdm2 activity towards p53 is a potential
therapeutic target in oncology. Several small-molecule inhibitors disrupting this interaction have been devel-
oped or are in current clinical trials (Wang et al., 2017). Some promising candidates are proteinogenic peptides.
Initially, former Bachelor student JanMarcel Smykalla, fused the p53 N-terminal TAD1 to the AsLOV2 domain
C-terminus, generatingwtLOV-TAD.Bydoing so, hehypothesized the tight interactionbetween the Jα-Helix and
the AsLOV2 domain core in the non-active dark state would sterically hinder accessibility of the TAD attached
to its C-terminus. Blue light illumination allows controlled, reversible exposure of the C-terminal TAD and thus
permitMdm2 binding. Yet, initially results obtained in yeast were contradictory.
AsecondstrategywasappliedbyBachelorstudent JanMarcelSmykallaandMasterstudentChristianScheeder,
who employed the TULIP approach(Strickland et al., 2012). Rather then fusing p53’s whole functional domain to
the AsLOV2 domain, a small bioactive peptide was fused to two C-terminal AsLOV2 truncations. Due to the re-
duced size of the C-terminally attached sequence, the photocaging should be facilitated. Additionally, bioactive
peptidesusuallypossess ahigheraffinity towards the itwasdesigned tobind to than theendogenous interaction
partner.
Initially, they selected the pDI peptide (peptide Dual Inhibitor, sequence: LTFEHYWAQLTS), a peptide that
blocks interaction with both Mdm2 andMdmX (Hu et al., 2007a). Yet, initial results in yeast could not demon-
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strate any diminished interaction of p53 andMdm2. Next, they selected the Mdm2 inhibitory peptide (MIP, Se-
quence: PRFWEYWLRLME),which has proved to be very efficient in disruptingMdm2’s binding to p53 (Shiheido
et al., 2011). The peptide was fused to two different truncations of the As LOV2 domain, register 4 (Reg4) and
register 5 (Reg5), truncated at I539 andD540 respectively (Figure 3.1A).
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Figure 3.1: Evaluation of effect of photocagedMIPpeptide onp53 levels inMCF7
A | Depiction of design strategy ofMIP constructs. Mdm2 inhibitory peptide (MIP)was fused to either I539 yield-
ingconstructReg5-MIPorD540generatingReg4-MIP.The3Apeptide is a controlpeptide supposedlynotbinding
Mdm2.
B | Western Blot of p53 levels. MCF7 cells were transfectedwith the indicated constructs. 24 hours post transfec-
tion, cells were illuminated for 24 hourswith blue light for 5 seconds every 20 seconds. Controls were kept in the
dark. Subsequently, cells were lysed, blotted and stainedwith the indicated antibodies.
Experiment carried out by Christian Scheeder.
Initial experiments in yeast carried out by JanMarcel Smykalla and Christian Scheeder showed promising re-
sults. In yeast, transformedMdm2andp53 exhibit co-localisation, unless the interaction is inhibited (Di Ventura
et al., 2008). Both constructs, Reg4-MIP and Reg5-MIP showed a light-controlled disassociation of Mdm2 and
p53 (data not shown).
To verify these results in mammalian cells, Christian Scheeder cloned both Reg4-MIP and Reg5-MIP inmam-
malianexpressionvectorsandexpressed theconstructs inMCF7cells. Onthenextday, cellswereeither subjected
toblue light, or kept in thedark. To limit phototoxicity, lightwas applied for 5 seconds every 20 seconds. Endoge-
nous p53 levels were determined byWestern Blot (Figure 3.1B).
Both samples expressing theMIP peptide fused to different truncations of the AsLOV2 domain exhibited ele-
vatedp53 levels uponblue light stimulation (Figure 3.1B). Curiously, the supposedly non-functional Reg5-3A also
affected p53 levels to a similar extent than Reg4-MIP. Yet, asmock transfected cells did not differ in their p53 lev-
els, the elevation of p53 throughout the other sampleswas likely not due to blue light exposure. When Chrisitan
Scheeder repeated the experiment, the observed increase in p53 levelswas even stronger (data not shown) com-
pared to samples expressing Reg5-3A, yet a mock-transfected control was missing. These results suggest that
theMIP peptide can be used to control p53-levels in a light-mediatedmanner, yet the observed effect has been
variable.
3.1.1.2 Characterisation of theMIPpeptide inMCF7 cells
I beganworkingon this project by independently reproducing the results obtainedbyChristian Scheeder. To this
end, I repeated the experiment in the exact fashion as carried out by Christian Scheeder. Contradictory to his re-
sults, I could not observe an increase of endogenous p53 levels as observed by Christian (Figure 3.2AB). Through-
out the experiments, p53 levels seemed to be constant, implying that the constructs do not impact p53 levels.
Throughout all replicates, the transfection efficiencywas the sameand similar to those indicatedbyChristian.
I also resequenced theplasmids, to excludeunlikelymutationsdue to repeated freeze-thawcyclesof theDNA. In
general, if constructs carried afluorescentmarker, usuallymCherry, the transfection efficiencywas verified prior
to cell lysis using afluorescence table topmicroscope. If thefluorescent signal or the number of fluorescent cells
was lower than the levels usual achieved with transfection, or cells seemed to be too stressed after transfection,
the experiment was aborted.
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Even though the inhibition ofMdm2binding to p53 shouldhave an integrative behaviour,meaning the longer
the binding is inhibited, the more p53 should accumulate, I reasoned to measure p53 at different time points.
In stressed cells, p53 and Mdm2 protein levels display a negative feedback loop behaviour. They are oscillating
with a certain offset, as p53 induces Mdm2 expression, which subsequently promotes p53 degradation. Thus, I
decided to take time points at 3, 6, 12 and 24 hours, and evaluate p53 levels.
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Figure 3.2: Re-evaluating the light-dependedeffect of thephotocagedMIPpeptide onendogenousp53 levels
A| ExemplaryWesternBlotofp53 levels. MCF7cellswere transfectedwith the indicatedconstructs. 24hourspost
transfection, cellswere illuminated for24hourswithblue light for 5 secondsevery 15 seconds. Controlswerekept
in the dark. Subsequently, cells were lysed, blotted and stainedwith the indicated antibodies.
B| Quantification of relative p53 expression levels of A. p53 levelswerefirst normalized to beta actin, then to the
mock-transfected, non-illuminated sample (mean± SD, n=3).
C | Exemplary behaviour of oscillatory p53 expression in stressed cells and indication of selected time points.
D | Quantification of relative p53 levels corresponding to C. MCF7 cells were transfected with the indicated con-
structs. 6hourspost transfection, cellswere illuminated for the indicated timingswithblue light for 5 secondsev-
ery 15 seconds. Controlswerekept in thedark. Subsequently, cellswere lysed, blottedandstainedwithbetaactin
andp53antibodies. p53 levelswerefirst normalized tobetaactin, then to themock-transfected, non-illuminated
sample at time point 0 h (mean± SD, n=3).
To this end, I transfected MCF7 cells with either a stuffer DNA or Reg5-MIP, the construct which showed the
highest elevationof p53 levels in the results presentedbyChristianScheeder. Similar to theprevious experiment,
the p53 levels were comparable throughout the samples and individual replicates. As p53 levels did not increase
upon blue illumination, it appears that the peptide itself is either caged, and thus not accessible for Mdm2, or,
the p53-Mdm2 axis inMCF7 cells is less susceptible for interruption.
3.1.2 Characterisation of theMIPpeptide inHCT116 cells
The MIP peptide has been identified in a two-stage mRNA display and has been demonstrated to successfully
inhibit p53-Mdm2 interaction in the human colon cancer cell line HCT116, a cell line widely used in p53 research
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(Shiheido et al., 2011).
To investigate the peptide’s functionality in HCT116, I expressed Reg4-MIP and Reg5-MIP in HCT116 cells and
exposed the transfected cells to blue light to analyse changes in p53 levels. To asses p53 levels upon stimulation,
control sampleswere treatedwithNutlin-3. Nutlin-3 is a smallmolecule inhibitor binding toMdm2and thereby
abolishing its control over p53 levels (Vassilev et al., 2004). Our peptide approach resembles nutlin-3 treatment,
as both inhibit p53 degradation by competingwith p53 forMdm2 binding.
Similarlyas inMCF7cells, I couldnotobservea light-induced increase inp53 levelsuponblue light illumination
(Figure 3.3AB). p53 levels in samples transfectedwithMIP constructswere constant inboth, darkand illuminated
conditions, as well as mock-transfected samples, arguing that MIP is not able to bind to Mdm2. On the other
hand, samples treatedwithNutlin-3 exhibited an approximately 9-fold increase in endogenous p53 levels, inde-
pendent of blue light illumination. Thus, HCT116 cells are sensitive to inhibition of the p53-Mdm2 interaction,
yet the photocagedMIP constructs can not exert this inhibition.
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Figure 3.3: Characterisation of theMIPpeptide inHCT116 cells
A | ExemplaryWestern Blot of p53 levels in HCT116 cells. HCT116 cells were transfected with the indicated con-
structs. 24 hours post transfection, indicated samples were treated with 8µMNutlin-3. Then, cells were illumi-
nated for 24 hours with blue light for 5 seconds every 20 seconds. Controls were kept in the dark. Subsequently,
cells were lysed, blotted and stainedwith the indicated antibodies.
B| Quantification of relative p53 expression levels of A. p53 levelswerefirst normalized to beta actin, then to the
mock-transfected, non-illuminated sample(mean± SD, n=3).
C | Western Blot of p53 levels. HCT116 cells were transfected with the indicated constructs. 24 hours post trans-
fection, cells were illuminated for 24 hours with blue light for 5 seconds every 15 seconds. Controls were kept in
the dark. Subsequently, cells were lysed, blotted and stainedwith the indicated antibodies.
D| Design strategy to facilitate peptide administration into cells. Peptideswere introduced in E. Coli thioredoxin
scaffold in between G33 and P35 (Hu et al., 2007a).
E | ExemplaryWestern Blot of p53 levels. HCT116 cells were transfected with the indicated constructs. 36 hours
post transfection, cells were lysed, blotted and stainedwith the indicated antibodies.
F | Quantification of relative p53 levels of E. p53 levels were first normalized to beta actin, then to the mock-
transfected sample(mean± SD, n=3).
As there is thepossibility that theMIP isbinding toMdm2, yet thenumberof correctly foldedMIPmolecules is
not sufficient to pass a potential threshold causing observable alterations in p53 levels, I transfected either twice
(500 ng) or eight times (2000 ng) the amount of Reg5-MIP inHCT116 cells, and exposed the cells to blue light for
24 hours (Figure 3.3C). Even though expression of themCherry transfectionmarker was clearly stronger than in
previous experiments, the p53 levels remained unchanged. Apparently, also excessive amounts of MIP-Reg5 do
not impactMdm2’s control over p53. Mock-transfected cells exhibit the same level of p53 than those transfected
with Reg5-MIP, so either the MIP peptide is not properly folded or sterically inaccessible. Otherwise, this would
suggest that, contrary to the reported results, MIP does not have an impact on p53 levels in vivo (Shiheido et al.,
2011).
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Next, Iwanted to excludemissfoldingor sterical hindrance as a causeof the apparent lack ofMdm2 inhibition.
Thus, I reconstructed the plasmids used by Shiheido et al. to demonstrate the functionality in HCT116 cells (Shi-
heido et al., 2011). As peptides can not be easily added to the cell culturemedia, theMIP peptidewas cloned in a
freely accessible loop of E. coli thioredoxin, in between G33 and P35 and aN-terminalmCherry, yielding the con-
struct trx-MIP (Figure 3.3D). Due to its small size and hight stability, thioredoxin is a perfect scaffold, providing a
platform that can present bioactive peptides within a cellular environment (Böttger et al., 1997).
Shihedoandcolleaguesusedaviral transductionsystem, incontrast to thechemical transfectionmethodused
here, to introduce the constructs into HCT116 cells, so it is hard to compare the actual amount of construct ex-
pressed within cells. Thus, I transfected 2000 ng of trx-MIP, and incubated cells for 48 hours to ensure sufficient
amount and time for perturbation of the p53-Mdm2 axis. Yet, in contrast to the published results, I could not
observe any changes in p53 levels 24 hours after transfecting trx-MIP (Figure 3.3EF).
Taken these results together, it appears that I can not reproduce the proposed bioactive function of the MIP
peptide, therefore I stoppedworkingwith this peptide.
3.1.3 Employing endogenous p53 sequences to enable light-mediatedMdm2 inhibition
3.1.3.1 Photocaging the p53-Mdm2binding interface
Since the MIP peptide did not show any functionality in any experiments done by myself, I decided to use p53’s
endogenous sequences, which are bound by Mdm2 to block p53 activity and subsequently induce its degrada-
tion. Here, I use the AsLOV2 domain to expose the endogenous binding interface in a light-dependent manner.
This endogenous binding interface (sequence: TFSDLWKLL) is located at amino acid position 16-28 of p53’s TAD1
(Figure 3.4A) (Kussie et al., 1996). It has been shown in in vitro studies, that this isolatedpeptide itself is sufficient
to bindMdm2, even when it is out of its natural structural context within the p53 TAD (Shiheido et al., 2011). As
residues next to the binding interface can contribute to binding conformation, I fused the endogenous binding
interface in4differentversions, differing inneighbouringaminoacid residuesadded, to theAsLOVdomains I539,
generating the constructs Reg5-enBI 1-4 (Figure 3.4A).
Blue light exposure did not result in any observable elevation in p53 protein levels. As samples transfected
with Reg5-enBI1-4 are comparable to the mock-transfected cells, either the sequence is caged too tightly, also
in the lit-state, or the sequence itself is not in the correct conformation to allow binding to Mdm2. As the three
dimensional structure is often determined by the surrounding residues and their secondary and tertiary struc-
ture, it is not surprising, that solely the endogenous binding interface is not sufficient in resembling the correct
structural arrangement, and an interaction in vitro cannot fully recapitulate in vivo kinetics. However, as a control
of the effect of the peptide itself is missing, it remains unclear whether the lack of effect on p53 levels is due to
the peptide itself, or too tight caging even in the lit-state.
3.1.3.2 Photocaging p53’s transactivationDomain
To acknowledge the structural impact of the neighbouring amino acids and allow the formation of the correct
three dimensional structure and thus allow binding to Mdm2, I fused the whole TAD of p53 to the AsLOV2 do-
mains C-terminal Jα-helix. Fusing the whole domain, I wanted to achieve light-mediated sterical hindrance of
access to the binding-interface, and so controlMdm2 binding based on illumination conditions. As described in
chapter 1.3.3.1, this common optogenetic approach employs structural rearrangement that the AsLOV2 domain
undergoes uponblue photon absorption. This response is obtainedby fusing the protein of interest C-terminally
to theAsLOV2domain. In the dark state, the fused protein domain is supposedly tightly caged to theAsLOV2do-
mains core, while blue light activation results in exposure of the fused protein and its accessibility for interacting
partners (Wu et al., 2009).
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Figure 3.4: Photocaging the endogenous Mdm2-
binding site of p53
A | Design strategy of constructs. The endoge-
nous Mdm2-binding site (enBI) of p53 was fused to
I539 of AsLOV. Different combinations of adding the
amino acids next to the endogenous binding site
were tested.
B| ExemplaryWesternblot of p21 levels upon trans-
fectionof constructsdepicted inA.HCT116 cellswere
transfected with the indicated constructs. 24 hours
post transfection, cellswere illuminated for24hours
with blue light for 5 seconds every 15 seconds. Con-
trols were kept in the dark. Subsequently, cells were
lysed, blotted and stained with the indicated anti-
bodies.
C | Quantification of relative p21 levels of B. p21
levels were first normalized to beta actin, then to
the untransfected, non-illuminated sample at time
point 0h (mean± SD, n=3).
In this case, the exposed p53’s TAD acts as a bait for endogenousMdm2 and thereby disrupting proper degra-
dationof p53. As I539 of theAsLOV2 is crucial for the recovery from lit to thedark state, truncating this aminoacid
residue results in a virtual permanent lit state (Harper et al., 2004), thus serving as a positive control.
To verifywhether this approach is suitable for controllingp53 levels, I fused thep53-TAD (AA 1 - 63) to different
truncations of thewt AsLOV2 domain, starting at N538 until P547, generating 539-TAD, with numbers indicating
the site of TAD attachment (Figure 3.5A). Next, these constructs were transfected into HCT116 cells, and one day
after transfection, cells were exposed for 24 hours to blue light. I selected p21 levels as a readout, as they should
reflect the impact on p53 better. BothMdm2 andMdmX interact with p53’s TAD and preventing transcriptional
activity of p53, yet only Mdm2 binding leads ultimately to degradation of p53. Thus, rather than p53 levels, p53
activitymight be effectedmore and act as better read out for the light-mediated effects of the TAD constructs.
In the initial experiments, three constructs with AsLOV2 truncations at 539, 541 and 545 showed slight ele-
vation in p21 levels upon blue light exposure, yet this effect could not be replicated (Figure 3.5BC). Throughout
all transfected samples, p21 expression is quiet homogeneous (Figure 3.5C). No light-induced changes could be
observed, posing the questionwhether this approach isworthwhile pursuing. It has been highlighted, that pho-
tocageable domains are rather found serendipitously, than by rational design (Winkler et al., 2014), but here it
appears rather that exposure of the TAD has not the desired effect, as also the putative positive control 538-TAD
does not exhibit any detectable changes in p21 levels compared tomock transfected cells.
3.1.4 Using thePMI peptide tomanipulate p53 levels light-dependently
3.1.4.1 Characterisation of thePMI peptide in a trx scaffold
Both strategies employingendogenous sequences topromote light-mediatedMdm2binding failed. As theposi-
tive control 538-TAD failed to induce changes in p21 levels, it appears that it is not sufficient to overload cellswith
p53-TAD. Thus, a sequencewith a stronger affinity towardsMdm2 is required.
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Figure 3.5: Photocaging p53’s endogenous transactivation domain.
A | Design strategy of TAD-constructs. p53’s TADwas fused to the C-terminus of the Jα-helix at different trunca-
tions, starting at N538.
B | ExemplaryWestern blot of p21 levels upon transfection of constructs depicted inA. HCT116 cells were trans-
fected with the indicated constructs. 24 hours post transfection, cells were illuminated for 24 hours with blue
light for 5 seconds every 15 seconds. Controls were kept in the dark. Subsequently, cells were lysed, blotted and
stainedwith the indicated antibodies.
C | Quantification of relative p21 levels of B. p21 levels were first normalized to beta actin, then to the untrans-
fected, non-illuminated sample at time point 0h (mean± SD, n=3).
Searching the literature, I discovered several peptides supposedly inhibiting p53-Mdm2 interaction in a supe-
rior manner. Yet, the majority of these consisted partly of non-proteinogenic amino acids (for example: Chang
et al. (2013)) and thus not useful here. The peptide PMI (p53-MDM2/MDMX inhibitor; sequence: TSFAEYWN-
LLSP), appeared to be a promising candidate (Pazgier et al., 2009). PMI supposedly has a higher affinity towards
Mdm2 then both p53’s endogenous binding site and the MIP peptide used in the beginning of my work (Figure
3.6). PMI was identified in a phage display, using the p53-binding domains of Mdm2 and Mdm4. Pazgier and
colleagues only present in vitrodata, sofirst Iwanted to verifywhether thepeptide exerts an impact onp53 levels
in vivo (Pazgier et al., 2009).
To this end, I cloned thePMIpeptide into a thioredoxin scaffold inbetweenG33 andP35 (as described inChap-
ter 2.1.2), generating the construct trx-PMI. This constructwas expressed inHCT116, togetherwith the trx-3Aand
trx-MIP constructs. Cells transfected with trx-PMI exhibited a clear increase in p53 levels 36 hours after transfec-
tion, implying that degradation of p53 is inhibited (Figure 3.6B). As seen in previous experiments, expression of
trx-3A and trx-MIP does not result in an p53 increase. Taken this promisingfirst result, I wanted to verifywhether
I could obtain light-dependent control over peptide accessibility.
To this end, I fused the PMI peptide to truncation of the AsLOV2 domain’s C-terminus, ranging from I539 to
543A, generating the constructs 539-PMI to 543-PMI (Figure 3.6C). These constructs were expressed in HCT116
cells. Onedayafter transfection, cellswereexposedto light for24hoursandsubsequentlyharvestedforanalysing
p53 levels. Unlike expression of trx-PMI, none of the putative light-responsive constructs caused an elevation of
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Figure 3.6: Characterisation of thePMI peptide inHCT116 cells
A | Comparison of amino acid sequences and bioactivity of employedMdm2-p53 inhibitory peptides and a con-
trol. One plus sign equals approximately one order ofmagnitude.
B | Western Blot of effect of PMI peptides on p53 levels. HCT116 cells were transfected with the indicated con-
structs. 36 hours post transfection, cells were lysed, blotted and stainedwith the indicated antibodies.
C | Design strategy of constructs to photocage the PMI-peptide. PMIwas fused to the C-Terminus to various sites
on the C-terminus of the AsLOV domain starting at I539.
D| WesternBlot of effect of constructs shown inConp53 levels. HCT116 cellswere transfectedwith the indicated
constructs. 24 hours post transfection, cells were illuminated for 24 hours with blue light for 5 seconds every 15
seconds. Controls were kept in the dark. Subsequently, cells were lysed, blotted and stained with the indicated
antibodies.
E | ExemplaryWestern Blot of effect of PMI peptides on p53 levels. HCT116 cells were transfected with the indi-
cated constructs. 0.5 µMDaunorubicin was applied 8 hours after transfection. 32 hours post transfection, cells
were lysed, blotted and stainedwith the indicated antibodies.
F | Quantification of relative p53 expression levels of E. p53 levels were first normalized to beta actin, then to the
mock-transfected sample (mean± SD, n=3).
p53 levels upon illumination (Figure 3.6D). As p53 levels remain constant throughout all samples, it appears that
Mdm2 can not bind the peptide, neither in the dark nor the lit state due to too tight caging and thus sterical hin-
drance.
Next, I wanted to investigate the in vivo function PMI further. First, I sought to compare the effect of PMI on
p53 target gene p21 to overexpression of p53 itself and addition of the DSB-inducing drug Daunorubicin. Addi-
tionally, I examinedwhether the effect of PMI is dependent on its localisationwithin the cell, so I added either a
NLS or a NES to the trx-PMI construct, yielding trx-NLS-PMI and trx-NES-PMI. Moreover, I explored whether the
trx-scaffold is necessary as a scaffold, or if it is possible to just fuse PMIN-terminally tomCherry, separated by ei-
ther one or two GGS-linker and aNLS to ensure nuclear localisation, yielding constructs 1xGGS-PMI and 2xGGS-
PMI. Transfected HCT116 cells were incubated for 36 hours, an untransfected sample was treated with 0.5 µM
Daunorubicin for 24 hours before cells were lysed tomeasure p21 levels.
Overexpression ofwild type p53 led to a two-fold increase in p21 levels (Figure 3.6EF), a similar elevation is ob-
served in samplesoverexpressingp53-NLS. In theabsenceofany localization tag, p53 remainsnuclear, explaining
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the similarity of the response. In contrast, p53-NES is largely cytoplasmic, and thusdoesnot exhibit any elevation
inp21 levels. Interestingly, not onlywas the effect of exposure of PMIonp21was stronger than solely overexpres-
sion of p53, it is apparently also dependent on a nuclear localisation. This supports the hypothesis that Mdm2
binds p53 in the nucleus and guides its nuclear export eventually leading to the degradation of p53 (Freedman
and Levine, 1998).
p21 levels exhibited a three-fold change in cells transfected with PMI-mCherry, showing that the trx-scaffold
is not necessary to present peptides to a cellular environment. In general, it appears that inhibition of p53 degra-
dation is more effective way in increasing p21 expression than plainly overexpressing p53. This might be due to
thenegative feedback loop, overexpressionofp53 causesalsoan increasedproductionofMdm2andMdmX, thus
compensate for the elevated p53 levels. Treatment with 0.5 µMDaunorubicin causes an approximately 3.3 fold
increase, which goes in linewith previously reported results (Seoane et al., 2002).
PMI exerting almost the same level of p21 activation asDaunorubicin treatment, with being highly specific to
the p53-Mdm2 axis and putatively causing less side effect than drug treatment, is a very promising result. Next,
I wanted to control the localisation of PMI light-dependent to switch degradation on and off.
3.1.4.2 Light-mediated import of PMI-LINuS
As the function of PMI is dependent on its localisation, I decided to use LINuS to control its nuclear import in a
light-dependent fashion. LINuS is a small versatile tag to reversibly control nuclear import for any kindof protein
(Niopek et al., 2014). LINuS consists of the AsLOV2 domain with a C-terminally attached synthetic NLS (Figure
3.7A). Visualisation and tracking of the localisation is achieved by an mCherry fused to the AsLOV2 domain. An
additional Pkit NES supports a more cytosolic localisation prior to illumination. LINuS is a modular tag, and a
wide range ofNESs andNLSswith differing strengths canbe chosen to optimize the localisation of the protein of
interest.
I selected three LINuS versions, differing in their initial localisation and the nuclear accumulation after illumi-
nation inHek293 cells (Figure 3.7B). PMIwas fusedN-terminally tobiLINuS02, 09and22, creating the respective
constructs (Figure 3.7A). HCT116 cells were transfected with the PMI-LINuS constructs, and then either exposed
toblue light for 24hoursor kept in thedark todeterminep21 levels after activation. Inparallel, initial localisation
and light-induced translocationwas examined on the confocalmicroscope.
A general nuclear accumulation of PMI-LINuS constructs could not be observed in HCT116 cells (Figure 3.7C).
Somesinglecells respondedtoblue lightbyshowinganelevated levelofnuclear signal,while themajorityof cells
did not exhibit any change in localisation of the fluorescent signal. Interestingly, initially cellular distribution of
PMI-LINuSconstructs inHCT116cellsdifferedto thoseobserved inHek293cellsexpressingLINuSvariants lacking
PMI. Forexample, biLINuS02hadaevenlydistributedsignal inHek293cells, yetPMI-LINuS02wasmorecytosolic
in HCT116 cells. Additionally, biLINuS02 had the strongest nuclear signal of all tested LINuS versions in Hek293
cells, but PMI-LINuS exhibited the weakest in HCT116 cells. Whether this is due to the attachment of the PMI
peptide, or due to cell-type specific variation remains tobe seen. The lack of nuclear accumulationof PMI-02and
PMI-22 could also be observedwhen analysing p21 expression upon blue light illumination (Figure 3.7D).
While PMI-02 and PMI-22 transfected cells exhibited a mild increase in p21 levels compared to the mock-
transfected sample, samples expressing PMI-09 showed a stronger increase in p21. Yet, nuclear levels of PMI-
09 after activation appeared to be only mildly elevated, compared to the other constructs. This suggests that
a certain threshold of nuclear abundance has to be passed, that PMI-LINuS can exert a biological function. Ap-
parently, LINuS accumulation is either impaired by PMI, or HCT116 cells in general have a low potential dynamic
range using LINUS, thusmaking the systemnot useful in our case.
38
CHAPTER 3. RESULTS
A
biLINuS02GGSPMI
biLINuS09GGSPMI
biLINuS22GGSPMI
PMI_02
PMI_09
PMI_22
PM
I_2
2
PM
I_0
9
PM
I_0
2
M
oc
k
light - + +- +-+-
MW [kDa]
21 kDa
42 kDa
p21
beta 
ac�n
Before
A�er
PMI_09 PMI_22PMI_02
D
BeforeNES mCherry AsLOV2 NLS
LINuS
A�er
biLINuS02 biLINuS09 biLINuS22
B
Before
C
BeforemCherry
BeforemCherry
BeforemCherry
Figure 3.7: Using LINuS to control PMI localization by blue light
A | LINuS is a small tag consisting of anNES,mCherry and a AsLOV2 domain photocaging an engineeredNLS of
varying strength. Three LINuS versions differing in their initial cytoplasmic nuclear localization and strength of
nuclear accumulation upon blue light activationwere selected for generating PMI_LINuS constructs.
B | Representative images of the three selected LINuS candidates lacking PMI inHEK293T cells before and after
15 minutes of activation. 24 hours post transfection, cells expressing the indicated constructs were illuminated
for 1 second every 30 seconds. Adapted fromNiopek et al. (2014). Scale Bar=15µm.
C | Representative fluorescence images of HCT116 cells expressing the indicated constructs from A before and
after activation. 24 hours post-transfection, cells expressing the indicated constructs were illuminated for 5 sec-
onds every 30 seconds. Scale Bar=20µm.
D|WesternBlotofeffectsofPMI-LINuSconstructsonp21 levels. HCT116 cellswere transfectedwith the indicated
constructs. 24 hours post transfection, cells were illuminated for the indicated timewith blue light for 5 seconds
every 15 seconds. Controls were kept in the dark. Subsequently, cells were lysed, blotted and stained with the
indicated antibodies.
3.1.4.3 Optogenetic control of PMI-LEXY
In contrast to LINuS, LEXY is a optogenetic tool tomediate light-dependent nuclear export (Niopek et al., 2016).
Insteadof aNLS, it exposes aNES in response to light (Figure 3.8A). LEXYhasbeen shown towork right awaywith
awide rangeofproteins. However, the initialnuclear localisationcanbeproblematic, if thepeptide/protein fused
to LEXY exerts its function in the nucleus. This can be addressed by blue light administration after transfection,
yet it increases theoverall illumination times and thus increases phototoxicity. Nonetheless, I fusedPMI and two
linker sequences differing in their length to theN-terminus of LEXY, thereby creating PMI-1xGGS-LEXYandPMI-
2xGGS-LEXY. Then, I expressed PMI-2xGGS-LEXY in HCT116 cells to observe initial localisation and evaluate its
response to blue light.
The initial florescent signal was visible throughout the cells, yet strongest in the nucleus (Figure 3.8B). To ob-
serve thepotential reaction toblue light, I exposedcells expressingPMI-2xGGS-LEXYtoblue light for40minutes.
After the activation, nuclear intensitywas strongly reduced in themajority of cells, with a lownumber of cells ex-
hibiting onlyminor changes in nuclear intensity or no reaction at all.
To verify the recoverypotential ofPMI-2xGGS-LEXY, I subjected cells to twoactivation/recovery cycles (40min-
utes either in the dark or illuminated, total cycle time: 80minutes) (Figure 3.8BC). HCT116 cells could repeatedly
translocate PMI-2xGGS-LEXY into the cytosol and back upon blue light activation or inactivation, respectively.
The relative nuclear intensity dropped to 36%, and reverts back to the initial values.
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Figure 3.8: Using LEXY to control PMI translocation by light
A | LEXY is a small tag consisting of an NLS, mCherry and a AsLOV2 domain photocaging an engineered NES of
varying strength. PMIwas fused to LEXY yielding PMI-LEXY constructs differing in the length of their linker.
B | Representative images of HCT116 cells expressing PMI_1xGGS_LEXY repeatedly activated for 40minutes. 24
hours post transfection, cells were illuminated for 5 seconds every 30 seconds. In between activation periods,
cellswere not exposed to blue light. ThemCherry channelwas imaged every 30 seconds during activation cycles,
and every 5minures during recovery. Scale Bar=20µm.
C | Quantification of relative nuclear intensity of B. Nuclear intensity over timewas normalized to initial nuclear
intensity (mean± SD, n=23).
D| ExemplaryWesternBlot of effect of PMI-LEXYonp53 levels. HCT116 cellswere transfectedwith the indicated
constructs and immediately exposed to blue light. 24 hours post transfection, cells were either illuminated for
24 hours, or not. Then cells were lysed, blotted and stainedwith the indicated antibodies.
E | Quantification of relative p53 expression levels ofD. p53 levelswerefirst normalized to beta actin, then to the
illuminatedmock-transfected sample (mean± SD, n=3).
F | ExemplaryWestern Blot of effect of PMI-LEXY on p53 levels. HCT116 cells were transfectedwith the indicated
amountof the respective constructsand immediatelyexposed toblue light. 24hourspost transfection, cellswere
either illuminated for 24 hours, or not. Then cells were lysed, blotted and stainedwith the indicated antibodies.
G | Quantification of relative p21 expression levels of F. p53 levelswere first normalized to beta actin, then to the
illuminatedmock-transfected sample (mean± SD, n=3).
As seen in other experiments, nuclear export appeared to bemore rapid than the import. Half-life of nuclear
export, meaning the time it takes for half of the final translocation to occur, was 93 s± 18 s. In contrast, nuclear
import toolmore than 4 times as long, namely 397.7 s± 21 s.
Noteworthy, the achieved reduction of the relative nuclear intensity in the second activation period is slightly
lower compared to thefirst activationperiod. As the intensitywas also stronger after the second recovery period,
this is likely due to continued expression of PMI-2xGGS-LEXYduring imaging. This suggests, that afixed fraction
of construct can be exported.
Next, I wanted to see, whether cells expressing PMI-LEXY exhibit light-dependent differential expression of
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p53 target genep21. To this end, I transfectedHCT116 cellswith either PMI-1xGGS-LEXYor PMI-2xGGS-LEXYand
incubated themover night. Then, I exposed cells to blue light for 24hours andmeasuredp53 andp21 expression.
Even though the translocation into the cytoplasm had appeared to be strong, this did not result in differential
levels of p53 and expression of p21 (data not shown). Expression of p21 levels were equal in cells exposed to light
or not, yet higher than in the mock-transfected control. I reasoned that overnight incubation in the dark, and
thus nuclear PMI-LEXYwas sufficient to increase p53 levels and induce p21 expression.
I repeated the experiment, but blue lightwas already applied immediately after transfection. Cellswere incu-
bated over night and exposed to blue light. On the next day, the dark control was removed from light and placed
in a darkmetal box shielded from light. 24 hours later, cells were lysed and p53 and p21 levels were determined.
Indeed, the applicationof light during transfectionpreventedpremature functionof PMI-LEXY in thenucleus.
Cells expressingPMI-LEXYexposed toblue light exhibited the samep53 levels asmock-transfected samples (Fig-
ure 3.8DE). Yet, samples expressing one of the PMI-LEXY constructs which were removed from the initial blue
light illumination had a three-fold increase in p53 levels. The increase in p53 levels was equal between both PMI
constructs.
As seen in p53 levels, a clear light-mediated change in p21 levels was observable (Figure 3.8FG). While both
mock- and untransfected cells were constant in the p21 levels independent off the illumination condition, both
PMI-LEXYexhibitedanapproximately2.6 fold increase inp21 levelswhennotexposed toblue light. Additionally,
I verifiedeffects on increasedamountof transfected construct. When I transfected twice theamountof construct
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Figure 3.9: Evaluation of recovery potential of PMI_LEXY
A| Illuminationandrecoverypattern fordifferentsamples. All sampleswere transfected (-24h)withPMI-1xGGS-
LEXYor PMI-2xGGS-LEXYand immediately exposed to 24hours of pulsatile blue light (5 seconds, 15 seconds). At
time point 0 h, they received different illumination schemes to evaluate the recovery of p53 levels.
B | Quantification of relative p53 expression levels. HCT116 cells were transfected with the indicated constructs
and immediately exposed to blue light. 24 hours post transfection, cells were exposed to illumination schemes
displayed in A. Then cells were lysed, blotted and stainedwith the p53 andbeta actin antibodies. p53 levelswere
first normalized to beta actin, then to the illuminatedmock-transfected sample (mean± SD, n=3).
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DNA, effects on p21 level seem to be reduced. Especially PMI-1xGGS-LEXY had a severely reduced impact on p21
levels when construct DNAwas doubled.
Thiscorrelationbetweenabundanceofproteins toshuttleandtheir translocationefficiencyhasbeenobserved
in a wide range of experiments using either LINuS or LEXY and is probably caused by an overload of the cellu-
lar import-export machinery. Yet, the reason why p21 expression is weaker in cells transfected with PMI-1xGGS-
LEXY than cells expressing PMI-2xGGS-LEXY remains elusive. Potentially, the length of the linker influences the
translocation efficiency.
One of the main advantages of optogenetic tools based on the AsLOV2 is recovery after blue light activation
into the dark state. As the localisation of PMI-LEXY is reversible (Figure 3.8B), I wanted to verifywhether also p53
can revert back to normal physiological levels once blue light exposure is terminated. To this end, I transfected
HCT116 cells with either PMI-1xGGS-LEXY or PMI-2xGGS-LEXY and exposed them tomultiple light regimes dif-
fering in recovery timings (Figure 3.9A). Subsequently, cells were lysed and p53 levels were analysed.
As previously observed, p53 levels were three-fold elevated when cells were shielded from the light for 24
hours. In general, both constructs exhibited the same behaviour, thus I will refer now only to PMI-LEXY. Sam-
ples protected from light for prolonged periods continued to have high p53 levels (Figure 3.9B).
Cells exposed to light permanently for up to 72 hours did not show any increase in p53 levels, same as mock-
transfected cells. Only cells exposed to blue light for 96 hours have slightly elevated levels of p53. This could be
due to improper retention of PMI-LEXY in the cytosol, caused by increasing levels of PMI-LEXY and problems for
the import-exportmachinery copingwith theworkload, or stress caused due to prolonged blue light exposure.
However, it appears that it is not possible to reverse the effect on p53 levels. Samples expressing PMI-LEXY
shielded from the blue light after the initial exposure for 24 hours, had high levels of p53 independent of time
period theywere re-exposed to blue light. Neither 24hours nor 48hours of recovery is sufficient to lower p53 lev-
els in a visible extent. This in contrast to the previous findings, that PMI-LEXY could be repeatedly and reversibly
translocated between nucleus and cytosol, yet only in shorter time periods.
Taken together, while it is possible to increase endogenous p53 levels in a light-mediated fashion by using
LEXY to control localization of the PMI-peptide, it seems as if p53 levels remain at the high level they exhibit
once PMI-LEXY was nuclear for a certain period of time. Thus, reversibly control of endogenous levels could not
be achieved.
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3.2 Light-controlled nuclear import using LINuS
Translocation of proteins from one cellular compartment to another enables cells to react rapidly to changes in
the environment. Especially transcription factors involved in stress signal pathways are commonly kept dormant
in the cytoplasm, only to get actively translocated into the nucleus upon the necessary signal (Di Ventura and
Kuhlman, 2016).
Here we wanted to mimic this general feature, even though p53’s activity is usually regulated by keeping it
at low levels in unstressed conditions. p53 activation dynamics, defined as the shape of the curve its transcrip-
tionally activity changes over time, have been linked to specific upstream stress signals, as well as to distinct cell
fates (Lahav et al., 2004; Batchelor et al., 2008; Purvis et al., 2012). While it has been established, which factors
shape p53 activation dynamics, it remains unknown how specific activation dynamics are decoded into the ap-
propriate gene expression. Here, we use optogenetic tools to control localisation of p53 by light, making use of
its unmatched spatial and temporal resolution. By assuming that p53 is transcriptionally active once it is in the
nucleus, light-mediated control over translocationwould allowfine-tuning of nuclear abundance and the appli-
cation of temporal dynamics, thus the amplitude and frequency of p53 signalling in the absence of stress.
3.2.1 Characterisation of p53wt-LINuS constructs inH1299
To achieve optogenetic control over p53’s localisation, I decided to employ LINuS. LINuS is a small versatile tag
consisting of the AsLOV2 domain and a synthetic NLS incorporated in its Jα-helix (Figure 3.10A) (Niopek et al.,
2014). Variants of LINuS differing in their C-terminal NLS exhibit contrasting nuclear accumulation. As initial
localisation and accumulation of LINuS is dependent on several factors, including the cell type, the expression
levels, and both, presence of localisation sequences and size of the tagged protein, usage potentially requires
fine-tuning of LINuS and the tagged protein itself.
I selectedH1299 cells as amodel to apply p53 dynamics, since this humannon-small lung cancer cell line lacks
expression of p53 protein due to a homozygous partial deletion of the p53 protein. The absence of endogenous
p53 renders this cell line a goodmodel system, and the cell line has been used in a wide range of studies in the
p53 area.
I selected twoLINuSvariants, biLINuS02andbiLINuS22, and fused these top53wt (Figure 3.10A). Both variants
differ in their localisationprior toblue light illumination, andthedegreeofnuclearaccumulationuponactivation
(see also Figure 3.7B). p53wt itself tagged with mCherry is localised exclusively in the nucleus (data not shown).
Thus I decided to add a constitutive PKit NES to the p53wt-LINuS constructs, to prevent nuclear localisation prior
to activation. I expressed these constructs in H1299 cells and imaged the cells at the confocalmicroscope.
Prior to activation, both constructs localised exclusively within the cytosol (Figure 3.10B). After 40minutes of
blue light exposure, aminor increase in nuclear intensity could be observed within single cells, yet themajority
of transfected cells did not react to blue light. In general, if not specifically mentioned otherwise, light was ap-
plied in light pulses. Periodic light pulses are sufficient to activate AsLOV2, as these pulses are shorter than the
LOV-domains reversion time. Additionally, light pulses reduce light applied to cells, reducing any potential toxic
effect. Pulses of 5 seconds every 30 seconds are considered as constant illumination.
Localisation of proteins appears to be a steady state, yet it is rather an equilibrium of ongoing import and ex-
port. The net localisation of a protein is determined by the presence and strength of NLS and/or NES sequences,
which eventually result in a localisation balance. Here, localisation of the constructs is strongly cytosolic, thus I
decided to remove the constitutive PKitNESon the onehand, and also try theweaker IkbαNES. I expressedboth
constructs in H1299 cells and observed localisation in the absence of blue light. Constructs lacking a constitu-
tiveNESwere exclusively nuclear (Figure 3.10),making blue light activation futile. Adding aweakerNES had the
same effect on localisation of p53wt-biLINuS22, fluorescencewas only visible in the nucleus (data not shown).
On the contrary, p53wt-biLINuS02 localised mostly within the nucleus, yet a cytosolic signal was also observ-
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Figure 3.10: Characterisation of p53wt-LINuS inH1299 cells
A | LINuS is a small tag consisting of the AsLOV2 domain photocaging an engineered NLS of varying strength.
p53wt was fusedN-terminally to a constitutiveNES,mCherry and one of two LINuS versions differing in their ini-
tial cytoplasmic-nuclear localization and strength of nuclear accumulation upon blue light activation, yielding
the constructs p53wt-biLINuS02 and p53wt-biLINuS22.
B | Representative images of the indicated p53wt-LINuS shown inA expressed inH1299 cells before and after 40
minutes activation. 24 hours post transfection cells were illuminated for 5 seconds every 30 seconds using a blue
laser. Scale Bar=20µm.
C | Representative images of the indicated p53wt-LINuS constructs lacking the constitutive NES of LINuS ex-
pressed inH1299 cells. 24hours post transfection cellswere analysedon themicroscope. Due to to initial nuclear
accumulation cells were not exposed to blue light. Scale Bar=40µM.
D | Representative images of p53wt-biLINuS harbouring the weaker constitutive IkbαNES expressed in H1299
cells before andafter 40minutes activation. 24hours post transfection cellswere illuminated for 5 seconds every
30 seconds using a blue laser. Scale Bar=20µm.
able. Even though this initial localisation is unfavoured in my case, due to putative transcriptional activity prior
to activation, Iwanted to verifywhether p53wt-biLINuS02 translocated in response toblue light. Thus, I activated
the sample 40 minutes using the blue laser of the confocal microscope. Indeed, after exposure a clear nuclear
accumulationwas visible inmost of the observed cells. This suggests that LINuS can be used to translocate p53wt
in the nucleus, yet further optimisation on the localisation state prior illumination is necessary.
3.2.2 Impairment of p53’sNES allows nuclear accumulation
So far, the two investigated p53wt-LINuS constructs did not show the desired characteristics of being exclusively
cytosolic before activation, and displaying a nuclear localisation sufficient to induce transcriptional activity. Ma-
nipulationof theconstitutiveNEShadanapparentbivalentbehaviour: either theconstructswere initially cytoso-
lic and remained cytosolic after activation, or exhibited a strong nuclear localisation already prior to activation.
Thus, I decided tomanipulate rather p53’s endogenousNES than theNES fused in between p53 and LINuS.
p53’s localisation is determined by a bipartite NLS sequence, and a C-terminal NES sequence (Figure 3.11A)
(O’Keefe et al., 2003). While p53 possesses functionswithin the cytosol, itsmain task is transcription and thus re-
quires nuclear localisation. TheNES consists of 4 amino acid residues, namelyM340, L344, L348 and L350. M340
and L344 are associated to the hereditary disease Li-Fraumeni, which pre-disposes patients to cancer develop-
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ment (Malkin et al., 1990; Kawaguchi et al., 2005). Thus, I mutated the two leucines at residue 348 and 350 to
alanines and fused p53L348AL350A to biLINuS02 or biLINuS22. Additionally, I added a constitutive NES. Both con-
structs were transfected and subsequently visualised at the confocalmicroscope.
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Figure 3.11:Manipulation of p53’s endogenousNES sequence
A | Schematics of p53 and its localization sequences. NLS sequences are highlighted in green, NES sequences in
red. Adapted fromO’Keefe et al. (2003).
B | Representative images of the indicated p53L348AL350A-LINuS expressed inH1299 cells before and after 40min-
utesactivation. 24hourspost transfectioncellswere illuminated for5 secondsevery30secondsusingablue laser.
Scale Bar=20µm.
C| Representative imagesof thep53L348AL350A-biLINuS22 throughout several activation-recovery cycles. 24hours
post transfection, the same cells were repeatedly subjected to blue light for 5 seconds every 30 seconds for 40
minutes, then left in the dark to recover. Scale Bar=20µm.
p53L348AL350A-biLINuS02 displayed a strong nuclear signal prior to activation (Figure 3.11B). In the majority of
cells expressing the construct, the fluorescent signal was exclusively nuclear. Few cells had evenly distributed
signal. Within these cells, a clear accumulation in the nucleus after 40 minutes of blue light exposure could be
observed.
Most cells expressing p53L348AL350A-biLINuS22 displayed a evenly distributed signal prior to activation (Figure
3.11B). Once activated by blue light for 40minutes, a clear accumulationwas observable.
Toverifywhether thisaccumulationwas reversible, I repeatedlyactivatedthesamefieldofviewfor40minutes
with blue light, followed by 40 minutes recovery intervals during which cells were not subjected to blue light
(from now on referred to as 40 minute activation/recovery intervals). As seen before, p53L348AL350A-biLINuS22
translocates into the nucleus upon activation, yet the nuclear signal remains strong during the recovery periods.
Rather, with every activation period, some cells accumulate the construct even further, or start accumulating it
within thenucleus. Interestingly, somecellsonlydisplayednuclearaccumulation in thesecondor thirdactivation
period, not before. As reversibility is crucial to apply pulsatile p53 dynamics, p53L348AL350A-biLINuS22 had to be
further optimised.
3.2.3 Introduction of compensatorymutations onp53’s endogenousNLS
I reasoned thatboth, initial nuclear localisationandnuclear retentionafterblue lightexposuremightbe reduced
bymanipulating p53’s endogenous NLS sequence. p53 harbours a bipartite NLS, the first stretch consists of a ly-
sine at position 305 and an arginine at position 306. The second part of the p53’s NLS consists of three lysines at
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positions 319, 320 and 321 (Figure 3.12A) (O’Keefe et al., 2003). While thesemutants have been studied already
in the combination with mutations to p53’s NES (Figure 3.11, I wanted to analyse their contribution to localisa-
tion of p53 individually, independent of the NES mutation. To this end, I mutated every individual lysine into
an alanine. Additionally, in one construct, I mutated both K305 and R306. These mutants were created in the
p53L348AL350A-biLINuS22 background. I expressed each construct inH1299 cells, and examined the localisation of
the constructs.
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Figure 3.12:Mutation of p53’sNLS sequence to improve translocation properties
A | p53 posseses two seperatedNLS sequences, here highlighted in green. Adapted fromO’Keefe et al. (2003).
B | Representative images of mutated NLS residues in the p53L348AL350A-biLINuS22 background. H1299 cells ex-
pressing indicated constructs before and after 40minutes activation. 24 hours post transfection cells were illu-
minated for 5 seconds every 30 seconds using a blue laser. Scale Bar=20µM.
C | Representative images of p53K320AL348AL350A-biLINuS22 construct expressed in H1299 cells. 24 hours post
transfection, cells were exposed to blue light for 40 minutes, then continuously imaged for 200minutes in the
absence of blue light. Scale Bar=20µM.
D | Quantification of relative nuclear intensity of cells before activation and during recovery. Nuclear intensity
was normalized to initial values (mean± SD, n=28).
Single and doublemutants of K305 andR306 exhibited the samebehaviour (Figure 3.12B). Prior to activation,
the signal was almost exclusively within the cytosol, yet after 40 minutes of activation, only a minority of cells
had detectable nuclear fluorescence.
LiketheK305andR306mutants,p53K319AL348AL350A-biLINuS22exhibitedanexclusivelycytoplasmicsignal,which
remainedat its initial localisationevenafter activation (Figure 3.12B). p53K320L348AL350A-biLINuS22was faintly vis-
ible within the nucleus of themajority of cells prior to blue light exposure. Upon activation, a clear translocation
was observable, leading to an increased nuclear fluorescence. Yet, a cytoplasmic signal remained, and tended to
have a similar intensity as the nuclear signal.
p53K321AL348AL350A-biLINuS22 exhibited a stronger nuclear intensity before activation (Figure 3.12B). The ma-
jority of cells responded to blue light by accumulating it further in thenucleus. Cells responding to blue light dis-
played a higher nuclear-cytoplasmic intensity ratio as cells transfected with p53K320L348AL350A-biLINuS22. These
findings suggest that the first basic stretch of p53’s bipartite NLS contributesmore to the nuclear localisation of
p53 than the second stretch, as the nuclear translocation appears to be dependent on the integrity of K305 and
R306.
I selected p53K320AL348AL350A-biLINuS22 for further analysis, due to its favourable initial equilibrium, and the
high fraction of cells responding to blue light activation. To verify the reversibility of nuclear accumulation, I
exposed cells expressing the construct to blue light for 40minutes and subsequently tracked the sample in the
absenceofblue light. Aspreviously seen, anuclear accumulationwasobservableafter activation (Figure3.12CD).
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Thenuclear intensity increasedapproximately four-fold (Figure3.12D).Onceblue light isdeactivated, thenuclear
intensity decreased, yet remainedmore than two-fold higher compared to the initial state prior to activation for
40minutes. This suggests that p53K319AL348AL350A-biLINuS22 can translocate back into the cytosol once p53-LINuS
is activated, but only to a certain extent. The initial cytosolic state could not be fully reverted.
3.2.4 Assessment of transcriptional activity of p53K320AL348AL350A
p53K320AL348AL350A-biLINuS22 is thefirstp53-LINuScandidatethat fulfilledthetwomaincriteria requiredtoachieve
light-regulated transcriptional activity of p53. First, p53K320AL348AL350A-biLINuS22was located primarily in the cy-
toplasmprior to activation. Second, the construct could be accumulated in the nucleus.
Iwanted to verify the transcriptional activity of p53K320AL348AL350A-biLINuS22andobserve,whether thep53 tar-
getgenep21wasdifferentiallyexpressed incells subjectedtoblue light. Tothisend, Iexpressedp53K320AL348AL350A-
biLINuS22 inH1299cells andsubjectedcells either to24hoursofblue light, or incubated themina light-shielded
environment.
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Figure 3.13: Evaluation of impact on transcriptional activity of introducedp53mutations
A | ExemplaryWesternblot of p21 levels upon transfectionwith indicated constructs. 24hours post transfection,
H1299 cellswere illuminated for 24hours in thepresenceof blue light (5 seconds/15 seconds). Controlswere kept
in the dark. Subsequently, cells were lysed, blotted and stainedwith the indicated antibodies.
B | Quantification of relative p21 levels of A. p21 levels were first normalized to beta actin, then to the mock-
transfected, non-illuminated sample (mean± SD, n=3).
C | ExemplaryWestern blot of p21 levels upon transfectionwith indicated constructs. 36 hours post transfection,
H1299 cells were lysed, blotted and stainedwith the indicated antibodies.
D | Quantification of relative p21 levels of C. p21 levels were first normalized to beta actin, then to the p53wt
transfected sample (mean± SD, n=3).
Expression of p53wt resulted in a four-fold increase of p21 expression, independent of blue light exposure (Fig-
ure 3.13A, B). On the other hand, p53K320AL348AL350A-biLINuS22 exhibited approximately the same level of p21 ex-
pression as the mock-transfected sample. I reasoned that the lack of transcription can be either caused by an
insufficient amount of nuclear p53, or that the introducedmutationsmight impair the transcriptional activity of
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p53K320AL348AL350A. I decided to first investigate the latter possibility, since the transcriptional activity is essential
for the continuationwith this construct.
I introduced the three individualmutationsK320A, L348AandL350A in thep53wt backgroundand fused them
tomCherry. To ensure nuclear localisation, I added a constitutiveNLS. Then, I expressed the constructs inH1299
cells to verify transcriptional activity of each singlemutant. All introducedmutations decreased p53’s transcrip-
tionalactivity (Figure3.13C,D).TheL350Amutationhadthestrongestnegativeeffectonp53 transcriptionalactiv-
ity, as it caused afive-fold reduction of p21 levels compared top53wt. MutatingK320A resulted in a 50%decrease
in p21 levels. Mutation of L348A reduced p21 levels by 20%.
Compared to p53wt, the transcriptional activity of the triple mutant p53K320AL348AL350A was only slightly more
reduced as the transcriptional activity of p53L350A.
3.2.5 Acetylation-mimickingmutants donot restore transcriptional activity of
p53K320AL348AL350A
Due to the essential functions of transcription factors, their regulation has developed into a highly complex pro-
cess. While regulation at the level of transcriptionor translation takes rather long (minutes tohours), other regu-
latory steps occur in seconds. Particularly post-translationalmodifications such as phosphorylation and acetyla-
tionhavebeendemonstratedto regulate transcription factors, allowingafine-tunedandrapid reactiontostimuli
(Planey et al., 2013).
p53 itself undergoes awide range of post-translationalmodifications. While phosphorylation is rather linked
to stabilisation of p53, acetylation is implicated in regulating p53’s affinity to a subset of target genes, includ-
ing p21 (Meek, 2004; Kruse and Gu, 2008; Tang et al., 2008). This hypothesis is based on in vitro and cell culture
studies; the role of acetylation on the transcriptional activity of p53 has not been established in animal stud-
ies. I thought to stimulate the transcriptional activity of p53K320AL348AL350A by introducing acetylation-mimicking
mutations at the key residues K120, K164 and K165 (see Chapter 1.1.3). K120 is located within the DNA-binding
domain of p53, and its acetylation is supposedly required for transcriptional activity and induction of apopto-
sis (Berns et al., 2004; Sykes et al., 2006; Tang et al., 2006). K164 and K165 have been particularly linked to p21
expression (Tang et al., 2008).
Introductionofaglutamineat these individual sitesmimicsacetylation, thus should stimulatep21expression.
Toverify this idea, I introducedacetylation-mimickingmutations inthep53K320AL348AL350A-biLINuS22background
and expressed the constructs in H1299 cells to verify p21 expression.
Introduction of the acetylation-mimickingmutations did not result in an increase in p21 levels (Figure 3.14A,
B). The mutants were not transcriptionally active, as demonstrated by the fact that p21 levels were as high as
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Figure 3.14: Introduction of acetylationmimickingmutants to recover transcriptional activity
A | ExemplaryWestern blot of p21 levels upon transfectionwith indicated constructs. 36 hours post transfection,
H1299 cells were lysed, blotted and stainedwith the indicated antibodies.
B| Quantificationof relativep21 levelsofA. p21 levelswerefirstnormalized tobetaactin, then to cells expressing
p53wt (mean± SD, n=3).
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those obtained with the negative control (cytoplasmic p53). Notably, according to the literature, loss of acetyla-
tion on one residue can be compensated by acetylation of another site, thus one acetylated site should be suf-
ficient to drive transcription (Tang et al., 2008). As transcriptional activity is mandatory for studying how p53
dynamics regulate the selection of target genes, I stoppedworkingwith this construct.
3.2.6 Characterisation of p53NLSmutants
The initial p53wt-LINuS constructs lacking a constitutive NES had been exclusively nuclear, while the constructs
harbouring a constitutiveNESwere localised in the cytosol (Figure 3.10). Due to previous observations, I decided
against mutating p53’s endogenous NES to prevent impairment of tetramer formation. I reasoned that the net
localisation of p53wt-LINuS constructs lacking a constitutive NES could be shifted towards a more cytosolic lo-
calisation by manipulating p53’s endogenous NLS sequence. Yet, prior to investigating potential translocation
efficiencies of individual p53 NLS mutant-LINuS constructs, I wanted to asses the initial localisation of p53 NLS
mutants to estimate the contribution of individual residues to overall localisation. Additionally, I needed to ver-
ify the transcriptional activity of individualmutants. Todo so, I fusedeachp53NLSmutant tomCherry toobserve
its localisation. Additionally, I fused the p53 NLS mutants to a NLS-tagged mCherry to evaluate p21 expression
(Figure 3.15A).
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Figure 3.15: Characterisation of p53NLSmutants
A| Schematicoverviewoverp53-NLSmutantconstructs cloned. p53mutantswere fusedtoNLS-mCherry toasses
transcriptional activity. Localization of NLSmutants was visualizedwith fusedmCherry.
B | ExemplaryWestern blot of p21 levels upon transfection with indicated NLS-mutant. 36 hours post transfec-
tion, H1299 cells were lysed, blotted and stainedwith the indicated antibodies.
C| Quantificationof relativep21 levels ofA. p21 levelswerefirstnormalized tobetaactin, then to cells expressing
p53wt (mean± SD, n=3).
D | Representative images of the p53NLS-mutants expressed inH1299 cells. Scale Bar=20µM.
E | Quantification of nuclear/cytoplasmic intensity of indicatedNLS-mutants (mean± SD, n=30).
p53K305A, p53K306A and p53K321A were not affected in their transcriptional activity (Figure 3.15B, C). Mutation of
K319 led to a dramatic reduction of p21 expression. This leads to the conclusion, that only the NLS residues K319
and the previously analysed K320 are necessary for p21 expression.
Next, I expressed the p53-NLSmutants fused tomCherry inH1299 cells, and examined their localisation. Mu-
tations in the first basic stretch of p53’s bipartite NLS had severe effects on the localisation of the construct, as
the they led to a cytosolic localisation (Figure 3.15D, E). Mutation of the K319A exhibited a nuclear localisation,
as observed in cells expressing p53wt. Mutation of K321A led to a clear nuclear signal. Some cells also exhibited
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cytosolic fluorescence, yet thenucleus had themost prominentfluorescent signal in all cells. As the contribution
of the first stretch of p53’s bipartite NLS sequence to nuclear localisation appears to be stronger, as well as mu-
tating K305 and R306 did not affect transcriptional activity, I selected the singlemutants K305A and R306A and
the doublemutant K305AR306A to further investigate their potential translocation ability when fused to LINuS
variants.
3.2.7 Nucleo-cytoplasmic translocation of p53-LINuS constructs
LINuS variants differ in the strength of their photocaged NLS. I selected variants with a strong NLS caged in the
AsLOV2, since the selected p53-NLSmutants displayed a strong cytosolic localisation. I fused either biLINuS02,
biLINuS09 or biLINuS11 to each of the three selected p53 NLSmutants p53K305A, p53R306A and p53K305AR306A, and
expressed the constructs inH1299 cells, to observe their initial localisation. Noteworthy, all constructs lack a con-
stitutive NES.
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Figure 3.16: Screening of p53NLSmutant-LINuS variants to investigate their translocation efficiency
A | Representative images of the indicated p53-NLSmutant to the respective LINuS-variant before and after 40
minutes activation. 24 hours post transfection cells were illuminated for 5 seconds every 30 seconds using a blue
laser. Scale Bar=20µM.
B | Quantification of nuclear intensity ration before and after blue light activation of B (mean± SD, n=22).
C | Representative images of p53R306A-biLINuS02 expressed inH1299 cells. 24 hours post transfection, cellswere
exposed toblue light for 40minutes, then continuously imaged for 80minutes in the absence of blue light. Scale
Bar=20µM.
Ingeneral, all p53NLSmutant-LINuSconstructsdisplayednuclearaccumulationafterblue lightexposure (Fig-
ure 3.16A). p53K305A-LINuS constructs exhibited already a strong nuclear fluorescent signal prior to illumination.
Activationwithblue light led toastrongernuclearaccumulation forp53K305A-biLINuS02andp53K305A-biLINuS09,
with an increase in nuclear accumulation up to 60% (Figure 3.16B).
p53-LINuS variants harbouring the R306A mutation tended to have a more cytosolic localisation compared
to p53K305A-LINuS constructs before cells were activated. Particularly p53R306A-biLINuS02 exhibited a rather cy-
tosolic signal prior to activation, and a three-fold increase in nuclear intensity upon blue light illumination. Also
p53R306A-biLINuS11 exhibited a similar behaviour, nuclear intensity was 2.3-fold elevated after blue light activa-
tion.
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Constructs harbouring the double mutant K305AR306A were initially rather evenly distributed between the
nucleus and the cytosol, and exhibited a two to 2.5-fold increase in nuclear intensity upon blue light exposure.
I selected p53R306A-biLINuS02 for further investigation, as it was located primarily in the cytosol prior to acti-
vation, and showed the highest fold-change in nuclear intensity after blue light stimulation. Additionally, the
response was homogeneous, the majority of cells reacted to blue light by increasing nuclear abundance of the
construct.
Next, I wanted to asses the reversibility of the nuclear accumulation of p53R306A-biLINuS02. Thus, I activated
cells expressing p53R306A-biLINuS02 for 40minutes, and then continued imaging for 80minutes in the absence
of blue light. While a clear nuclear accumulation appeared upon blue light exposure, no reduction in nuclear
intensity could be observed during the recovery phase in the absence of light, suggesting that re-translocation
into the cytosol impaired.
3.2.8 Introduction of a constitutiveNES to achieve reversible translocation of
p53R306A-biLINuS02
The lack of reversibility of nuclear accumulation prohibits application of pulsatile p53 dynamics. So far, the only
p53mutant thatshowedat leastpartial re-translocation intothecytosolonceblue lightwasturnedoffwasp53K320AL348AL350A,
yet the introduced mutations rendered it transcriptionally inactive. Presumably, this mutant was impaired in
forming tetramers, due to the mutations within p53’s NES sequence. This suggests that that the formation of
tetramersmight cause the impairment of re-translocation into the cytosol once illumination is turnedoff. Under
phsyiological conditions, p53 canbeexported in the cytosol. However, p53 ismore likely to formtetramersathigh
nuclear levels. p53 tetramer dissociation half-times have been estimated to be around 40minutes in unstressed
conditions (Natan et al., 2009), thus might lead to the translocation impairment of p53R306A-biLINuS02 (Figure
3.16).
synthe�c NES
PKIt NES
Before
0 min
A�er
40 min
NES11
Recovery
120 min
NES21
weak strong
NES12
Figure 3.17: Assessment of effect of introducingNES’s on translocation of p53R306A-biLINuS02
Representative imagesof indicatedNESspossessingvaryingstrengthcloned inbetweenp53R306A andbiLINuS02.
H1299 cells expressing the indicated constructs were subjected to blue light for 40 minutes. If a visible nuclear
accumulation could be detected, cells were incubated for 40minutes at the absence of light. Scale Bar=20µM.
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But the sheer size might not the be the cause of the nuclear retention. The net localisation is an equilibrium
of p53R306A’s localisation sequences and those of LINUS. During blue light stimulation, the increase in nuclear
abundanceputatively leads to the formationof tetramers. Asp53’s tetramerisationdomainand itsNESsequence
partly overlaps, the NES sequence is shielded after tetramer formation (Stommel et al., 1999). Once the NES is
not accessible any more, the localisation equilibrium could be shifted to a more nuclear position, which is not
reversible until the tetramers dissociate.
I reasoned that adding a constitutive NESmight lead to amore cytosolic signal prior to activation, andwould
potentially enable reversibility once p53 becomes nuclear and forms tetramers. To this end, I added either a PKit
NES, or three synthetic NESs from a NES library created by Dominik Niopek, ranging from weak to strong. I in-
serted the NES in between p53R306A and LINuS and expressed the respective construct in H1299 cells to observe
the cells at themicroscope.
The strength of the PKit NES is average and supposedly similar to the synthetic NES11. Introducing these two
NESs top53R306A-LINuS02 resulted ina cytoplasmic localisationof the construct (Figure3.17). Upon light stimula-
tion,onlyaminorityofcells seemedtorespondbyaslight increase innuclear intensity. Duetotheseunfavourable
translocation conditions, the experiments were not continued.
Introduction of the synthetic NES12, the supposedly weakest of the tested NESs, did not result in any change
of initial localisation, compared to the construct lacking a constitutive NES (Figure 3.16). The most prominent
signal was visible in the cytosol, yet also nuclear fluorescence could be seen. Upon blue light exposure, a clear
increase in nuclear intensity was observable, which was not shuttling back into the cytosol once blue light was
turned off.
As suspected, introductionof the syntheticNES21 causedaclear cytosolic signal,withnonuclear signal visible.
Surprisingly, blue light exposure led to nuclear translocation, even though the NES is supposedly the strongest
selectedNES. The nuclear accumulationwas not reversible.
However, using LINuS to control localisation of p53 by lightwas not successful. Manipulation of p53’s endoge-
nous localisation sequences was necessary to enable light-mediated translocation into the nucleus. Only the
transcriptionally inactive p53K320AL348AL350A exhibited partial re-translocation into the cytosol, once illumination
was turned off. At this point, I stopped working with LINuS, and began trying to control localisation of p53 by
LEXY.
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3.3 Controlling p53 localisationwith LEXY
3.3.1 Characterisation of transiently transfected p53wt-LEXY inH1299 cells
Similarly to LINuS, LEXY is an optogenetic tool to control localisation of tagged proteins (Niopek et al., 2016).
InsteadofexposingaNLSsequenceuponblue light illumination, aNESisunmasked. Therefore, aprotein initially
located in the nucleus can be translocated into the cytoplasm. LEXY consists of the AsLOV2 domain harbouring
aNESwithin its Jα helix (Figure 3.18A). LEXY is usually fused tomCherry, to track localisation, and a constitutive
NLS, toprovideanuclear localisationof the taggedproteinprior toactivation. Yet thenecessityof theconstitutive
NLS depends solely on the cargo protein and its localisation sequences.
3.3.1.1 Light-mediated translocation of p53wt
Due to the irreversibility of nuclear translocation observed in p53-LINuS constructs, I wanted to verify whether
p53wt can be translocated using LEXY as straightforward as other proteins, or whether further optimisation was
necessary. One disadvantage when using LEXY to control localisation of transcription factors like p53 is the nu-
clear localisation prior to blue light exposure, potentially inducing transcription prior to the start of an experi-
ment. Yet, p53-LINuS constructs were either transcriptionally inactive, or could not be fully re-translocated into
the cytoplasm once the construct was nuclear, thus can not be used to apply p53 dynamics. Therefore, I decided
that itwasworthnonetheless trying to control p53dynamicswith LEXY, even if thatmeant shining light from the
beginning on to prevent p53 transcriptonal activity before the start of the experiment.
I started out by fusing p53wt to LEXY, and added either the constitutive cMyc NLS, or the weaker cMycP1A NLS
(Figure 3.18A). Additionally, I insertedmCherry, tomonitor localisation of the p53wt-LEXY constructs. I expressed
both constructs in H1299 cells. Both constructs showed a clear, nuclear localisation prior to blue light exposure
(Figure 3.18B).
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Figure 3.18: Characterisation of p53wt-LEXY
A | LEXY is a small tag consisting of an AsLOV2 domain photocaging an engineered NES. p53wt was fused N-
terminally tomCherry, one of two constitutive NLS sequences of differing strength, and LEXY.
B| Representative imagesof the indicatedp53wt-LEXYconstructs shown inAexpressed inH1299 cells beforeand
after 40minutes of activation. 24 hours post transfection cells were illuminated for 5 seconds every 30 seconds
using a blue laser (458 nm). Scale Bar=20µm.
C | Quantification of the relative nuclear intensity of the indicated constructs shown inB. Nuclear intensity over
time was normalized to the initial nuclear intensity of the respective construct. Dots represent images taken
(mean± SD, n=30).
Thenuclearsignalwasstronger incellsexpressingtheconstructharbouringthestrongercMycNLS.ThecMycP1A-
constructwasalsopredominantly nuclearbefore activation. 40minutesof activationwith theblue laser resulted
in a visible translocation of both constructs into the cytosol, yet more effective for p53wt-LEXY harbouring the
weaker cMycP1A.
Incontrast, onceactivatedwithblue light, thecMycP1A constructwasalmostexclusively in thecytosol,withonly
barely visible nuclear fluorescence in a minority of cells. In general, translocation was observed in the majority
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of cells expressing the constructs, yet translocation efficiencywas depending on the abundance of the respective
construct. The higher the protein levels, the less efficient the translocation appeared to be.
Cytoplasmic translocation occurred faster and more efficiently for the cMycP1A-construct, a reduction of nu-
clear intensity toapproximately20%wasobserved(Figure3.18C).Thep53wt-LEXYconstructpossessingthestronger
cMyc NES exhibited a reduction of nuclear intensity to around 30% upon activation. The high nuclear intensity
prior to activation led to a still prominent nuclear signal, even thoughmore than two thirds of the expressed con-
struct was translocated.
Based on its translocation kinetics, I selected p53wt-LEXY harbouring the cMycP1A NLS, from now on referred
to as p53-LEXY, for further analysis. Next, I wanted to observewhether p53-LEXY could be reversibly translocated
between the cytoplasm and the nucleus, thus I expressed p53-LEXY inH1299 cells and repeatedly activated cells
for 40minutes with blue light, followed by 40minute recovery phases. In contrast to any of the p53-LINuS con-
structs, p53-LEXY could be repeatedly shuttled between the nucleus and the cytosol without any manipulation
on p53’s localisation sequences (Figure 3.19A). Half-time of nuclear export was 83s± 27.5s, half-life time of im-
port was about 462s± 39.4s (Figure 3.19B). As seen before, for both LINuS and LEXY constructs, nuclear export
occurredmore rapid than nuclear import.
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Figure 3.19: p53wt-LEXY canbe repeatedly translocated into the cytosol
A | Representative images of p53wt-LEXY repeatedly activated for 40 minutes. 24 hours post transfection cells
were subjected to 40minute activation and recovery intervals. Scale Bar=20µm.
B | Quantification of the relative nuclear intensity of p53wt-LEXY. Nuclear intensity over timewas normalized to
the initial nuclear intensity (mean± SD, n=29).
Within thefirst seconds of each activationphase, relative nuclear intensity reached almost itsminimum,with
only a slight further reduction during the remaining activation period. Re-import into the nucleus during the
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recovery period was slower. In the course of the experiment, there was a slight increase in nuclear fluorescence,
probably due to continued expression of p53-LEXY.
These data suggest that p53wt canbe reversibly translocated, in contrast to data obtainedwith p53-LINuS con-
structs. LEXY was shown to efficiently translocate a range of tagged proteins, with, if at all, only minor adjust-
mentsnecessary. Yet, asbothoptogenetic toolsmakeuseof theendogenous translocationmachinery, it remains
puzzling that LEXY shuttling appears to be reversible, yet LINuS-induced translocation is not.
3.3.1.2 Light-mediated control over transcriptional activity of p53
p53-LEXY’s ability to be reversibly accumulated in and out of the nucleus is a first step towards the application
of p53 dynamics. Next, I needed to verify whether p53-LEXY remains transcriptionally active. To this end, I ex-
pressed p53-LEXY inH1299 cells. 24 hours post transfection, cells were either exposed to light or not. Expression
levels of p21were high in both, illuminated and non-illuminated samples (data not shown). Probably, the initial
incubation in theabsenceof light leads tonuclearp53 levelshighenough to triggera full transcriptional response
that cannot further be increased/decreased. Thus, I repeated the experiment, and exposed cells immediately af-
ter transfection to blue light to prevent premature expression of p53 target genes. 24 hours later, illumination
was either continued or stopped.
The adapted protocol led to differential p21 expression in cells expressing p53-LEXY, dependent on blue light
exposure (Figure 3.20A). Cells not receiving light had p21 expression levels similar to samples expressing p53wt,
while light-exposed p53-LEXY samples exhibited a three-fold reduction in p21 expression (Figure 3.20B). Light-
exposedp53-LEXYexpressingcellspossessedslightlyhigherp21 levels thanmock-transfectedorp53wt-NES-expressing
cells. Presumably, the prolonged activation did not result in complete cytosolic translocation.
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Figure 3.20: Light-mediated expression of p21 by p53wt-LEXY
A | ExemplaryWestern Blot of light-dependent effect of p53wt-LEXY on p21 levels. H1299 cells were transfected
with the indicatedconstructs and immediatelyexposed toblue light. 24hourspost transfection, cellswereeither
illuminated for 24 hours, or not. Then cells were lysed, blotted and stainedwith the indicated antibodies.
B | Quantification of relative p21 expression levels of A. p53 levelswerefirst normalized to beta actin, then to the
illuminated p53wt-transfected control (mean± SD, n=3).
Takentogether, p53-LEXYcouldbe reversibly translocatedbetweencytosolandnucleus,while remaining tran-
scriptionally active. Additionally, the transcriptional activity could be controlled by blue light exposure. Thus,
p53-LEXY possesses all necessary features to apply p53 dynamics in the absence of upstream stress.
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3.3.1.3 High andheterogeneous p53-LEXYexpression impairs its translocation
Sincep53-LEXY is transcriptionallyactiveandcanbe reversibly translocated, Idecided toapplypulses resembling
the physiological p53 dynamics observed upon γ-irradiation. The number of these pulses induced byDNAdam-
age correlate to the severity of DNA damage, while the period of the pulses is apparently fixed at about 4 hours
(Batchelor et al., 2011). Prolonged pulsatile activation has been linked to cell cycle arrest, whereas continuous
activation of p53 induced byUV-radiation triggers apoptosis (Purvis et al., 2012). Applying the different patterns
lacking the upstream stress and thus any side-effects of the induced stress could help elucidate the precise role
of p53 dynamics.
So far, I only applied simple illumination schemes,meaning either light is turnedonor off. These experiments
have been carried out in the incubator. Cells have been either shielded from the light, or were illuminated by 6
LEDs locatedwithin the cell incubator driven by an external power box. The power boxwas connected to a note-
book running the manufacturer’s software to manipulate the two settings of the power box, the voltage, and
thus the intensity of the LEDs, and the activation state,meaning theon/off state of the LEDs. The software lacked
functionality to generate more complex illumination routines, mostly due to a limited amount of commands
that could be entered and sent to the power box. Additionally, the software did not have a logging-system, so
no record of executed commands could be retrieved after an experiment. To address these issues with theman-
ufacturer’s program, I decided to use a Raspberry Pi, a small single-board computer, to control the power box.
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Figure 3.21:High p53-LEXYexpression levels impair translocation
A| Schematicsof the illuminationpatternapplied inB. Immediatelyafter transfection,H1299cellswereexposed
toblue light. 24hours later, cells received6periodsof2hours remaining in thedarkand2hoursof lightexposure.
B | Normalized mRNA expression of indicated p53 target genes after application of illumination pattern de-
scribed in A. Control cells were shielded from light after initial 24 hours of blue light exposure. Then, cells were
lysed and RNAwas extracted. Expression levels were first normalized to beta actin and Rpl0, then to the expres-
sion values of the sample remaining in the dark for 24 hours (mean± SD, technical replicates n=3).
C | Normalized mRNA expression of p53 of identical treated replicates on different days. After 24 hours of ex-
posure to blue light, H1299 cells expressing p53-LEXYwere lysed and RNAwas extracted. Expression levels were
normalized to beta actin and Rpl0 (mean± SD, technical replicates n=3).
D | Representative image of fixed H1299 cells expressing p53-LEXY after being subjected to the pulsatile light
scheme shown inA. Picture takenwith a table topmicroscope. Scale Bar=20µm.
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The Raspberry Pi runs a python script written byme to control activation and intensity of the LEDs, which can be
customized to any possible light illumination regime.
I expressed p53-LEXY in H1299 cells, and exposed cells to blue light immediately after transfection. Then I
applied either repeatedly 2hour activation-recovery intervals, or kept cells in thedark (Figure 3.21A), resembling
either pulsatile activation by γ-irradiation or continuous activation triggered by UV-radiation. p53 target genes
involved in cycle arrest (p21) and apoptosis (bax andpuma)were not differentially expressed after application of
the two different illumination regimes (Figure 3.21B).
The fact that there was no difference between the two conditions could be due to a technical or a biological
reason. Technical reasons comprise heterogeneous p53 levels. If p53 levels are are very different among cells and
if thedifferencebetweenp53dynamicswereapparentonlyata specific concentrationofp53, apopulation-based
readout, like the RT-PCR I am using, won’t be able to capture the response of individual cells. Additionally, cells
with too high levels of p53-LEXYmay not be able to export it efficiently, thus naturally responding as if p53 levels
were always high,masking the difference between the pulses and the constant activation.
When I set out to repeat the experiment, I immediately realised that the fluorescent signal was weaker than
the intensity observed during the first experiment. Thus I compared expression of p53 in biological replicates
after the initial illumination period, to verify if p53 levels were similar. I expressed p53-LEXY in cells for 24 hours
during light exposure on twodifferent days and comparedp53 expression levels. In twodifferent days, p53 levels
were highly variable, exhibiting a two-fold difference in expression (3.21C). Presumably, the difference is caused
by different transfection efficiencies between experiments.
The difference in p53 levels wasworrying, as it was technically not possible at this time to observe the translo-
cation in cells during an optogenetic experiment carried out in the incubator. To compensate for this, I decided
to fix cells during the experiment to visualize the efficiency of translocation. I decided to first verify localisation
at the end of the pulsatile illumination scheme. I expressed p53-LEXY in H1299 cells, and illuminated cells for
24 hours. Then, I applied pulsatile illumination for 24 hours and fixed cells right before the end of the last acti-
vation phase. The cells displayed widely heterogeneous expression of p53-LEXY within a single sample (Figure
3.21D). Most cells expressed so much p53-LEXY that it was not possible to distinguish between the cytosol and
the nucleus.. As seen in previous experiments, high expression of LINuS or LEXY constructs impaired transloca-
tion. This suggests that expression levels are too high for the import-export-machinery to copewith the ongoing
translocation between nucleus and cytosol, and the lack of differential gene expression observed here is due to
lack of p53-LEXY translocation.
3.3.2 Design of a stable cell line expressing p53-LEXY
Transfection of p53-LEXY resulted in a highly heterogeneous expressionwithin and between samples. Addition-
ally, expression over prolonged time was too high, and not constant, which is a requirement for ensuring long-
term application of p53 dynamics. Lowering the transfected amount of DNA resulted in an overall reduction of
p53-LEXY expression, yet increased the heterogeneity between cells (data not shown). Thus, I decided to gener-
ate a stable cell line expressing p53-LEXY, as stable integration enables a homogeneous expression of a protein
of interest.
3.3.2.1 Integration of TetR andp53-LEXY inH1299 cells
Cells respond to stress by stabilisation and activation of p53, and continuous activity of p53 eventually triggers
irreversible cell fates, such as apoptosis or senescence (Purvis et al., 2012). Thus, an inducible gene expression
system for regulation of p53-LEXY expression is required to prevent constitutive p53-LEXY expression. Inducible
gene expression systems enable triggering the expression of the gene of interest at a specific time point via the
addition of an activator, for instance a smallmolecule.
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Figure 3.22: Generation of a stable cell line expressing p53-LEXY
A | Schematic representation of the T-REx™system. In the absence of doxycyclin, TetR is tightly bound to the
tetO binding sites within theminimal cmv promoter. Upon doxycyclin treatment, doxycyclin binds TetR and se-
questers it from the tetO sites, thus stimulating expressing the gene of interest. GOI=Gene of interest.
B | Representative images of 4 clones after integration of constitutively expressed TetR transfected with a plas-
mid harbouring a tet-responsive promoter driving mCherry. Cells were transfected with the plasmid and incu-
bated for 24hours. Then, cellswere treatedwith 1000ng/ml doxycyclin for 24hours. Then, cloneswere screened
for differentially expressedmCherry. Scale Bar=40µM.
C | Representative images of two clones expressing integrated p53-LEXY upon doxycyclin stimulation. Clones
were either treated with 1000 ng/ml or not, and screened for differentially expressed p53-LEXY. Scale Bar=20
µM.
D | Western Blot of doxycyclin-dependent p53-LEXY expression. Indicated clones were incubated with the re-
spective doxycylin conditions for 24 hours. Then cells were lysed, blotted and stainedwith a p53 antibody.
I decided touse theT-REx™system to enable inducible geneexpressionof p53-LEXY in response todoxycycline
(Yao et al., 1998). It consists of two plasmids, the first harbouring a constitutively expressed tet repressor pro-
tein (TetR) and a blasticidin resistance and the second plasmid containing a minimal CMV promoter with two
integrated tetracycline operator sequences (tetO) sites, regulating expression of a gene of interest and a con-
stitutively expressed Zeocin™resistance gene. In the inactivated state, the constitutively expressed TetR forms
homodimers and binds the tetO sequences in theminimal CMV promoter, and thus prohibits expression of the
target gene (Figure 3.22A) (Hillen and Berens, 1994). Doxycyclin binds the TetR repressor, which subsequently
can not bind the tetO sequences any more. Thus addition of doxycyclin corresponds to the release of the tran-
scriptional repression, allowing expression of the gene of interest.
First, I generated a stable cell line constitutively expressing TetR. After incubation of cells transfected with
the plasmid carrying the TetR and the blasticidin resistance in media supplemented with the experimentally
determinedminimal selective concentrationofblasticidin (0.03%), sampleswere seededout in96-well plates at
a concentration of 0.5 cells per well. Twoweeks later, 96 well-plates were screened for individual colonies. Wells
lacking cells or havingmore than one single colonywere neglected. Monoclonal colonieswere further expanded
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and then transfectedwith aplasmidharbouring aTetR-responsivepromoter drivingmCherry. From243 clones, 4
displayed the desired behaviour upon doxycyclin treatment. mCherry fluorescence prior to doxycycline was not
visible or weak, while fluorescencewas high after induction (Figure 3.22B).
I selected theclones2and29 for integratingp53-LEXY, since theyhadeitherno, oraveryweakmCherryexpres-
sion in the absence of doxycycline, while displaying strong homogeneous expression after induction. I decided
not to focus on a single clone, as integration into the genome is a stochastic process and the site of integration
contributes to the expression of the integrated gene of interest. Here, I needed to have sufficient levels of TetR
high enough to repress p53-LEXY in the absence of doxycycline but low enough to be able to allow expression in
the presence of the molecule. I reasoned that this balance of repression and activation can rather be achieved
when assessing p53-LEXY integration inmultiple clones.
Then, I cloned p53-LEXY into the plasmid carrying the TetR-responsive promoter and transfected the plasmid
into both clones cultured in the presence of 0.03%blasticidin and 0.05%Zeocin™. After applying the previously
describedworkflow, twoclonesoutof378displayednoexpression in theabsenceof induction, andaclearnuclear
signal after 24 hours of doxycycline treatment (Figure 3.22C). Interestingly, both clones derived from the same
parental clone C29.
Surprisingly,while cloneC29-48expressedhigher levelsofp53 thancloneC29-36, theconcentrationofdoxycy-
cline did not affect expression levels (Figure 3.22D). Presumably, doxycycline concentrations did affect p53-LEXY
levels to somedegree, yet theWesternBlotwas not sensitive enough todetect subtle changes in expression. No-
tably, in the absence of doxycycline there was no detectable p53-LEXY expression, like in the parental C29 cell
line.
This suggests, that regulation of p53-LEXY expression was tight enough in the absence of doxycycline. Upon
doxycycline addition, repression is relieved, and thus expression of p53-LEXY is initiated.
Asmentioned above, both the TetR repressor and p53-LEXY are randomly inserted into the genome. Random
integrationbrings the risk that integrationoccurred in important genetic regions. Even though I couldnot detect
changes in cellular appearance or cell proliferation, the chance remained that integration occurred in a general
regulatory regionor evenonanodewithinp53’s regulatorynetwork,whichdisplaysnophenotype in theabsence
of stress, yet is crucial in regulating p53’s transcriptional response.
To investigate the localisation of the random integration of the two transfected plasmids, I repeatedly tried
inverse PCR with several protocols and various primers, but could not identify the site of integration (data not
shown).
3.3.2.2 Characterisation of the stable cell line
Next, Iwanted to verifywhether p53-LEXYexpressionwasmorehomogeneous in the stable cell lines C29-36 and
C29-48 than in transiently transfected H1299 cells. Homogeneous expression is a requirement for population-
based experiments.
I expressed p53-LEXY, either by transient transfection or doxycycline induction, and compared their normal-
ized intensity of p53-LEXY expression (Figure 3.23A). It is important to note that clones stably expressing p53-
LEXY upon induction were imaged with identical microscopy settings, while the transiently transfected sample
was imagedusing less laser intensity due to thehigher expression levels. Theheterogeneity of expressionwithin
the transiently transfected sample, represented by the error bar, is high, while the expression of p53-LEXY was
more heterogeneous in the created stable cell lines.
Doxycycline induced expressionwas about 2.5-fold higher in C29-48. Relative to the overall intensity, the het-
erogeneity of expressionwas almost identical between the two clones. While C29-36 cells displayed comparable
p53 levels in independentexperiments, C29-48 reducedboth intensityof individual cells and thenumberoffluo-
rescent cells over the course of twoweeks (data not shown). Even though I initially consideredworkingwithboth
cell lines, I continued focussing on C29-36.
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Figure 3.23: Characterisation of themonoclonal C29-36 cell line
A | Quantification of the relative fluorescent intensity of transfected and induced C29-36 cells after 24 hours of
p53-LEXY expression. Different microscope settings were used for transiently transfected cells and stable cell
lines (mean± SD, n=37).
B | Quantification of percentage of eitherH1299 or C29-36 cells expressing p53-LEXY after transient transfection
or inductionwith 100 ng/ml for 24 hours (mean± SD, samples=3, cells per sample n=27).
C | Quantification of relative nuclear intensity of indicated constructs expressed for 24 hours. Then, cells were
illuminated for40minuteswithblue light. Nuclear intensityover timewasnormalized to initial nuclear intensity
of the respective construct. Dots represent imaged time points (mean± SD, n=23).
DEF | Quantification of the relative nuclear intensity of C29-36 expressing p53-LEXY for 24 hours exposed to 15
minute pulses (C), 1 h pulses (D) or 2 hour pulses (E) of blue light. Nuclear intensity over timewas normalized to
the initial nuclear intensity of the respective construct(mean± SD, n=32).
G | Quantification of the number of formed colonies after p53-LEXY expression. C29-36 cells and the parental
cell line were either incubated for 24 hours or 72 hours in the presence of indicated doxycycline concentrations.
Then, cells were trypsinized, counted, and 100 cells were seeded in a newwell. Cells were incubated for 10 days,
then cellswerefixedand subsequently stainedwithCrystal Violet. Numbers of colonieswerenormalized tonon-
induced C29 cells (mean± SD, n=3).
The amount of C29-36 cells expressing p53-LEXY after doxycycline inductionwas higher than 90%,while only
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about 65%of the transiently transfectedH1299 cells expressed p53-LEXY (Figure 3.23B). Thismeans, that a third
of the cells did not express the construct at all. Additionally, heterogeneity in transfection or induction efficiency
across three independent experimentswas higher in transfected cells. This shows that the stable cell line C29-36
ensures amore robust expression of p53-LEXY than transiently transfectedH1299 cells.
Next, I sought to compare the translocation kinetics in the transiently transfected H1299 cells and the stable
cell line C29-36. Translocation occurred faster, and more efficiently in the C29-36 cells (Figure 3.23C). It has to
been mentioned, that the transiently transfected p53-LEXY did translocate slower and remained more nuclear
than in previous experiments during blue light exposure, highlighting oncemore that the heterogeneity in tran-
siently transfected samples can impact population-based read-outs.
p53-LEXY expressed in C29-36 cells could be repeatedly translocated in a pulsatile fashion, with periods of 30
minutes (15 minutes activation/recovery intervals), 2 hour (1 hour activation/recovery intervals) and 4 hours (2
hour activation/recovery intervals) (Figure 3.23D, E, F), thus covering a wide range of periods, even faster than
physiological p53 pulses, which show periods of about 4 hours upon activation (Batchelor et al., 2011) .
Constitutivep53expressionhasbeenlinkedtosenescence (Batcheloretal.,2011). Iwantedtoevaluatewhether
prolonged nuclear presence of p53-LEXY can trigger the physiological effect. I could show that transiently trans-
fected p53-LEXY remained transcriptionally active, and that p21 levels increased due to nuclear abundance of
p53-LEXY. Yet, an increase of p21 protein levels do not necessarily result in senescence as perturbation of a com-
plex network does not necessarily result in a change of outcome, due to the high regulation of individual nodes.
Especially for senescence, it is suggested that a single marker is not sufficient to correctly define its onset
(Hernandez-Segura et al., 2018). To facilitate the readout, and avoid complexmarker combinations, I selected a
more straight-forward approach. I induced C29-36 and the parental C29 cell line with different doxycycline con-
centrations. As p53-LEXY levels seemed to be to similar for different doxycycline concentrations after 24 hours,
I incubated C29-36 cells either 24 or 72 hours in the presence of doxycycline. I reasoned that longer incubation
period could result in higher p53-LEXY levels. C29 cells were incubated only at the highest doxycycline concen-
tration for 72 hours. Then, 100 cells of each sample were seeded in a new well to evaluate their colony-forming
potential. After 10 days of incubation, single colonies were visualized by Crystal Violet Staining.
The number of newly formed colonies of C29-36 was clearly dependent on p53-LEXY levels (Figure 3.23G).
Doxycycline induction for 24 hours led to 33% reduction in the number of colonies, independent of the doxy-
cycline concentration. Longer doxycycline incubation periods caused a more severe phenotype, as the colony
number was 8-fold reduced. Prolonged doxycycline exposure did not affect colony number in the parental C29
cell line. Thus, the reduction of colonies is due to p53-LEXY levels.
Notably, no stress has been applied, the induction of senescence is solely triggered by p53-LEXY expression.
Either post-translationalmodifications pf p53 only play aminor role in causing senescence, or prolongednuclear
abundance caused the requiredmodifications.
Non-inducedC29-36cells exhibitedabout80%of thecolonynumberof theparentalC29cell line. Presumably,
basal p53-LEXY expression occurred even in the repressed state, and contributed to the reduction in colony for-
mation. This is in contrast to the p53-LEXY levels determined byWestern Blot, as there was no p53 signal visible
in non-induced C29-36 cells (Figure 3.22D).
In conclusion, p53-LEXY stably integrated in H1299 cells exhibits homogeneous expression, can be reversibly
translocated in pulses of different frequencies and can induce senescence in the absence of stress. This makes
the C29-36 cell line a suitablemodel system to analyse differential gene expression triggered by p53 dynamics.
3.3.3 Prolonged light exposure affects p53-LEXYexpression
The stable cell line C29-36 exhibits reliable and homogeneous expression of p53-LEXY, which can be reversibly
translocated. I reasonedthat theoptimisedexpressionsystemshouldaddress theproblemsthatoccurredduring
thefirst applicationofpulsatile activation (Figure 3.21), namelyheterogeneity of expressionand toohighexpres-
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sion levels. Thus, I repeated the pulsatile p53 activation, to compare the transcriptional response between cells
subjected to pulses and cells subjected to sustained p53 levels.
I choose to apply the illumination scheme resembling physiological p53 pulses (Figure 3.24A). I selected 4 tar-
get genes, associatedwith either cell cycle arrest (p21), senescence (pml) or apoptosis (bax and puma). Pulsatile
p53 translocation caused differential expression of pml, which exhibited an almost two-fold increase (Figure
3.24B). Apoptosis-related target geneswere transcribedat the same level in both conditions, independent of the
subjected illumination scheme. Puzzling, the strongest effect was observed in p53 transcript levels, exhibiting
an almost 2.5 fold increase in cells subjected to the pulsatile illumination regime.
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Figure 3.24: p53-LEXY transcription correlateswith blue light intensity anddoxycycline concentration
A| Schematics of the illuminationpatternapplied inB. Immediately after inductionwith 100ng/ml, C29-36 cells
were exposed to blue light. 24 hours later, cell received 6 periods of 2 hours remaining in the dark and 2 hours of
light exposure.
B | NormalizedmRNAexpression of p53 and indicated p53 target genes after application of illumination pattern
described inA. Control cells were shielded from light after the initial 24 hours of blue light exposure. Then, cells
were lysed and RNA was extracted. Expression levels were first normalized to beta actin and Rpl0, then to the
expression values of the sample remaining in the dark for 24 hours (mean± SD, technical replicates n=3).
C| Schematicsof the illuminationpatternapplied inD. Immediately after inductionwith 100ng/ml , C29-36 cells
were exposed to blue light for 16 hours.
D | NormalizedmRNA expression of p53 after application of illumination pattern described in C. Blue light was
applied eitherwith ~20µmolm-2s -1 (normal intensity) or ~15µmolm-2s -1 (reduced intensity). Control cellswere
shielded from the light. After 16 hours, cells were lysed and RNAwas extracted. Expression levels were first nor-
malized to beta actin and Rpl0, then to the expression values of the dark sample induced with 100 ng/ml doxy-
cycline (mean± SD, technical replicates n=3).
p53-LEXYexpression is supposedly only dependent ondoxycycline. Thedifference in transcript levels can only
be caused by a stabilization effect that pulsatile activation may have on p53-LEXY mRNA, as samples shielded
from the light and samples subjected to pulsatile light were induced with the same doxycycline concentration.
Whilemechanisms ofmRNA regulation have been described for p53, these occur only in the 5’ or 3’ UTR regions
(Yin et al., 2002; Vilborg et al., 2009).
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Theonlydifference in the treatment of samples shielded from light and subjected topulsatile activation is the
illumination scheme, and thus the total amount of light cells were exposed to. While both received the initial 16
hours of light to prevent premature nuclear localisation of p53-LEXY, the sample exposed to the pulsatile light
regime receivedadditional 12hoursof light. Doxycyclinehasbeen reported tobephotosensitive, anda reduction
of photostability is observed under UV-light (Kogawa et al., 2014). Moreover, these data suggest that expression
of p53-LEXY is stimulated by blue light, rather than reduced. Thus, light-induced doxycycline degradation can
not explain the increased p53mRNA levels.
As p53-LEXYexpression is controlledby anorthogonal systemdrivenby aTetR-responsiveCMVpromoter, reg-
ulation of expression by other cellular processes as a response to blue light can be ruled out.
To further investigate the effect of blue light intensity on p53-LEXY mRNA levels, I induced cells with either
100ng/ml or 1000ng/ml doxycycline and exposed them toblue light or not for 16 hours (Figure 3.24C). Blue light
was either applied with the commonly used intensity (~20 µmol m-2s -1), or a reduced intensity (~15 µmol m-2s
-1).
The p53 transcript levels correlated with light intensity and doxycycline concentration (Figure 3.24D). Sam-
ples exposed to blue light with reduced intensity had approximately the same p53 transcript levels. Samples
subjected to theusually applied intensity showeddifferential p53expression, dependenton thedoxycycline con-
centration.
This clearly indicates that blue light triggers the differential expression levels of p53-LEXY. Yet, the reason for
differentexpression levels remainselusive. Regulationontheexpression levelsofboth,p53-LEXYandTetRcanbe
excluded, due to orthogonal promoters driving the expression of both proteins. Potentially, the p53-LEXYmRNA
levels are stabilized upon blue light exposure due to an unknownmechanism.
3.3.4 Adapting the illumination settings to prevent differential expression of p53-LEXY
Since the energy of an electromagneticwave is directly proportional to its intensity and inversely proportional to
its wavelength, I thought of adjusting these parameters to reduce the impact of light on doxycycline. First, I de-
cided to evaluate the effect of reducing the intensity. I induced p53-LEXY expression and analysed translocation
on the confocal microscope. In previous experiments, I set the laser intensity to 80%, leading to the cytoplas-
mic translocation of about 80% of p53-LEXYmolecules (Figure 3.23C). The reduction of intensity led to reduced
translocationefficiencyofp53-LEXY(Figure3.25A). Lowering the laser intensity to 70%resulted ina translocation
of 70%ofp53-LEXYmolecules. Thus, reductionof intensitywasnotpossiblewithout compromisingperformance
of LEXY.
When looking at the absorption spectrum of the AsLOV2, the main peak is located around 445 nm (Figure
3.25B). The laser line on the confocal and the LEDs used for activation emit light at a wavelength of 458 nm. The
absorption at 458 nm is only slightly higher than that in correspondence to the secondpeak around 490nm. The
difference of 30 nm corresponds roughly to a reduction of 6% light energy. To verify the effects of an increased
activation wavelength, I activated cells expressing p53-LEXY with different laser lines and quantified transloca-
tion (Figure 3.25C). Activation with 488 nm triggered the same p53-LEXY translocation efficiency as the initially
used 458 nm laser. Yet, going even further towards the yellow spectrum is not possible, as light exposure using
the 499 nm laser caused reduced translocation.
As there was no detectable differences between using the 458 nm and the 488 nm lasers, I decided to switch
to using the 488 nm light to activate cells. I updated the current setup to illuminate cells within the incubator by
exchanging the old LEDs (458 nm)with LEDs emitting blue lightwith a 488 nmwavelength. Then, I assessed the
effect of prolonged light exposurewith 488 nm LEDs on p53 transcript levels (Figure 3.25D).
Activationwithhigherwavelengthsdidnotcausedifferentialexpressionbetweenilluminatedandlight-shielded
samples after the initial 16 hours period (Figure 3.25E). Even prolonged blue light exposure up to 40 hours in the
presenceof doxycyclinedidnot result in thedifferential expressionof p53. Apparently, usinghigherwavelengths
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Figure 3.25: Evaluation of translocation efficiency upon activationwith reduced light energy
A | Quantification of relative nuclear intensity of C29-36 expressing p53-LEXY activated with the indicated laser
intensities. Cells were induced with 100 ng/ml doxycycline and incubated for 24 hours. Then, cells were illumi-
nated for 40 minutes with blue light with indicated intensities. Nuclear intensity over time was normalized to
initial nuclear intensity at time point 0 h. Dots represent imaged time points (mean± SD, n=26).
B | Photoabsorption spectrumof the AsLOV2 domain. Adapted from Salomon et al. (2000).
C| Quantificationof relativenuclear intensityofC29-36expressingp53-LEXYactivatedwith indicated laserwave-
lengths. Cellswere inducedwith 100ng/ml doxycycline and incubated for 24hours. Then, cellswere illuminated
for 40minutes with blue light with indicated wavelength. Nuclear intensity over time was normalized to initial
nuclear intensity at time point 0 h. Dots represent imaged time points (mean± SD, n=22).
D | Schematics of the illumination pattern applied in E. C29-36 cells were induced for 16 hours with 100 ng/ml
doxycycline. Cells were exposed to blue light (488 nm) throughout the induction period or not. Cells incubated
for 40 hours in the presence of light or in the dark received new, doxycycline-freemedia after 16 hours. Lightwas
applied at indicated intensities.
E | NormalizedmRNAexpressionof p53 after applicationof illuminationpatterndescribed inD. Then, cellswere
lysed and RNAwas extracted. Expression levels were first normalized to beta actin and Rpl0, then to the p53 ex-
pression values of the sample remaining in the dark for 16 hours exposed to low intensity of blue light (mean±
SD, technical replicates n=3).
was sufficient to have consistent p53 transcript levels during different illumination patterns.
Nodifferential expression in samples due to their illumination state is a sign of the absence of a light-induced
effect on p53 transcription. Also general transcription seemed not to be influenced by light, as transcription lev-
els of reference genes Rpl0 and beta actin remained constant throughout all samples. Yet, the six-fold increase
of p53-LEXY expression after 40 hours compared to the 16 hours time point was problematic. The transcription
of p53-LEXY after cells are supplemented with new media lacking doxycycline is presumably caused by resid-
ual doxycycline in the cells. Having constant p53-LEXY levels during an experiment is vital for the experimental
validity and the comparison between individual time points. Additionally, p53-LEXY translocation efficiency is
dependent on its expression levels, as increased levels can cause impairment of translocation.
Thus, I needed to adapt the doxycycline protocol, to provide stable p53-LEXY levels over the course of the ex-
periment, and to achieve reliable translocation.
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3.3.5 Tracing translocation of p53-LEXYduring ongoing experiments
Even though I could solve the problem of the light-dependent increase in p53 transcript levels, p53-LEXY levels
were still not constant throughout an experiment. Moreover, I lacked the possibility to trace translocation dur-
ing experiments in the incubator to verify cellular behaviour according to the applied illumination pattern. Yet,
themicroscope I used for the initial characterisation of p53-LEXY constructs could only activate a subset of cells,
since the same field of view has to be activated every 30 seconds. The vast majority of cells remain inactivated,
distorting the results taken on a population level. In contrast, whole cell populations can be activated using the
LED set up in the incubator, yet cannot bemonitored. To address these limitations, I could either apply blue light
to a limited number of field of views at the confocal microscope and remove non-activated cells, or investigate
how to track cells in the incubator during illumination regimes.
3.3.5.1 Single Cell Laser Tag
Binan and colleagues presented a method to selectively stick cells to an adherent surface, called cell labelling
via photobleaching (CLaP) (Figure 3.26A) (Binan et al., 2016). Culture media was supplemented with biotin-4-
fluorescein, a compound forming crosslinks with the cellularmembrane upon photoactivation with a GFP laser.
The crosslinked biotin can then be labelledwith fluorescently-labelled streptavidin. Alternatively, the GFP laser
activation induces biotin-crosslinks with the surface of the culture dish cells are grown in, and thus increases
adherence strength. After activation, non-activated cells can be selectively detached by trypsinization.
In a first experiment, I tested the feasibility with our setup. I grew C29-36 cells in the presence of biotin-4-
fluorescein and either activated half of the field of viewwith a GFP laser, or not. Then, I stained cells with Alexa-
488-streptavidin. After the staining process, GFP fluorescence was visible in the GFP laser-exposed half of the
field of view, while non-activated cells were not stained (Figure 3.26B). Importantly, GFP fluorescence is not visi-
ble in samples not supplementedwith biotin-4-fluorescein.
Thesharpborderseparatingtheactivatedandnon-activatedpartshighlights thespatial resolutionof labelling
CLaP can achieve. Interestingly, activated cells on the border of the activated side distributed the fluorescent
signal evenly in themembranewithin seconds.
Together with master student Jonas Fleck, we developed a protocol allowing application of an illumination
scheme, subsequent additionofbiotin-4-fluorescin and selective labellingof blue light-exposed cells. Cellswere
seeded inwellswith anengravedgrid on thebottom, to allowus tofindback the activated cells after the staining
andwashing procedures. Using the protocol, we could selectively remove cells, which had not been illuminated,
exemplified here with H1299 cells transiently transfected with mCherry (Figure 3.26C). Only a small number of
cells outside the activated area remained adherent.
As I was now able to discard all cells not receiving the applied light illumination scheme, I needed to extract
RNA from the remaining cells. Initially, I tried using the standard RNA extraction kit, yet no RNA could be de-
tected after RNA isolation. In the 4 fields of view that can be activated on the confocal microscope within 30
seconds there were roughly 100 cells, which is not sufficient to yield enough RNA via standardmethods. Next, I
used SmartSeq2, amethod to generate cDNA libraries from single cells (Picelli et al., 2013), yet eventually failed
toyielddetectableRNAlevels. Presumably,RNAcouldnotbeamplifiedduetoa too large reactionvolume. Alsoa
commercially available kit basedonSmartSeq2andSmartSeq4 failed to yield detectable amounts of RNA. Even-
tually, I discontinued optimising the RNA isolation, as I found a way to observe translocation during ongoing
experiments in themeantime.
3.3.5.2 Self-built LEDdevices enable concomitant tracking and activation of cells
The inability to monitor cells activated in the incubator during an optogenetic experiment leaves the suspicion
that a certain outcome may be due to failed translocation of p53-LEXY at some point during the experiment.
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Figure 3.26: Induction of selective fluorescence and increased adherence of individual cells using single-cell
laser tag.
A| Schematicworkflowofsingle-cell laser tag. In thepresenceofbiotin-4-fluorescein, indivual cellsareactivated
with theGFP laser, causing crosslinking of biotin-4-fluorescein and the activated cells. Crosslinked cells can than
be labbeldwith a streptavidin tagged fluorophore. Crosslinking leads to an increased adherence strength,mak-
ing cells less resistant to trypsination. Adapted fromBinan et al. (2016).
B | Representative images of C29-36 cells either grown presence of biotin-4-fluorescein or not. Either half of the
field of viewwas illuminated with the GFP laser (activated) or not (not activated). Then, cells were washed with
PBS and incubatedwith 488-streptavidin and imaged. Scale Bar=20µm.
C | Representative images ofH1299 cells transfectedwithmCherry grown in thepresenceof biotin-4-fluorescein
before and after trypsin treatment. 4 field of views were activated with the GFP laser. Then, cells were la-
belledwith488-streptavidinand subsequently treatedwith trypsin. Experiment carriedoutby Jonas Fleck. Scale
Bar=20µm.
Ideally, I would need to monitor the translocation in all cells at all time points to be able to link the effect on
target gene expression to p53 dynamics. As commonmicroscopes are not able to image and/or activate a whole
cell population given the constraint imposed by the photocycle of the AsLOV2 domain whereby light has to be
applied every 30 seconds if I wish to keep the construct in the activated state. I could not use the microscope
for blue light activation given that my read-out is not in individual cells but is population-based. Additionally, I
wanted to establish a versatilemethod to apply light, without being restricted to a singlemicroscopical setup or
a single experimental work flow.
Together with people from the electrical workshop, I designed new LED illumination devices, in which blue
light LEDs were embedded in the lids of well plates, enabling highly reproducible illumination of a given well
(Figure 3.27A). Asmost fluorescencemicroscopes are inverted lightmicroscopes, I decided to place the LEDs on
top of the well plates. LEDs were attached to cooling bodies to prevent overheating. Possible spatial limitations
were addressed by selecting small cooling bodies with an enlarged surface.
Initially, I decided to use 24-well plates, as these plates seemed to offer a good compromise between the sur-
face area to illuminate and the total number of cells that grow in a single well. I selected LEDs with a high beam
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Figure 3.27: Design of self-made LED chambers to track translocation during an experiment
A| Pictureof a self-made24-LEDchamber. Blue light LEDswere integrated in the lidof a24-well plate, andglued
to cooling bodies. The LEDs were powered by a power box connected to a Raspberry Pi running a self-written
python script to control illumination patterns.
B| Representative imagesofC29-36 cells grown in24-well plates coveredwith the LED-lid shown inA. Cellswere
inducedwith 100ng/ml doxycycline. Cellswere subjected to blue light, anddifferent areas of thewell platewere
imaged. Scale Bar=20µm.
angle, essentially thewidthof light emitted fromthe LEDs, toprovideahomogeneous illuminationon thewhole
well. A single 24-well plate yields sufficient biological material for downstream analysis, avoiding more elabo-
rate, and thus time consuming and error prone sample collection procedures.
Yet, initial experiments using the self-built 24-well plates to apply blue light during imaging were not suc-
cessful. Live tracking of cells was possible, yet an inhomogeneous translocation behaviour was revealed (Figure
3.27B).While cells in the center of awell translocatedp53-LEXY in the cytosol, cells located at theouter rimof the
same well exhibited a nuclear signal. Increasing the intensity to an extent that cells residing close to the outer
perimeter exhibited translocation of p53-LEXY resulted in cell death of cells growing in the center, presumably
due to phototoxicity (data not shown). Thus, the area to be illuminated needed to be reduced.
I continued embedding LEDs in 96-well plates. I reasoned that the reduced surface would allow for a more
homogeneous illumination. Yet, the drawback in using 96-well plates is the limited biological material to be
yielded, thus I needed to pool several wells for downstream analysis of target gene expression. Application of
blue light in 96-well plates covered with the LED lid resulted in a homogeneous translocation in the whole well
(data not shown). Therefore, monitoring of cells during an ongoing optogenetic experiment was possible using
the new LED lids.
3.3.6 Optimisation of p53-LEXY levels and translocation efficiency
3.3.6.1 Adjustment of doxycycline treatment leads to constant p53-LEXY levels
During the time I was exploring approaches tomonitor cells during an ongoing experiment, David Lauer, amas-
ter student inour lab, establishedanupdateddoxycyclineadministrationprotocol, that ensured stablep53-LEXY
protein levels over at least 40hours. He reduced the initial doxycycline treatment to 8hours, followedby incuba-
tion of cells with blue light for 16 hours (Figure 3.28A). Additionally, he found that reducing the light activation
pulses applied during illumination from 5 seconds every 20 seconds to 2.5 seconds every 30 seconds resulted in
the same translocation kinetics of p53-LEXY, although light exposure is reducedmore than three-fold.
When I tested the updated doxycycline administration protocol in C29-36 using the illumination chambers
placed in the incubator, p53 target geneswere differentially expressed in samples exposed to constant,meaning
2.5 seconds blue light every 30 seconds or kept in the dark (Figure 3.28B). Cells shielded from light after the ini-
tial illumination exhibited a strong increase in p21 transcript levels, and amore than two-fold increase inmdm2
expression. Xpc, amarker for DNAdamage, was onlymildly increased.
However, when I repeated the experiment in the Lionheart, an automated table top microscope, to monitor
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Figure 3.28: Live cellmonitoring visualizes impaired translocation of p53-LEXY
A | Schematics of the newly established protocol byMaster student David Lauer. 24 hours post seeding, C29-36
cells were inducedwith 100 ng/ml doxycycline for 8 hours. Then, cells werewashed and exposed to blue light for
16 hours. Subsequently, cells were either kept in the dark, or exposed to blue light for 24 hours.
B | Normalized mRNA expression of p53 target genes after application of illumination pattern described in A.
Then, cells were lysed and RNA was extracted. Expression levels were first normalized to beta actin and Rpl0,
then to the p53 expression values of the sample exposed to blue light (mean± SD, technical replicates n=3).
C | Schematic protocol of doxycycline and illumination administration. Cells were inducedwith 100 ng/ml doxy-
cycline for 8 hours, followed by 16 hours incubation in the light. Then, cells were left in the dark for 1 hour.
D | Representative images of C29-36 treated according to the protocol shown in C. Scale Bar=20µM.
E| Representative imagesofC29-36expressingp53-LEXYtreatedaccordingtoaboveprotocol. Cellswere induced
with 100 ng/ml doxycycline for 8 hours, followed by 16 hours incubation in the dark. Then, cells were subjected
to six 15min activation/recovery intervals. Next, cells received eight 2 hour activation/recovery intervals.
translocation during the experiment, I observed impaired translocation when using the same protocol (Figure
3.28C, D). As expected, cells exhibited a cytosolic signal at the end of the 16 hour illumination period (Figure
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3.28C). Yet,when lightwasdeactivated to trigger nuclear re-import of p53-LEXY, thefluorescent signal remained
mainly cytosolic (Figure 3.28D). A limited number of cells eventually had an even distribution between the cyto-
plasmand thenucleus,while themajority of cells exhibited either aweakor nonuclear signal. The same translo-
cation impairment has been observed in experiments carried out in a second Lionheart or in an Incucyte, a live-
cell analysis system tomonitor cells within an incubator (data not shown). Thus, I would exclude the possibility
of technicalmalfunctions during the incubation causing the observed impairment.
Previously, I could demonstrate that p53-LEXY can induce transcription of p53 target genes and increase p21
protein levels, despite having illuminated cells with blue light for 16 or 24 hours (Figure 3.20 and Figure 3.28).
Presumably, the limited amount of nuclear p53 observed here is sufficient to drive this increase in expression.
As I had observed ongoing translocation induced by 15minute activation pulses in cells that had not been ex-
posed to blue light during or shortly after doxycycline induction, I reasoned that the initial 16 hours of light expo-
suremight impair translocation. To investigate the impactof the initial blue light exposure, I expressedp53-LEXY
using the newly established doxycycline regime, but did not expose cells to blue light immediately after induc-
tion (Figure 3.28E (top)). 24 hours later, I subjected cells to twelve 15 minute activation/recovery intervals, and
then switched to 2 hour activation/recovery intervals.
In the absence of the initial blue light exposure, the 15minute activation/recovery intervals led to the respec-
tive export and import of p53-LEXY (Figure 3.28E (bottom)). Only after 10 hours of repeated shuttling, transloca-
tion appeared to be impaired. The cytoplasmic signal remained present during non-illumination phases, while
only a fraction of p53-LEXYmolecules becamenuclear (timepoint 10:00h). From this timepoint on, during each
recovery interval less p53-LEXYwas re-imported into the nucleus. Similarly, application of different illumination
regimes of prolongedperiods of light exposure led to the cytoplasmic localisation of p53-LEXY (data not shown).
These data suggest that prolonged light exposure causes impairment of translocation efficiency. It is unclear,
whether these findings are due the light illumination or prolonged cytosolic localisation of p53.
3.3.6.2 Translocation impairment of p53-LEXY is not causedby p53
I could show that prolonged blue light exposure impairs p53-LEXY translocation efficiency. This has not been
observed for other LEXY constructs, yet nobody has applied dynamics after an initial period of constant light
illumination like the illumination regime used here. The reason for the observed impairment of translocation
and the resulting cytosolic localisation is unknown. I thought it to be crucial to find the causes for the observed
behaviour.
One possible reason is the forced and prolonged cytoplasmic localisation of p53 during illumination. High
levels of p53 are only observed in case of severe damage, when p53 co-localises with mitochondrial membrane
proteins to facilitate apoptosis (Chipuk et al., 2004, 2005). Cytosolic retention of p53 has been observed in the
presenceofParc, a cytoplasmicanchor forp53 (Nikolaevet al., 2003). To investigate theeffect of reducedParc lev-
els on p53-LEXY translocation efficiency, I co-expressed two shRNAdirected against Parc in p53-LEXY-expressing
C29-36cellsandappliedblue light for 16hours. Yet, p53-LEXYtranslocation remained impaired (datanot shown).
As the experiment lacked a proper control of Parc levels, the informative value of the experiment is weak.
Thus, Idecidedto investigate the translocationkineticsofmCherry-LEXY lackingp53afterprolongedblue light
exposure. Additionally, I testedwhether the impairment of translocation also occurred inH1299 cells transiently
transfected with p53-LEXY. To this end, I transfected either p53-LEXY ormCherry-LEXY in H1299 cells. I reduced
the time cellswere supplementedwith the transfectionmix from24hours to 8hours, to reduce theoverall abun-
dance of the respective construct, as expression levels affected translocation efficiency. Immediately after trans-
fection or induction, cells were exposed to blue light for 16 hours (Figure 3.29A).
Translocation was impaired in all samples (Figure 3.29B, C, D). Neither transfected p53-LEXY nor mCherry-
LEXY could be translocated into the nucleus after prolonged blue light exposure. This suggests, that the impair-
ment of translocation of p53-LEXY is not caused by p53.
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Figure 3.29: Cytosolic localisation of p53-LEXYafter prolonged activation is independent of p53
A | Schematics of the applied protocol. 24 hours post seeding, C29-36 cells were induced with 100 ng/ml doxy-
cycline and H1299 cells were transfected with the indicated construct for 8 hours. Then, cells were washed and
exposed to blue light for 16 hours. Subsequently, cells were kept in the dark and imaged.
B | Representative images of C29-36 treated according to the protocol shown inA. Scale Bar=20µM.
C | Representative images of H1299 cells transfected with p53-LEXY treated according to the protocol shown in
A. Scale Bar=20µM.
D| Representative imagesofH1299cells transfectedwithmCherry-LEXYtreatedaccordingtotheprotocol shown
inA. Scale Bar=20µM.
Duringhis PhD in our lab,DominikNiopekhas illuminated cellswith blue light for 24hours and subsequently
assessed phototoxicity by carrying out aMTT cell proliferation and viability assay and could not detect any light-
induced effects on the physiology of cells. Similarly, prior to starting this work I have donemultiple γH2AX im-
munostainings after blue light exposure. γH2AX is a histone variant, that associates with double strand breaks
and subsequently forms aggregates at the site of genetic lesion, and thus acts as marker for DNA damage (Kuo
and Yang, 2008). Yet staining of light-exposed cells did not reveal any γH2AX aggregates (data not shown).
However, while cells undergo neither morphological changes, nor changes in proliferation, they can appar-
ently not copewith the stress induced either by blue light or continuous nucleocytoplasmic protein transport.
3.3.6.3 Reduction of the initial illumination period
As the period of blue light exposure clearly contributed to cytosolic retention of LEXY constructs and induced
stress, Idecided toshorten theblue lightexposureperiodcells are subjected toprior to thestartofanexperiment.
I reasoned that blue light exposure is only necessary when doxycycline-induced cells start expressing p53-LEXY.
To estimate when the translation of p53-LEXY occurs, I induced p53-LEXY expression in C29-36 cells and imaged
them immediately. Within the first 8 hours, no fluorescence was observable (data not shown). I supplemented
cells withmedia lacking doxycycline and continued imaging. Slowly, mCherry fluorescence became visible, and
thenumber offluorescent cells rose linearly, similarly to the total number of cells per field of view (Figure 3.30A).
Both, number and intensity of fluorescent cells increased over time. At the end of the incubation period, approx-
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Figure 3.30: Adjustment of the initial illumination period increased translocation efficiency
A | Quantitative time course of proliferation and p53-LEXY expression upon induction with 100 ng/ml. Cells
were induced in the microscope and imaged every 30 minutes. Number of total(blue) and number of fluores-
cent cells(red) were counted.
B | Schematic protocol of doxycycline and illumination administration. Cellswere inducedwith 100ng/ml doxy-
cycline for 8 hours, followed by 8 hours incubation in the dark. Then, cells were subjected to 8 hour light activa-
tion.
C | Representative images of C29-36 cells inducedwith 100ng/ml treated likedepicted in (B). Cellswere exposed
with to indicated blue light intensities and imaged after the 8 hour light treatment (time point 0 h) and 1 hour
after recovery in the dark (1h). Scale Bar=20µM.
D | Quantification of relative nuclear intensity of C29-36 cells activatedwith the indicated blue light intensities.
Nuclear intensity over time was normalized to initial nuclear intensity of the respective sample. Dots represent
images taken (mean± SD, n=30).
imately 90%of the cells exhibited fluorescence.
Notably, while fluorescence was heterogeneous in the beginning, it was homogeneous throughout all cells
16 hours post induction. In a compromise between shortening the light exposure, and preventing premature
nuclear accumulation, I decided to change the protocol by exposing cells to light for 8 hours prior to the start of
anexperiment (Figure 3.30B). Even thoughabout40%of the cells hadavisiblep53-LEXYexpression8hours after
doxycycline was washed away (time point -8 h), the intensity was rather low in the majority of the fluorescent
cells.
Application of the adapted illumination scheme led to an exclusively cytosolic p53-LEXY at the end of the 8
hour illumination period (Figure 3.30C). Yet, translocationwas not fully reversible once blue lightwas turned off.
The majority of p53-LEXY remained localised in the cytosol, while only a fraction translocated into the nucleus
(Figure 3.30D). Apparently, the reduced light application time still impacted translocation efficiency. I reduced
the light intensity by one quarter from 20 µmolm-2s -1 to 15 µmolm-2s -1, and repeated the experiment. Cells re-
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ceiving 8 hours of reduced blue light intensity displayed a rather even distribution of fluorescent signal between
thenucleusand the cytosol, however, once the illuminationwas stopped, p53-LEXYbecamenuclear, and reached
the samenuclear intensity as prior to the illumination phase. This suggests, that the reduced light intensity low-
ers the stress applied on cells, since translocationwas fully reversible.
Despite being insufficient to completely deprive the nucleus of p53-LEXY, the lower blue light intensity re-
sulted in abetter dynamic range.While residual nuclear p53-LEXY could induce target genes independent of the
applied illuminationpattern, the impaired translocationkinetics seen in samples illuminatedwith20µmolm-2s
-1 blue light intensity renders these illumination settings not useful. I did not want to further reduce initial illu-
mination time, as p53-LEXY protein levels increased 8 hours prior of the experimental begin (Figure 3.28). Thus,
I decided to illuminate cells 8 hours after doxycycline inductionwith the reduced light intensity.
3.3.7 Reduction of light intensity still leads to impairment of p53-LEXY translocation
With the reviseddoxycyclineadministrationprotocol and the reduced light intensityduringblue lightactivation,
p53 levels remained constant over the experimental run time, and translocation was apparently more reliable.
Additionally, the LED devices now enabled monitoring translocation during an experiment. With the updated
experimental setup, I set out to investigate differential gene expression in samples subjected to either pulsatile
or constitutive activation of p53-LEXY.
Like in previous experiments, I decided to use 2 hour pulses of activation, as these resemble the pulsatile re-
sponse of p53 observedwhen cells are exposed to γ-radiation (Batchelor et al., 2008). Due to the previously ob-
servedeffectofprolonged light illuminationontranslocation, Idecided to limitexperimental run timeto8hours,
to ensure reliable translocation throughout the experiment and to reduce the applied stress on cells caused by
blue light.
After the initial 8hours of illumination, I subjectedC29-36 cells expressingp53-LEXYeither topermanentblue
light exposure, to 2 h activation pulses or placed them in the dark (Figure 3.31A). I collected time points every 2
hours. Cellsweremonitoredduring theexperiment, and translocationkinetics for each sampleweredetermined
(Supplementary Figure 7.1)
Overall, there was no consistent differential gene expression detectable between the different illumination
conditions (Figure 3.31B). A maximum of 1.5-fold increase in transcription levels of the investigated genes was
observed. Changes in expression appeared to be rather arbitrary and not dependent on p53. Apart from puma
andpml, geneexpressionofp53 targetgenes in samplesnotexposed to lightexhibiteda trendof slightly increas-
ing expression during the time course, reaching the highest level at 8 hours.
Samples subjected to pulsatile activation exhibited onlymild changes in expression. Except for puma, whose
expression peeked after 4 hours, but decreased at later time points.
For somep53 target genes, the light-exposed sample exhibited thehighest fold change ingeneexpression, for
example the cell cycle arrest marker p21 after 2 hours, or the apoptosis marker puma after 4 hours, yet as these
are individual time points, and the respective levels are reduced or back to base levels in later time points, the
expression is presumably not indicating stress.
In general, it appears that p53-LEXY expression of illuminated and non-illuminated samples exhibited only
minor differences. As the tracked translocation kinetics followed the applied illuminationpatterns (Supplemen-
tary Figure 7.1), the lack of differentially gene expression between constantly illuminated and non-illuminated
samples can not be explained by impaired translocation. Only cells receiving pulsatile activation exhibited a re-
duced translocation efficiency during later time points. Cells shielded from light exhibited a roughly two-fold
increase in nuclear p53-LEXY intensity, compared to cells exposed to light. Yet, this increase apparently does not
cause differential gene expression.
As described in Chapter 3.3.6.1, already a small increase in nuclear intensity can apparently induce gene ex-
pression. Reduction of blue light intensity resulted in higher nuclear levels of p53-LEXY during blue light expo-
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Figure 3.31: Expression of p53 target genes upon exposurewith different illumination regimes
A| Schematic protocol of theexperimentalworkflow. Cellswere inducedwith 100ng/mldoxycycline for 8hours,
followed by 8 hours of incubation in the dark. Then, cells were exposed to blue light for 8 hours. Next, cells were
either left in the dark, exposed to constant light or subjected to 2 hour intervals of light activation and recovery
in the dark. Time points were taken every 2 hours.
B | Normalized mRNA expression of indicated p53 target genes after application of illumination patterns de-
scribed inA. Then, cells were lysed and RNAwas extracted. Expression levels were first normalized to beta actin
and Rpl0, then to the expression values of the control sample at time point 0 h (mean± SD, technical replicates
n=3).
sure, and is presumably sufficient to trigger p53 target geneexpression. However, it is puzzling, that the two-fold
increase of nuclear intensity in cells shielded from the dark is not sufficient to further stimulate transcription.
Additionally, the observed impairment of translocation in samples exposed to pulsatile illumination suggests
that the reduced illumination regime still imposes stress on the cells. Potentially, the stress induced by light is
highest in the sample exposed to blue light permanently, thus the transcriptional readoutmight not be trusted.
Yet, transcription of house keeping genes was constant in all conditions.
This highlights how difficult it is to balance the parameters in optogenetic experiments. High blue light in-
tensity caused translocation impairment and cellular stress, while reduced intensity led to higher abundance of
nuclear p53-LEXY, and thus presumably to higher background expression of p53 target genes, while still causing
stress to cells.
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3.3.8 Drug treatment reveals high variability in transcriptional response in C29-36 cells
Cytosolic and nuclear p53-LEXY localisation did not result in a consistent differential expression of p53 target
genes. The transcriptional response at individual time points did not exhibit any visible trend, and fluctuated
independently of the illumination scheme. Presumably, increasing the experimental run time to potentially
achieve higher transcript levels would increase phototoxicity and have a detrimental effect on translocation ef-
ficiency, as translocationwas already impaired in shorter experiments.
In physiological conditions, p53 becomes rapidly active once the cell encounters a stress situation. Subse-
quently, p53 induces transcriptional programs to cope with the encountered situation, and eventually triggers
cell fate according to the severity of the stress. Here, I wanted to investigate effects of p53 dynamics in the ab-
sence of stress. Yet, I could not find settings which allowed reversible translocation without causing phototoxic
stress and still yield differential expression of p53 target genes.
Thus, I decided not to expose cells to light prior to the start of the experiment, but rathermanipulate localisa-
tion of p53-LEXY during the application of stress to cells. I selected two drugs to induce stress, neocarzinostatin
(NCS) and gefitinib.
3.3.8.1 Neocarzinostatin treatment reveals un-reproducibility of observed transcriptional response in
C29-36 cells
NCS is an antibiotic used as a chemotherapeutic drug in cancer treatment (Ishida et al., 1965). NCS triggers
sequence-specificDNAdamage, andsubsequently causesactivationof theDNA-damagerepairpathway leading
to p53 activation by the ATM kinase (D’Andrea and Haseltine, 1978; Banin et al., 1998). I reasoned that the DNA
damage should activate p53 to its full extent, and thus induce p53 target genes. I applied the same doxycycline-
induction scheme as before, yet I omitted the initial blue light period, due to the apparent stress it caused to the
cells (Figure 3.32A). The absence of blue light will lead to a nuclear p53-LEXY pool prior to NCS administration.
p53-LEXYwill then either reside in the nucleus, or be translocated to the cytosol due to blue light exposure, lead-
ing to either nuclear or cytosolic p53-LEXY duringNCS treatment.
Additionally, I selected further p53 target genes to investigate, based on a study elucidating p53 target gene
mRNAexpression kinetics (Porter et al., 2016). Porter and colleagues groupedmRNAs according to their expres-
sion profiles in strongly or weakly pulsing, or rising in expression. I picked the strongest responding genes from
thegroupof stronglypulsinggenes, namely eGadd45, btg2andwip1, and the strongest fromthegroupofweakly
pulsing genes, namely fas, and took time points at 2 hours and 6 hours, according to the described peaks of the
respective pulses (Porter et al., 2016).
Of the eight selected target genes, eGadd45, fas, pml and bax exhibited onlyminor fluctuations in expression
(Supplementary Figure 7.2). p21 andwip1 had higher fold changes in transcript levels, and both peaked at the 2
hour timepoint. Notably, drug-treated samples appeared tohavehigher expression levels of p53 target genesaf-
ter 2hours. After 6hours, expressionof p21 andwip1 in cells expressingp53-LEXYwasmore similar, independent
of the illumination condition and drug treatment.
After2hours, btg2expressionwasapproximately twotimeshigher in thedark than in thecorresponding light-
exposed control (Figure 3.32B (left)). Even innon-induced cells, an almost two-fold increasewasobservable, pre-
sumably due to residual p53 expression. C29-36 cells expressing p53-LEXYhad a four-fold increase in btg2 levels,
cells additionally treated with NCS exhibited a six-fold increase in btg2 levels. This suggests that p53-LEXY can
induce btg2 expression, yet the expression can further be stimulated byNCS treatment.
Also cells exposed to blue light and thus supposedly having cytosolic p53-LEXY showed an increase in btg2
transcript levels upon NCS treatment. As p53 levels are stable throughout the experiment, the cells supposedly
hadthesameamountof residualnuclearp53-LEXY,yet theNCStreatmentcausedahigher transcriptionalactivity
of p53-LEXY. In general, fold changes were reduced after 6 hours.
The btg2 fold changes in samples treated with NCS resembled the results reported by Porter and colleagues
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Figure 3.32: Evaluation of btg2 expression uponNCS treatment
A| Schematic protocol of theexperimentalworkflow. Cellswere inducedwith 100ng/mldoxycycline for 8hours,
followedby16hour incubation in thedark. Then, cellswere treatedwith500ng/mlNCSfor2or6hoursandeither
exposed to blue light or not.
B | Normalized mRNA expression of btg2 after application of illumination patterns described in A. Then, cells
were lysed and RNA was extracted. Expression levels were first normalized to beta actin and Rpl0, then to the
expression values of thenon-induced, light exposed andNCS treated sample at timepoint 2h. (left)mean±SD,
technical replicate 1, n=3) (middle) mean± SD, technical replicate 2, n=3) (right)± SD, biological replicate n=2,
technical replicates n= 2x3)
(Porter et al., 2016), who, having a higher temporal resolution in their read-out, claimed a pulsatile activation of
btg2 upon treatment with NCS. Cells treated with NCS for 6 hours showed the same fold changes as untreated
cells.
These results were promising, as clear fold changes dependent on p53 localisation were observed, and pre-
viously published results demonstrated the same effect on btg2 levels as described here (Porter et al., 2016).
btg2 and puma showed the highest differential expression (Figure 3.32 and Figure 3.33), thus I selected these
two genes for further investigation.
When the experiment was repeated, btg2 transcript levels were not reproducible (Figure 3.32B (middle)). In
general, fold changes were drastically reduced. Only cells expressing nuclear p53-LEXY treated with NCS exhib-
ited higher than two-fold change in expression. Similarly to the first replicate, expression of btg2 was higher at
the first time point than at the second time point. Statistical analysis of both replicates revealed the high error,
demonstrating the heterogeneous response in cells (Figure 3.32B(right)).
Similarly to btg2, puma exhibited a drastic difference of the fold changes between individual replicates (Fig-
ure 3.33 (left) and (middle)). While the first replicate exhibited a similar expression profile as btg2, the second
replicateexhibitedonlyminorfluctuations in targetgeneexpression. C29-36cellsexpressingp53-LEXYexhibited
similar expression levels of puma in the first replicate, independent of illumination and NCS treatment. Solely
the sampleadditionally treatedwithNCSandshielded fromthe lightdisplayedasix-fold change. It appears, that
nuclear levels of p53 are not themain determinant of puma transcription, as non-illuminated and light-exposed
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Figure 3.33: Evaluation of pumaexpression uponNCS treatment
Normalized mRNA expression of puma after application of illumination patterns described in Figure 3.32 A.
Then, cells were lysed and RNA was extracted. Expression levels were first normalized to beta actin and Rpl0,
then to the expression values of the non-induced, light exposed andNCS treated sample at time point 2 h. (left)
mean± SD, technical replicate 1, n=3) (middle) mean± SD, technical replicate 2, n=3) (right)± SD, biological
replicate n=2, technical replicates n= 2x3)
samples exhibited almost the same puma expression levels. The nuclear levels of p53-LEXY only contributed to
puma in the presence of NCS. In non-induced samples, puma levels are only slightly elevated in samples kept in
the dark compared to samples exposed to blue light.
Yet, in replicate 2, illuminated, non-induced samples are more elevated as in light-shielded samples. NCS
treatment did not have a stimulating effect on puma levels as seen in the first replicate. While non-NCS-treated
C29-36 cells showed stronger light-induced transcription,NCS-treated cells expressingp53-LEXYappeared tobe
not responsive to light.
Technical errors in preparation of the RNA and cDNA can be excluded, as both, isolation of RNA and reverse
transcription,were carriedout inparallel. Also the identical qPCRmastermixwasused, andboth replicateswere
run on the same plate. Additionally, cells appeared normal in both replicates when checked at the microscope,
and theCt values of the referencegeneswere constant in all RNAsamples. Thus, theheterogeneitywasprobably
not caused by technical issues.
Due to the heterogeneity observed here, no definitive conclusion can be drawn from this data set.
3.3.8.2 Gefitinib treatment confirmsun-reproducibility of transcription of p53 target genes in C29-36 cells
Gefitinib is a tyrosine kinase inhibitor used as a chemotherapeutic agent (commercial name: Iressa). Gefitinib
specifically targets theEGFRreceptorandtriggersapoptosis (Rhoetal., 2007). Additionally, gefitinibadministra-
tion causes rapid activationof p53 (Changet al., 2008). Here, Iwanted to asses p53 localisation-dependent target
gene expression upon gefitinib treatment. Expression of p53-LEXY was induced applying the updated doxycy-
cline administration protocol and cells were then treated for either 2 or 6 hours with 1 µMgefitinib. During the
drug administration, cells were illuminatedwith blue light, or shielded from light (Figure 3.32A).
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Figure 3.34: Evaluation of btg2 expression upongefitinib treatment
A | NormalizedmRNA expression of btg2. Cells induced with 100 ng/ml doxycycline for 8 hours, followed by 16
hour incubation in the dark. Then, cells were treated with 1µM gefitinib for 2 or 6 hours and exposed to blue
light, or not. Next, cells were lysed and RNAwas extracted. Expression levels were first normalized to beta actin
and Rpl0, then to the expression values of the non-induced, light exposed and 1 µM gefitinib treated sample
at time point 2 h (mean± SD, technical replicates n=3). B | Normalized mRNA expression of btg2. Cells were
induced with 100 ng/ml doxycycline for 8 hours, followed by 16 hour incubation in the dark. Then, cells were
inducedwithdoxycyclineandtreatedwithgefitinib for2or6hours. Next, cellswere lysedandRNAwasextracted.
Expression levelswere first normalized to beta actin andRpl0, then to the expression values of the non-induced,
lightexposedandgefitinib treatedsampleat timepoint2h. (left)mean±SD, technical replicate 1, n=3) (middle)
mean± SD, technical replicate 2, n=3) (right)± SD, biological replicate n=2, technical replicates n= 2x3)
Similar to NCS treatment, the highest fold change upon gefitinib treatment could be observed in btg2 and
puma levels. eGadd45 and pml showed only mild increase of transcript expression throughout all conditions
(Supplementary Figure 7.3). Wip1 and fas exhibited a light-dependent increase in transcription, yet overall ele-
vation in transcriptionwasweak (1.5 fold induction). Baxandp21expressionwas three-fold increased ingefitinib-
treated cells shielded from light. Depended on the illumination, both genes were differentially expressed after
2 hours, yet after 6 hours expression exhibited similar levels in all conditions. Gefitinib treated samples shielded
fromdark had strongly elevated p21 transcript levels.
In thefirst replicate, btg2 levels resembledapulsatile response,with transcript levelshigher after 2hours than
after 6 hours (Figure 3.34 (left)). As seen before, the highest fold change was observed in the non-illuminated
sample expressing p53-LEXYupon gefitinib treatment for 2 hours. btg2 levelswere generally two-fold increased
when p53-LEXYwas nuclear.
A second independent experiment, however, had very different results (Figure 3.34 (middle), (right)). Fold
changesweredrastically reduced, themaximal increase in transcription levelsdecreased fromeight- to two-fold.
Theeffectofgefitinibtreatmentwasneglectable. Expressionwasslightlyhigherafter2hours, yetoverall changes
weremarginal. Apparently, un-reproducibility is persistent, and not caused byNCS.
The same unreproducible results were obtained for puma (Figure 3.35). As seen before, fold changes were
reduced in the replicate. Taken together, drug treatment resulted in a highly variable response. Initial promising
results were not reproducible. As reproducibility is key for any experiment and usually points to an underlying
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Figure 3.35: Evaluation of pumaexpression upongefitinib treatment
A | NormalizedmRNA expression of puma. Cells were inducedwith 100 ng/ml doxycycline for 8 hours, followed
by 16 hour incubation in the dark. Then, cellswere treatedwith 1µMgefitinib for 2 or 6 hours and either exposed
toblue light or not. Next, cellswere lysed andRNAwas extracted. Expression levelswerefirst normalized tobeta
actin and Rpl0, then to the expression values of the non-induced, light exposed andNCS treated sample at time
point 2 h (mean± SD, technical replicates n=3).
B | NormalizedmRNA expression of puma. Cells were inducedwith 100 ng/ml doxycycline for 8 hours, followed
by 16 hour incubation in the dark. Then, cells were induced with doxycycline and treated with gefitinib for 2 or
6 hours. Next, cells were lysed and RNAwas extracted. Expression levels were first normalized to beta actin and
Rpl0, then to the expression values of the non-induced, light exposed and NCS treated sample at time point 2
h. (left) mean ± SD, technical replicate 1, n=3) (middle) mean ± SD, technical replicate 2, n=3) (right) ± SD,
biological replicate n=2, technical replicates n= 2x3)
problem in the experimental setup, I needed to find the origin of the heterogeneous response.
3.3.9 Finding the cause of un-reproducibility
So far, experiments resulted only in mild changes of transcript levels, or obtained results were un-reproducible.
The cause of the previously observed variation could not be identified. There was no apparent correlation be-
tweenthevariationandanyof thetreatmentscellsweresubjectedto, asun-reproducibilitywasobservedthrough-
outall samples. Prior to trying to furtheroptimise theexperimental setup, I decided to look for thepossible cause
of this strong unreliability.
I decided to investigatewhether a similar variation in transcriptional response could be observed in other cell
lines. To this end, I selected the colon carcinoma cell line HCT116, a cell line commonly used in p53 research.
Additionally, IusedMCF7cellswithan integratedp53-Venus, astablecell linecreatedbyBatchelorandcolleagues
(Batchelor et al., 2008). This cell line has been used intensively for investigating p53 dynamics, and harbours a
constitutively expressedp53 taggedwithVenus (Batchelor et al., 2008, 2011; Purvis et al., 2012; Stewart-Ornstein
and Lahav, 2017). I treatedHCT116 andMCF7-p53-Venus cellswith gefitinib for 2 or 6hours and investigatedbtg2
and pumamRNA levels (Figure 3.36A).
In contrast to thepreviousexperiments, theseexperimentswerenicely reproducible. Gefitinib treatment trig-
gered an increase in transcript levels of btg2 in both cell lines (Figure 3.36B, C). HCT116 exhibited an almost two-
79
CHAPTER 3. RESULTS
fold change in transcriptionofbtg2, at both investigated timepoints. btg2expression inMCF7-p53-Venus resem-
bled a pulsatile transcription profile, reaching a three-fold increase after 2 hours, then decreasing to a two-fold
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Figure 3.36: Evaluation of the contribution to un-reproducibility of the individual treatments
A | Schematic protocol of the experimental work flow. Cells were treatedwith 1µMgefitinib for 2 h or 6 h.
B | NormalizedmRNA expression levels of btg2 in HCT116 cells treated according to protocol shown inA. Then,
cells were lysed and RNAwas extracted. Expression levels were first normalized to beta actin and Rpl0, then to
the expression values of the non-treated sample at time point 2 h. (left) replicate 1 (mean± SD, n=3), (right)
replicate 2 (mean± SD, n=3).
C| NormalizedmRNAexpressionofbtg2 inMCF7-p53-Venuscells treatedaccordingtoprotocol showninA. Then,
cells were lysed and RNAwas extracted. Expression levels were first normalized to beta actin and Rpl0, then to
the expression values of the non-treated sample at time point 2 h. (left) replicate 1 (mean± SD, n=3), (right)
replicate 2 (mean± SD, n=3).
D | Schematic protocol of the experimental work flow. Cells were transfected with p53-mCherry or p53-NES-
mCherry and treatedwith Gefinitib and/or blue light for 6 h.
E | NormalizedmRNAexpression of indicated p53 target genes inHCT116 transfectedwith indicated constructs.
Cells were treated according to protocol shown in C. Then, cells were lysed and RNA was extracted. Expression
levels were first normalized to beta actin and Rpl0, then to the expression values of the non-treated sample at
time point 6 h. (mean± SD, biological replicates 2, technical replicates 2x n=3).
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change after 6 hours. Non-treated samples had constant btg2 transcript levels.
Pumaexpressionwas likewise reproducible (Supplementary Figure 7.4B, C).Drug treatment resulted in a con-
tinuous increase of puma levels in HCT116 cells, exhibiting aminor increase after 2 hours, and higher than a 2.5
fold increase after 6 hours. In MCF7-p53-Venus cells, there was a 1.5-fold increase of puma levels upon stimula-
tion, whichwas slightly reduced after 6 hours.
These results suggest that gefitinib is not the cause of the previously observed un-reproducibility, as btg2 and
puma expression was reproducible in both, HCT116 and MCF7-p53-Venus cells. Another possible cause of un-
reproducibility could be the high abundance of cytosolic p53 during illumination periods. In physiological con-
ditions, high cytosolic p53 levels are observed in case of severe stress to induce apoptosis (Chipuk et al., 2004,
2005). Thus, I reasoned this unnatural localisationmight contribute to un-reproducibility, especially when cells
are additionally exposed to blue light.
To test this hypothesis I expressed either nuclear or cytosolic p53 in HCT116 cells, and subjected cells to blue
light for 6 hours (Figure 3.36D). Controls were shielded from blue light. In general, cells reacted similarly to the
stimulation, and expressed similar levels of btg2 and puma in both replicates. Btg2 expression levels were inde-
pendent of light, and increased upon gefitinib treatment (Figure 3.36E). Transfection of cytosolic p53 stimulated
expression of both, btg2 and puma in respect to the mock-transfected control, presumably due to residual nu-
clear p53.
These results suggest that p53 localisation and expression levels do not contribute to differences between
replicates. Between replicates, the transcription level of btg2 and puma were similar. Lastly, also the blue light
did not cause un-reproducibility.
Thus, the only remaining factor is the stable cell line C29-36. Apparently, the transcription is highly variable
in this cell line, as even unstressed cells exhibit huge variations. As the project depends on reliable p53-LEXY
expressionandaconsistent response to thep53-LEXYtranslocation, this cell line turnedoutnot tobeappropriate
for the aim of this project.
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4 Discussion andOutlook
Cellular signalling is a truly dynamic process. At the centre of many signalling networks is a transcription factor
(TF), which senses various internal and external stimuli and translates these inputs in the appropriate response.
The term "dynamics" indicates the shape of the curve describing the temporal profile of a certain feature of the
transcription factor, such as its concentration, localisationor activity (Purvis and Lahav, 2013). It is suggested that
TF dynamics determine the transcriptional outcome.
p53 is a transcription factor vital for the cell; itmediates the cellular response tomultiple internal and external
stress signals. Different p53 dynamics have been linked to distinct transcription profiles and thus cellular fates
(Batcheloretal., 2011;Purvisetal., 2012). Typically, investigationofp53dynamicsarebasedonexperimentsusing
chemical perturbation or radiation to induce them. Both treatments trigger cellular stress, thus potentially lead
to undesired side effects influencing the transcriptional response.
While it is well understood how different stress signals induce different p53 dynamics, the mechanism used
by the cells to "interpret" these dynamics to selectively activate target gene expression remains unknown.
Moreover, it isunclearwhether thedynamicsalonearesufficient to inducespecificgeneexpression,orwhether
further factorsare involved in shapingp53’s appropriate transcriptional response. In thiswork, I usedoptogenetic
methods to artificially create different p53 dynamics, and analyse the transcriptional output derived from them
in the absence of upstream stress. In the following, I will discuss the results I obtained.
4.1 Controlling endogenous p53 levels by light-dependent inhibition of p53
degradation
4.1.1 Light-mediated steric hindrance of peptides or protein domains to control p53
degradation
p53 levels are mainly regulated by the E3 ubiquitin ligase Mdm2, which binds p53 N-terminal TAD eventually
leading to p53 degradation. MdmX, a homologue of Mdm2, binds to same binding interface as Mdm2, but is
not able to induce p53 degradation. Yet, MdmX binding inhibits p53 transcriptional activity. Here, I applied op-
togenetic methods to inhibit p53 degradation light-dependently using two proteinogenic peptide candidates
designed to have a higher affinity towardsMdm2 andMdmX than the endogenous TAD of p53.
Initially, I applied the Tulip approach to enable light-controlled inhibition of p53 degradation. The approach
employs the natural property of theAsLOV2domain to expose its Jαhelix uponblue light illumination (Salomon
etal., 2001;CrossonandMoffat, 2002; Stricklandetal., 2012). This structural change isharnessed toenable light-
controlledexposureofapeptidewhich is incorporatedwithinorappendedto the Jαhelix (Stricklandetal., 2012).
Preliminary work of Christian Scheeder in our group suggested that fusing the MIP peptide (Shiheido et al.,
2011) to two truncations of the AsLOV2 domain enabled light-mediated control of p53 levels (Figure 3.1). How-
ever, when I tried to replicate his findings, I could not observe any effect on p53 levels (Figure 3.2 and Figure 3.3).
Un-reproducibility in experiments is often caused by changes in experimental set up and work flow. However,
Christian and I used the same protocol, constructs, lab instruments and reagents. Thus it remains unclear why
he could observe an effect and I could not.
My own data indicate that the MIP peptide has no effect on p53 levels (Figure 3.3). This is in contrast also to
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published findings (Shiheido et al., 2011) . Shiheido and colleagues reported increased p53, Mdm2 and p21 pro-
tein levels inHCT116 cells expressing theMIPpeptidewithin the thioredoxin scaffold. Thehigher levels ofMdm2
andp21dependonendogenousp53 levels, as the increase is absent inHCT-p53-/- cells. In theirwork, a viral trans-
duction systemwas used, in contrast to the chemical transfectionmethod used here, thus expression levels are
not comparable. Yet, not even increasing 8-fold the amount of transfected DNA resulted in higher p53 protein
levels. Moreover, I could not find further literature supporting the in vivo effects of the MIP peptide. Structural
data suggest that theMIP peptide bindsMdm2with higher affinity than endogenous p53 (Nagata et al., 2014).
Yet, inmy own experiments high levels of theMIP peptidewithin the thioredoxin scaffold were not sufficient to
impact p53 levels, suggesting that the affinity determined in vitro is either too low, or different in vivo.
The second peptide candidate was the PMI peptide, which supposedly has a superior affinity to Mdm2 and
MdmX than theMIP peptide (Pazgier et al., 2009). I could show that the PMI peptide is a potent inhibitor of p53
degradation and deactivation (Figures 2.6 and 2.8). As Pazgier and colleagues have only presented in vitro data,
this is tomy knowledge the first in vivo validation of the potency of this peptide (Pazgier et al., 2009).
As with the MIP peptide, I was not able to find AsLOV2-PMI fusion proteins, which elevated p53 levels, even
thoughmultiple C-terminal AsLOV2 domain truncations were investigated (Figure 3.6). Additionally, hybrids of
AsLOV2 domain and p53 TADdid not result in increase of p53 levels inmammalian cells, independent of the illu-
mination conditions I used (Figure 3.5). The fact that p53 levels do not increase after exposing cells to blue light
suggests that the fusion constructs are unable to undergo the light-induced conformational change that would
result in the uncaging of the peptide. Whether this is caused by an impaired structural rearrangement due to
altered biochemical properties of the fusion proteins, or whether Mdm2/MdmX are sterically hindered to bind
the exposed sequences due to the presence of theAsLOV2domain is unknown. Interestingly, N-terminal fusions
of PMI tomCherry connected via a linker could inhibit p53 degradation (Figure 3.6).
During their investigation of how to best photocage peptides within the Jα helix of AsLOV2, Strickland and
colleagues tested numerous C-terminal truncations of the AsLOV2, and only a minority resulted in the desired
light-dependent behaviour (Strickland et al., 2012). In general,most optogenetic tools based on fusing peptides
or functional domains to truncations of theAsLOV2domainhaveundergone screeningprocesses, andonly a lim-
ited number of tested constructs exhibited the desired light-dependent function (Wu et al., 2009; Renicke et al.,
2013; Bonger et al., 2013). Standardisation of this process has revealed to be ineffective. Design criteria cannot
be transferred, even for closely related proteins (Winkler et al., 2014). Thus, further screening of AsLOV2-PMI
fusionsmight be necessary to identify candidates exhibiting favourable behaviour.
A more rational design process was developed in our laboratory by my colleague Dominik Niopek (Niopek
et al., 2016). In an iterative process called Jα helix topping, instead of simply fusing a peptide to the Jα helix, the
native helix is progressivelymutated in order tomatch key conserved residues that are necessary for the activity
of the peptide to be caged. Since several residues are kept unmutated, the Jα helix is more likely tomaintain its
photo-responsiveness. Obviously, this approach requires a certain similarity between the Jαhelix and the amino
acid sequence of the peptide to be caged, but it was shown to be very effective in the design of LEXY.
However, Albert Fàbregas Flavià, a Bachelor student in our lab, tried to use this method (Jα helix topping) to
embed into the Jα helix the PMI peptide, but failed to find a promising candidate.
4.1.2 Controlling the localisation of thePMI peptide
I could demonstrate that the effect of the PMI peptide is dependent on its cellular localisation (Figure 3.6). This
suggests that Mdm2 binds p53 predominantly in the nucleus, as inhibition of theMdm2-p53 complex in the cy-
toplasmdid not alter p53 levels.
Severalmodels have been proposed of howp53 activation can lead to selective transcriptional responses. One
of thesemodels states that acetylationof key residuesofp53alters itsbindingaffinity towards specificpromoters
(Kruse and Gu, 2009). This model hypothesises that the number of acetylated residues of p53 correlates to the
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severity of the encountered stress.
p21 is a marker for cell cycle arrest and a prominent target gene of p53(Gartel et al., 1996). According to this
model, expression of p21 is dependent on acetylation of p53 (Kruse and Gu, 2009). Expression of PMI-mCherry
led top21 levels close to levels observed in cells treatedwith thegenotoxicdrugDaunorubicin. This suggests that
PMI administration is sufficient to drive p21 levels in the absence of stress. Whether the acetylation of p53 still
occurs upon PMI transfection, or whether acetylation of p53 is not essential for it to transcribe p21 needs to be
clarified.
4.1.3 PMI-induced increase in p53 levels is not reversible
Using LEXY, I could control the localisation of PMI with blue light. PMI-LEXY could repeatedly be exported out
of the nucleus when activation periods were short (40 minutes) (Figure 3.8). The fact that p53 levels decreased
onlymarginally in samples where light was re-applied after 24 h of darkness (Figure 3.9) could be interpreted in
two ways: a) cells are unable to efficiently export PMI-LEXY and therefore enough peptide remains nuclear and
continues to blockMdm2. This could bedue to the fact that PMIbindsMdm2 in thenucleus and theMdm2/PMI-
LEXY complex might be too big for LEXY to efficiently drive its export. Moreover, Mdm2 itself possesses a NLS
and aNES (Roth et al., 1998), whichmight play a role in the localisation of the complex.
PMI-LEXY is exported in complexwithMdm2,which is therefore still unable to exert its function towards p53.
Oncedissociated from the complex,Mdm2might bind to residual cytosolic PMI-LEXYdue to the increasedbind-
ing affinity towards the PMI peptide, thus remaining sequestered in the cytosol away from nuclear p53, which
would remain at high concentrations.
In either case, it is unclear howa limitedpool of peptide (indeed, after somehours transcription from theplas-
mid can only decrease) can so efficiently inhibitMdm2,whose levels are bound to increasewith timedue to new
transcription of the gene by the stabilized p53.
To discern between these two scenarios, localisation of PMI-LEXY should be traced during an ongoing experi-
ment, to investigatewhether PMI-LEXY remains in the nucleus once cells are subjected to blue light after 24 h of
darkness, whichwould argue for an impediment of nuclear export. Moreover, immunostaining ofMdm2 in cells
exposed to light regimes including a prolonged recovery time should reveal its localisation, and thus whether it
is bound to PMI in the cytosol.
4.2 Efficiency of PMI-LINuS andp53-LINuS fusions is low
Cellular localisation of any protein is an equilibrium of its localisation sequences, namely its NES and NLS se-
quences. Protein localisation is not a finite state, as import and export are dynamic processes. The net localisa-
tion of a protein is determined by the relative strength of its NLS and NES. Thus, achieving control over nucleo-
cytoplasmic transport requires balancing of NLS andNES sequences.
I initially tried to achieve optogenetic control of PMI localisation by using LINuS. Yet, PMI fused to selected
LINuS variants did not behave as expected inHCT116 cells (Figure 3.7). LINuShas been shown towork in a variety
of cell lines (Niopek et al., 2014), however it had not been used so far in HCT116 cells. As the size of the cells
seems to contribute to translocation efficiencies, the fact thatHCT116 cells are small compared tomost common
cell linesmay be the reason of this inefficiency.
In previous work for collaboration partners, I could observe similar effects. N- or C-terminal peptide fusion
to LINuS or LEXY could alter the initial localisation drastically, even though the peptides were not localisation
sequences. While it is obvious, that taggedproteins that contain localisation sequences canalter the initial state,
it remains elusivewhypeptides canhave suchahigh impact on the localisationof peptide LINuSor LEXY fusions.
As LINuShasbeen shown towork in several cell lines, it is unlikely that LINuS cannot beused inHCT116 cells as
the import-export machinery LINuS employs is highly conserved in eukaryotes (Cautain et al., 2015). Yet, mam-
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malian cell lines deviate in total and relative abundance of transport receptors and nuclear pores, thus some cell
lines might require optimisation of LINuS constructs for them to be able to robustly translocate upon exposure
to light citepmaul1977quantitative, van2014elevated. Moreover, AsLOV2-based optogenetic tools, such as LEXY
and LINuS, require the co-factor FMN. The number of freely available FMNmolecules could thus affect translo-
cation of LINuS constructs. It has been shown that FMN concentrations can vary significantly between different
cell types; unfortunately, numbers for HCT116 cells are lacking (Hühner et al., 2015).
Putatively, import and export receptor isoforms possess different binding and dissociation affinities towards
specific localisation sequences. This could explainwhyNLS andNES sequences have different relative strengths
in different cell lines, as seen in the evaluation of various constitutive synthetic NESs in p53K306A-biLINuS02 con-
structs (Figure 3.17) compared to their strength inHek293T cells.
In contrast toPMI-LINuS,PMI-LEXYconstructswereable to reversibly translocate, and induce light-dependent
changes in p53, and consequently, p21 levels (Figure 3.8). Similarly, p53-LEXY could reversibly translocate in and
out of the nucleus, while various LINuS candidates were not able to do so (Figure 3.10 and Figure 3.18).
Duringthecourseofoptimisationofp53-LINuSconstructs, ImutatedbothendogenousNLSandNESsequences,
yet ultimately failed to generate a p53-LINuS variantwhich could be reversibly accumulated in the nucleuswhile
remaining transcriptionally active. Manipulation of endogenous localisation sequences has been successfully
demonstrated to optimize translocation of Cyclin B1 (Niopek et al., 2014), yet did not yield the favoured results
here.
Impaired translocation is obviously not dependent onp53, since p53-LEXYexhibited thedesired translocation
kinetics without any optimisation. It remains unclear why p53-LINuS accumulation was never fully reversible.
Initial assumptions, that it could not exit the nucleus due to the formation of tetramers, can be excluded, given
that p53-LEXY could reversibly translocate in and out of the nucleus and, being transcriptionally active, is likely
able to tetramerize. A potential reasonmight be that, while export of NES-harbouring proteins is dependent on
only one receptor (Crm1), importmay depend on several receptors (importin alpha and beta), depending on the
type of NLS (Marfori et al., 2011). For the nuclear localisation sequences photocaged in certain LINuS variants it
is not knownwhether importin alpha is required for their import,making it hard to compare p53-LINuS andp53-
LEXY constructs. Apparently, LINuS requiresmore optimisation and fine-tuning of NLS/NES balancing. In both,
LINuS and LEXY, nuclear export requiresmore time than the import (This work, (Niopek et al., 2014, 2016).
4.3 p53mutant constructs lack transcriptional activity
p53K320AL348AL350A-biLINuS22wastheonlyp53-LINuSvariant thatexhibitedgoodnuclearaccumulationuponblue
light stimulation, while still being partly re-accumulating into the cytoplasm once blue light was switched off
(Figure 3.12). Unfortunately, the introduced mutations rendered it transcriptionally inactive (Figure 3.13). I was
so focused on finding a way to control the localization of p53 that I did not realize right away that touching the
NES would have an influence on tetramerisation. L348 and L350 are located in the tetramerisation domain and
are implicated in the formation of tetramers. Tetramerisation are essential for p53 to become fully transcrip-
tionally active (Stommel et al., 1999). p53L348AL350A double mutant can indeed form tetramers only at very high
concentrations (Itahanaet al., 2007). Inmyexperiments, tetramerisation seemed tohavea stronger impact than
acetylation as introduction of acetylation-mimickingmutations did not stimulate p53 target expression (Figure
3.14).
Also the impact on transcriptional activity of K320 has been investigated. The histone acetyl transferase PCAF
specifically acetylates p53 on lysine 320 (K320) upon DNA damage (Liu et al., 1999). This acetylation increases
p53-DNA binding in vitro, yet in vivo changes in transcription were minor (Love et al., 2012). It is suggested that
K320 is one of the residues crucial to be acetylated, and required for p53 to bind to other co-factors, which are
essential for p21 transcription (Barlev et al., 2001). Yet, Barlev and colleagues only present data for a p53mutant
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having four lysines (K320/373/381/382R)mutated.
Since theonlyp53mutantwhose localisation I could controlwithLINuS lacked transcriptional activity, Imoved
on and tested another optogenetic tool, LEXY.
4.4 Comparing the transcriptional response to pulsatile and sustainedp53
4.4.1 p53 abundance determines translocation efficiency
I could show that LEXY can be used to control p53 translocation and thus its transcriptional activity with light
(Figure 3.18). Moreover, diverse p53 dynamics akin to physiological ones could be applied (Figure 3.23).
Initial comparison between constant and pulsatile p53 resembling stress-induced p53 dynamics did not re-
veal differential expression of selected target genes (Figure 3.21). Yet, these results were tainted by the inhomo-
geneous expression levels of p53-LEXY in the cells. We have observed in multiple LINuS and LEXY applications
that the translocation efficiency correlates with the protein abundance. Presumably, too high concentrations of
the p53-LEXY construct result in the saturation of the exportmachinery, leading to less efficient export after illu-
mination. Unfortunately, reducing the amount of transfected DNA resulted in a reduced number of transfected
cells, and therefore inmoreheterogeneity, rather than in adecrease of transfectedprotein levels. For this reason,
I decided to generate a stable cell line, to ensure homogeneous expression and stable p53-LEXY levels during the
course of an experiment.
4.4.2 The effect of doxycycline onp53 transcript levels
After the elaborate process of generating a stable cell line with an inducible expression system regulating p53-
LEXY, protein abundance was reduced and could be tightly controlled. Using this stable cell line, I repeated the
experiment to compare constant to pulsatile p53 activation (Figure 3.24). Even though expression levels were
reduced, pulsatile activation resulted only in the differential expression of the senescencemarker PML. Yet, the
highest elevation in transcript levels was observed for p53 itself.
p53-LEXY is regulated by the T-REx™system, which enables expression of a target gene by doxycycline. The
parental cell line H1299 is p53-/- and expresses only partial p53 mRNA due to a homozygous partial deletion of
the TP53 gene. Therefore, the introduced p53-LEXY is the sole source of expressed, full-length p53 transcripts
in the cell. The integrated p53-LEXY is driven by a CMVmin promoter containing two tetO2 sequences, which are
bound tightly by the continuously expressed TetR, thus preventing transcription of p53-LEXY. Upon doxycycline
induction, TetR is removed from the promoter, and therefore transcription is activated. Consequently, p53 levels
should not be under any regulation other than doxycycline. Light should not affect p53 levels; it is expected to
have only an effect on its target genes, due to the regulation of p53 localization and not abundance.
Heterogeneity in p53-LEXY expressionwas observed inH1299 cells transiently transfectedwith p53-LEXY. Yet
in this experiment, the stable lineC29-36wasused, anddoxycycline induction triggered similar expression levels
across cells and resulted in a rather homogeneous expression of p53-LEXY protein.
It is suggested thatdoxycyclinepossesses a lowphotostabilitywhenexposed toUVLight (Kogawaet al., 2014);
nevertheless, existing inducible induction systems based on chemically-caged doxycycline useUV light as a trig-
ger for expression and do not report any side-effects (Cambridge et al., 2009). Anyway, if prolonged light illumi-
nationwas indeed inducing doxycycline degradation, then this should lead to decreased p53-LEXYmRNA levels
in the samples exposed to light; however, I observed the opposite trend, with higher p53-LEXY mRNA levels in
cells exposed to light of higher intensity.
Interestingly, the observed effect on p53-LEXYmRNA levels could not be observed when cells were activated
with blue light of longer wavelength (488nm) (Figure 3.25). As translocation efficiency is not affected by the
change of light wavelength, the observed increase in p53-LEXYmRNA levels under pulsatile illumination must
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have been triggered by the illumination regime. The overall reduction in the energy the cells are subjected to
when being exposed to light of longer wavelength is, however, onlyminimal. If anymanipulation of doxycycline
occurs at 458 nm, it supposedly also happens at 488 nm, potentially on a smaller scale. Light-induced chemical
degradation of doxycycline can be excluded, as expression levels, and thus doxycycline levels, were higher in the
presence of light.
A general increase in mRNA levels could not be observed, as levels of reference and p53 target genes beside
PML remained unaffected. One possible explanation for the increase of p53-LEXYmRNA levels is an increase in
mRNA stability due to prolonged light exposure. Severalmechanisms for the regulation of p53mRNAhave been
reported (Yin et al., 2002; Vilborg et al., 2009), and it has been demonstrated that transcript variants exhibit
different stability (Zydowicz-Machtel et al., 2018). Yet, all reported regulation steps are mediated on either the
5’ or the 3’ UTR regions of p53 mRNA, which are lacking in my construct. Alternatively, the observed increase in
mRNA levels could also be independent of p53, but rather due to mCherry or LEXY. To investigate this further,
one could transfected either only untaggedp53,mCherry or LEXY, andmeasure the respectivemRNA levels after
blue light exposure.
4.4.3 Prolonged illumination of the cells impairs their import/export capacity and leads to
phototoxicity
In multiple experiments I have observed that, after a prolonged illumination period, cells were unable to re-
import LEXY-tagged proteins into the nucleus once put back in the dark. This was true regardless of the specific
protein fused to LEXY, suggesting that the problem is the toxicity of the light to the cells.
Particularly inmyinitialexperimentswithp53-LEXY, I couldobserve thatprolongedblue lightexposurecaused
sequestrationof the construct in the cytosol (Figure3.28, Figure3.29andFigure3.30). Thishasnotbeenobserved
before.
Also in shorter experiments, an increase inp53-LEXYmolecules that remain cytosolic during thedark recovery
phase is visible after somehoursofblue light exposure (Figure 3.19). Given that I couldobserveefficient repeated
nuclear/cytosolic translocation events of p53-LEXY for more than 30 hours when the illumination regime was
made of shorter light phases (15min), I would conclude that prolonged illumination causes phototoxicity to the
cells, rendering themprogressivelyunable toefficiently import/exportproteins.While theselected light settings
did not affect phenotype or proliferation of cells, recent studies suggest that prolonged blue light illumination
can indeed alter expression profiles and differentiation potential in primary cells (Cheng et al., 2016; Stockley
etal.,2017). Moreover,blue lightexposurecausesoxidativestress,whichhasbeenlinkedtonuclearaccumulation
of import receptors, and thus import blockage (Kodiha et al., 2004; Godley et al., 2005).
In support of this conclusion, I could exclude that the cytoplasmic retentionwas p53-specific. Even thoughp53
is known to interact with Bcl-family proteins in the cytosol and on the mitochondrial membrane (Li et al., 1999;
Chipuk et al., 2004), as well to bind to the cytosolic anchor Parc (Nikolaev et al., 2003), mCherry-LEXY exhibited
the same impaired translocation as p53-LEXY (Figure 3.29). Additionally, it can be excluded that stable integra-
tion of TetR or p53-LEXY has occurred at genetic locations that corrupt the import/export machinery, since also
the transiently transfected LEXY construct exhibited the same behaviour.
As this effect has only been observed in H1299 cells, it might be cell type specific. As mentioned before, cell
linesdiffer in theirexpression levelsofparticular componentsof the import/exportmachinery (MaulandDeaven,
1977; Van derWatt et al., 2009, 2014). Yet, whether potential differences contribute to the observed phenotype
is unknown.
Ingeneral, nuclear importseemstobearate-limitingstep inH1299cells. Cellswithcytoplasmically-sequestered
LEXYmolecules exhibit bright speckles close to the nucleus. Presumably, these are p53-LEXY aggregates, which
cannot be re-imported in the nucleus. As the speckles are located close to each other and do not move, they
are apparently not freely diffusing in the cell, which suggests they are either within or associated to a cellular
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compartment. Since their number and intensity increase over time, correlating to higher inefficiency of nuclear
import, it is likely that these speckles are associated to the failed import of p53-LEXY.
To verify whether this phenotype is indeed caused by phototoxicity or by toomany translocation events, one
could reduce p53-LEXY expression levels. Alternatively, it is possible to reduce the dark recovery kinetics of the
AsLOV2 domain. The AsLOV2 domain has been extensively studied, and several mutations are known, which
affect dark recovery kinetics (Alexandre et al., 2007; Zoltowski et al., 2009; Raffelberg et al., 2011). Increasing the
dark recovery time would reduce the stress on the import-export machinery, since the AsLOV2 would remain in
its excited state for longer times and therefore theNESwould be exposed for longer, all in all leading to a longer
cytoplasmic localisationwithout the need for shining light every 30-40 seconds.
4.4.4 Changing the light application settings to reduce phototoxicity reduced
light-dependent transcription of p53 target genes
Once the doxycycline administration regimewas optimised to permit stable p53-LEXY protein levels during the
experimental window, I re-applied p53 pulsatile and sustained dynamics to analyse their effects on p53 target
genes (Figure3.31). Optimisationof the illuminationconditionsandshorteningof thedurationof theexperiment
resulted in reliable translocation in samples exposed to constant (always intended as short repeated light pulses
with 30 sec interval) blue light, (Supplemental Figure 7.1). On the other hand, pulsatile translocation resulted
in a reduction of translocation efficiencywith every new illumination phase. Presumably, the reduction is due to
an overload in the nuclear-cytosolic translocation system.
Exposure to either no light, pulsatile light or "constant" light resultedonly inmarginal changes in geneexpres-
sion (Figure 3.31). In general, the transcriptional response to nuclear presence of p53 was minor, as the greatest
observed change in expressionwas 1.5 fold. Purvis and colleagues report higher fold-changes for p53 targets un-
derdifferentp53dynamics. For example, after 8hours, p21mRNA levels increased for them16-foldwhenp53was
sustained compared towhen it was pulsatile (Purvis et al., 2012).
Inprevious experiments, I couldobserve a light-dependent inductionof >2-foldof thep53 target genesMdm2
and p21 (Figure 3.28); yet after changing the illumination set up, the differential expression was marginal. This
is presumably caused by the reduced light intensity used in this experiment, to reduce phototoxicity and allow
translocation to occur (Figure 3.30). While the reduction of light intensity indeed resulted in an efficient translo-
cation (Supplemental Figure 7.1), a two times larger fractionof p53-LEXYmolecules remained in thenucleusdur-
ing the illumination phase (Figure 3.30). Potentially this increase in nuclear p53-LEXY in cells subjected to light
is sufficient to drive p21 expression to the same extent than cells which remain in the dark . This, however, would
suggest that a two-fold increase in nuclear levels of p53 observed in samples shielded from the dark after the
initial illumination period do not increase expression further, which seems unlikely. Alternatively, it can be that
even the reduced light settings cause phototoxic effects and influence the transcriptional activity of the cells,
which renders these results unreliable.
Taken together, p53-LEXY could be reliably and reversibly translocated between the cytosol andnucleus. Cells
exposed to activation/recovery intervals of 15 minutes or 2 hours could translocate p53-LEXY for more than 15
hours, yet longer constant illuminationperiods causedandecrease in translocation efficiency. If possible Iwould
advise to use LINuS instead of LEXY when investigating transcription factors, as LINuS is located in the cytosol
when cells are shielded from the light, thus rendering the initial illumination period unnecessary. exposure
would become no longer necessary.
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4.5 Un-reproducibility y of p53’s transcriptional activity in response to drug
treatment
As exposing cells to blue light for several hours to keep p53-LEXY inactive until the beginning of the experiment
led to phototoxicity and impaired LEXY functioning, I decided to change entirelymy experimental set up. I reck-
oned that I should leave the cells in the dark in the initial phase, after induction with doxycycline. Clearly this
would lead to nuclear p53-LEXY, and therefore to activation of gene expression, before the start of the experi-
ment. However, my idea was to rather test the response of the cells to a drug treatment depending on p53 dy-
namics. Cells would have a certain amount of p53-LEXY to begin with at the time at which the stress-inducing
agent is applied, but this would be similar across conditions. Then I would apply different light regimes and see
if cells responded differently if p53-LEXY was left always nuclear to when it was brought in and out of the nu-
cleus in pulses. Unfortunately, while performing the first control experiments to check if there was a difference
between always nuclear and always cytoplasmic p53-LEXY after addition of the drug, I discovered that the stable
cell line I generated is unreliable (Figure 3.32, Figure 3.33, Figure 3.32 and Figure 3.33). The datawere highly vari-
able between biological replicates and this was true for all samples, independent of a single factor. p53 response
to stress is known to be highly variable (personal communication with Jared Toettcher); however, here the re-
sponse seemedbinary: in replicate 1, the fold-change in transcription of btg2 andpumawas similar to previously
published results (Porter et al., 2016), while replicate 2 exhibited hardly an increase in transcription.
First, I want to exclude several technical causes of lack of reproducibility:
Preparation of cDNA, and subsequent reverse transcription were run in parallel for both replicates. Yielded
RNA concentrations were similar, and the A260/A280 ratio, a value for RNA purity, was > 2.0 in both cases (indi-
cating that the RNA was pure). The samemaster mix was used for cDNA preparation and qPCR. Samples were
distributedover several qPCRplates, toavoidaplatebias. Melting curvesofprimerswerevalidated. Additionally,
theabsoluteCt valuesof the referencegenesbeta-actinandRpl0wereconstant. Iwouldalsoexcludeexperimen-
tal work-flow-related factors. The same aliquot of the respective drugs was used. Additionally, the cells used for
both experiments were at the same passage number and stemmed from the same batch. Cells were seeded at
thesamedensity, andp53-LEXYfluorescencewasverifiedontheLionheart, showingsimilar levels. Effects caused
by different cell cycle stages should beminor, since thewhole population of cellswas collected. Taken together, I
wouldexclude technical reasons for lackof reproducibility, suggesting that this isdue to somebiologicalproperty
of either the p53-LEXY construct or the cell line.
To understand if the problemwas the cell line, I decided to analyse in the sameway two different cell lines. In
contrast to the results observed in C29-36 cells, MCF7-p53-Venus andHCT116 cells responded consistently to the
applied stress (Figure 3.36). I also tested whether the problem could be high levels of cytosolic p53 (a rather un-
physiological condition), by transiently transfecting a NES-p53-mCheryr construct. The results, however, clearly
indicate that neither drug administration, nor light exposure nor cytosolic p53 are the reason behind the lack of
reproducibility. I am leftwith the conclusion that the cell line C29-36 is the problem. Theparental cell lineH1299
previously exhibited reliable results with transiently transfected p53-LEXY (Figure 3.18), thus integration of TetR
and p53-LEXY is the likely cause.
Stable cell lines tend to silence transgenes bymethylation, particularly expression driven from the CMV pro-
moter has been shown to be down-regulated over time (Brooks et al., 2004). While this could explain why the
second successfully generated stable cell line C29-48 lost expression over time, it is not the reason for lack of
reproducibility in C29-36 cells, where p53-LEXY levels are stable.
This suggests that the random integration of TetR, p53-LEXY or both occurred presumably in a genomic lo-
cation that contributes to the variance in response. However, it is hard to come up with potential mechanisms,
as biological noise is observed in single cells, yet is unlikely to exert differences in a population-based read-out.
Since reference genes are stably expressed, and cells exhibit no observable morphological changes, effects on
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general transcription are unlikely. Likely integration occurred on genomic loci associated to the p53 regulatory
network.
4.6 Outlook
Here, I presented two approaches to take control over p53 dynamics. First, I tried to achieve optogenetic con-
trol over the inhibition of p53 degradation, aiming at fine-tuning levels of endogenous p53 levels. In a second
approach, I tried to control nucleocytoplasmic translocation of p53, assuming that only nuclear p53 would be
transcriptionally active.
In the current state, both approaches couldnot beused for the intendedpurpose, that is, applyingdefinedp53
dynamics and linking them to the respective downstream transcriptional response.
While PMI-LEXY was successfully used to inhibit degradation of p53, the lack of reversibility renders applica-
tionofp53dynamics impossible. The cause for the irreversibility couldnotbe identified, yet further investigation
could improve re-translocation into the cytosol, particular examining shorter periods of the individual activation
or recovery intervals, whichwould also reflect better the physiological response to stress.
Alternatively, re-examining LINuS variants inHCT116 cells, or selecting a cell linewhere LINuShasbeenestab-
lished,might improve translocationof PMI-LINuS. Translocationefficiencyof potential PMI-LINuS variants could
be further improved by using LOVTRAP, an optogenetic system used to trigger light-induced dissociation of the
AsLOV2domainandZdk, aprotein that selectively binds theAsLOV2domain in thedark state (Wanget al., 2016).
Thiswould allow, for instance, tethering theAsLOV2domain of PMI-LINuS to the cellularmembraneduringnon-
illuminated periods, while not impairing translocation during blue light exposure, thereby reducing occurring
translocation during non-illuminated phases.
Working with LEXY to control p53 localisation, it became apparent that prolonged blue light exposure harms
cells. In several steps, the light energy applied to cellswas lowered, but the reductionwasnot sufficient to ensure
p53 translocationover thewholeexperimental runtime. Thus, it is vital to further reduceblue lightexposure. This
could be achievedby reducing theAsLOV2’s reversionhalf-life,meaning the time it takes for theAsLOV2 to spon-
taneous rearrange to the dark state. The illumination timings used during illumination are dependent on the
photocycle of the AsLOV2 domain, thus increasing the time of one photocycle would allow for further reduction
of illumination, while still allowing the application of p53 dynamics observed in physiological stress situations.
The experiments using LEXY have demonstrated that p53 can be repeatedly translocated. Thus, it might be
reasonable to screen various combinations of constitutive NESs and LINuS variants, to achieve light-mediated
nuclear import of previously cytosolic p53-LINuS. Using LINuS, the initial blue light exposure would become no
longer necessary.
Additionally, the stable cell line C29-36 has turned out to be compromised, given the lack of reproducibility I
obtainedwhen analysing its response to any kind of treatment. Yet, turning back to transfection is not advisable,
due to the heterogeneous expression of the transfected target gene. Rather, commercial systems with specific
genome integration sites or lentiviral transduction should be used, to guarantee homogeneous and reliable ex-
pression.
Next to the optimisation of the control of p53 dynamics, further development should be done to find the best
downstream read-out. Single cell studies have revealed that observations on the population-based level can be
misleading, particularly when investigating noisy processes as cell signalling. Thus, a read-out at single cell res-
olution should be used in further experiments. Staining procedures like single molecule FISH would allow for
application of p53 dynamics followed by direct quantification of gene expression in the same cells, thus a di-
rect link between the frequency and amplitude of nuclear p53 and the number of targetmRNAs at specific time
points would be possible. Moreover, more sophisticated fluorescent labelling approaches have been developed
that allow quantification of transcription and translation of target genes, using modern gene editing tools like
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CRISPR/Cas9 to introduce the fluorescent tags in the endogenous loci of the respective target genes.
Overall, I believe that optogenetic approaches can contribute to investigating p53 regulatory network and cell
signalling pathways in general, as the unmatched spatial and temporal resolution of light enables investigation
and perturbation of individual nodes in these highly dynamic cellular systems.
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7 Appendix
7.1 List of Constructs used in this study
Number Name Backbone Promoter Source
PW001 reg4-MIP pcDNA 3.1 (+) CMV Christian Scheeder
PW002 reg5-MIP pcDNA 3.1 (+) CMV Christian Scheeder
PW003 reg5-3A pcDNA 3.1 (+) CMV Christian Scheeder
PW004 NLS-trx-MIP pcDNA 3.1 (+) CMV This work
PW005 NLS-trx-3A pcDNA 3.1 (+) CMV This work
PW006 Reg5-enBI1 pcDNA 3.1 (+) CMV This work
PW007 Reg5-enBI2 pcDNA 3.1 (+) CMV This work
PW008 Reg5-enBI3 pcDNA 3.1 (+) CMV This work
PW009 Reg5-enBI4 pcDNA 3.1 (+) CMV This work
PW010 AsLOV2-538-TAD pcDNA 3.1 (+) CMV This work
PW011 AsLOV2-539-TAD pcDNA 3.1 (+) CMV This work
PW012 AsLOV2-540-TAD pcDNA 3.1 (+) CMV This work
PW013 AsLOV2-541-TAD pcDNA 3.1 (+) CMV This work
PW014 AsLOV2-542-TAD pcDNA 3.1 (+) CMV This work
PW015 AsLOV2-543-TAD pcDNA 3.1 (+) CMV This work
PW016 AsLOV2-544-TAD pcDNA 3.1 (+) CMV This work
PW017 AsLOV2-545-TAD pcDNA 3.1 (+) CMV This work
PW018 AsLOV2-546-TAD pcDNA 3.1 (+) CMV This work
PW019 AsLOV2-547-TAD pcDNA 3.1 (+) CMV This work
PW020 AsLOV2-539-PMI pcDNA 3.1 (+) CMV This work
PW021 AsLOV2-540-PMI pcDNA 3.1 (+) CMV This work
PW022 AsLOV2-541-PMI pcDNA 3.1 (+) CMV This work
PW023 AsLOV2-542-PMI pcDNA 3.1 (+) CMV This work
PW024 AsLOV2-543-PMI pcDNA 3.1 (+) CMV This work
PW025 PMI-biLINuS02 pcDNA 3.1 (+) CMV This work
PW026 PMI-biLINuS09 pcDNA 3.1 (+) CMV This work
PW027 PMI-biLINuS11 pcDNA 3.1 (+) CMV This work
PW028 p53-NES-mCherry pcDNA 3.1 (+) CMV This work
PW029 p53-NLS-mCherry pcDNA 3.1 (+) CMV This work
PW030 p53-mCherry pcDNA 3.1 (+) CMV This work
PW031 NLS-trx-PMI pcDNA 3.1 (+) CMV This work
PW032 NES-trx-PMI pcDNA 3.1 (+) CMV This work
PW033 PMI-1xGGS-mCherry pcDNA 3.1 (+) CMV This work
PW034 PMI-2xGGS-mCherry pcDNA 3.1 (+) CMV This work
PW035 PMI-1xGGS-Lexy pcDNA 3.1 (+) CMV This work
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PW036 PMI-1xGGS-Lexy pcDNA 3.1 (+) CMV This work
PW037 p53wt-PKit-biLINuS02 pcDNA 3.1 (+) CMV This work
PW038 p53wt-PKit-biLINuS22 pcDNA 3.1 (+) CMV This work
PW039 p53wt-biLINuS02 pcDNA 3.1 (+) CMV This work
PW040 p53wt-biLINuS22 pcDNA 3.1 (+) CMV This work
PW041 p53wt-Ikbα-biLINuS02 pcDNA 3.1 (+) CMV This work
PW042 p53wt-Ikbα-biLINuS22 pcDNA 3.1 (+) CMV This work
PW043 p53L348L350A-PKit-biLINuS02 pcDNA 3.1 (+) CMV This work
PW044 p53L348L350A-PKit-biLINuS22 pcDNA 3.1 (+) CMV This work
PW045 p53K305AL348L350A-PKit-biLINuS22 pcDNA 3.1 (+) CMV This work
PW046 p53K306AL348L350A-PKit-biLINuS22 pcDNA 3.1 (+) CMV This work
PW047 p53K305AK306AL348L350A-PKit-biLINuS22 pcDNA 3.1 (+) CMV This work
PW048 p53K319AL348L350A-PKit-biLINuS22 pcDNA 3.1 (+) CMV This work
PW049 p53K320AL348L350A-PKit-biLINuS22 pcDNA 3.1 (+) CMV This work
PW050 p53K321AL348L350A-PKit-biLINuS22 pcDNA 3.1 (+) CMV This work
PW051 NLS-p53K320A-mCherry pcDNA 3.1 (+) CMV This work
PW052 NLS-p53L348A-mCherry pcDNA 3.1 (+) CMV This work
PW053 NLS-p53L350A-mCherry pcDNA 3.1 (+) CMV This work
PW054 NLS-p53K120RL348L350A-mCherry pcDNA 3.1 (+) CMV This work
PW055 NLS-p53K120QL348L350A-mCherry pcDNA 3.1 (+) CMV This work
PW056 NLS-p53K164RL348L350A-mCherry pcDNA 3.1 (+) CMV This work
PW057 NLS-p53K164QL348L350A-mCherry pcDNA 3.1 (+) CMV This work
PW058 NLS-p53K165RL348L350A-mCherry pcDNA 3.1 (+) CMV This work
PW059 NLS-p53K165QL348L350A-mCherry pcDNA 3.1 (+) CMV This work
PW060 NLS-p53K164RK165RL348L350A-mCherry pcDNA 3.1 (+) CMV This work
PW061 NLS-p53K164QK165QL348L350A-mCherry pcDNA 3.1 (+) CMV This work
PW062 NLS-p53K305A-mCherry pcDNA 3.1 (+) CMV This work
PW063 NLS-p53K306A-mCherry pcDNA 3.1 (+) CMV This work
PW064 NLS-p53K305AK306A-mCherry pcDNA 3.1 (+) CMV This work
PW065 NLS-p53K319A-mCherry pcDNA 3.1 (+) CMV This work
PW066 NLS-p53K321A-mCherry pcDNA 3.1 (+) CMV This work
PW067 p53K305A-mCherry pcDNA 3.1 (+) CMV This work
PW068 p53K306A-mCherry pcDNA 3.1 (+) CMV This work
PW069 p53K305AK306A-mCherry pcDNA 3.1 (+) CMV This work
PW070 p53K319A-mCherry pcDNA 3.1 (+) CMV This work
PW071 p53K321A-mCherry pcDNA 3.1 (+) CMV This work
PW072 p53K305A-biLINuS02 pcDNA 3.1 (+) CMV This work
PW073 p53K305A-biLINuS09 pcDNA 3.1 (+) CMV This work
PW074 p53K305A-biLINuS22 pcDNA 3.1 (+) CMV This work
PW075 p53K306A-biLINuS02 pcDNA 3.1 (+) CMV This work
PW076 p53K306A-biLINuS09 pcDNA 3.1 (+) CMV This work
PW077 p53K306A-biLINuS22 pcDNA 3.1 (+) CMV This work
PW078 p53K305AK306A-biLINuS02 pcDNA 3.1 (+) CMV This work
PW079 p53K305AK306A-biLINuS09 pcDNA 3.1 (+) CMV This work
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PW080 p53K305AK306A-biLINuS22 pcDNA 3.1 (+) CMV This work
PW081 p53K306A-PKit-biLINuS02 pcDNA 3.1 (+) CMV This work
PW082 p53K306A-synthNES11-biLINuS02 pcDNA 3.1 (+) CMV This work
PW083 p53K306A-synthNES12-biLINuS02 pcDNA 3.1 (+) CMV This work
PW084 p53K306A-synthNES21-biLINuS02 pcDNA 3.1 (+) CMV This work
PW085 p53wt-cMyc-LEXY pcDNA 3.1 (+) CMV This work
PW086 p53wt-cMycP1A-LEXY pcDNA 3.1 (+) CMV This work
PW087 TetR-Krab pcDNA 3.1 (+) CMV kind gift from Benjamin
Kachel
PW088 CMVmin-p53-LEXY pcDNA4.0 TO
(+)
CMV This work
PW089 mCherry-cMyc-LEXY pcDNA 3.1 (+) CMV Dominik Niopek
114
CHAPTER 7. APPENDIX
7.2 List of qPCRPrimer
Name Sequence
qPCR-bax fw agcaaactggtgctcaagg
qPCR-bax rv ggaggaagtccaatgtccag
qPCR-beta-actin fw caccatgtaccctggcatt
qPCR-beta- actin rv aatgatcttgatcttcattgtgc
qPCR-btg2 fw aggcactcacagagcactac
qPCR-btg2 rv tggggtccatcttgtggttg
qPCR-eGadd45 fw tgctggtgacgaatccacatt
qPCR-eGadd45 rv tgatccatgtagcgactttccc
qPCR-fas fw cccggacccagaataccaag
qPCR-fas rv tgttcacatttggtgcaaggg
qPCR-p53 fw cctgaggttggctctgactg
qPCR-p53 rv gcccatgcaggaactgtta
qPCR-MDM2 fw tcctgaaatttccttagctgact
qPCR-MDM2 rv ccaacatctgttgcaatgtg
qPCR-p21 fw cagaccagcatgacagatttc
qPCR-p21 rv ggattagggcttcctcttgg
qPCR-puma fw ggagacaagaggagcagcag
qPCR-puma rv ctgggtaagggcaggagtc
qPCR-PML fw ccgcaagaccaacaacatct
qPCR-PML rv gtagatgctggtcagcgtagg
qPCR-wip1 fw gaagaaactggcggaatggc
qPCR-wip1 rv ccaagaaccacccctgagtc
qPCR-Rpl0 fw agggtcctggctttgtctgtgg
qPCR-Rpl0 rv agctgcaggagcagcagtgg
qPCR-XPC fw gccatcacttggctttgattt
qPCR-XPC rv cagtcacgggatgggagtag
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7.3 Supplemental Figures
7.3.1 Monitoring of translocation kinetics
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Figure 7.1: Translocation kineticsmonitored of cells receiving no, constant or pulsatile light
Quantification of relative nuclear intensity of samples of experiment described in Figure 3.31. Nuclear inten-
sity over time was normalized to initial nuclear intensity of the respective sample. Dots represent images taken
(mean± SD, n=20-30).
116
CHAPTER 7. APPENDIX
7.3.2 p53 target gene expression uponneocarzinostatin treatment
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Figure 7.2: p53 target gene expression uponneocarzinostatin treatment
NormalizedmRNA expression of indicated p53 target genes. Cells were induced with 100 ng/ml doxycycline for
8 hours, followed by 16 hour incubation in the dark. Then, cells were treated with 500 ng/ml NCS and blue light
for 2 or 6hours. Controlswerenot treatedwithNCSandblue light. Next, cellswere lysed andRNAwas extracted.
Expression levelswere first normalized to beta actin andRpl0, then to the expression values of the non-induced,
light exposed and neocarzinostatin treated sample at time point 2 h (mean± SD, technical replicates n=3)
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7.3.3 p53 target gene expression upongefitinib treatment
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Figure 7.3: p53 target gene expression upongefitinib treatment
NormalizedmRNAexpressionof indicatedp53 target genes. Cellswere inducedwith 100ng/mldoxycycline for 8
hours, followedby 16hour incubation in thedark. Then, cellswere treatedwith 1µMgefitinib andblue light for 2
or 6 hours. Controls were not treatedwith gefitinib and blue light.Next, cells were lysed and RNAwas extracted.
Expression levelswere first normalized to beta actin andRpl0, then to the expression values of the non-induced,
light exposed and gefitinib treated sample at time point 2 h (mean± SD, technical replicates n=3)
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7.3.4 Gefitinib treatment resulted in reproducible pumaexpression inHCT116 and
MCF7-p53-Venus cells
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Figure 7.4: Gefitinib treatment inducedpumaexpression
A | Schematic protocol of the experimental work flow. Cells were treatedwith 1µMgefitinib for 2h or 6h.
B | NormalizedmRNAexpression levels of puma inHCT116 cells treated according to protocol shown inA. Then,
cells were lysed and RNAwas extracted. Expression levels were first normalized to beta actin and Rpl0, then to
the expression values of the non-treated sample at time point 2 h. (left) replicate 1 (mean± SD, n=3), (right)
replicate 2 (mean± SD, n=3).
C | Normalized mRNA expression of puma in MCF7-p53-Venus cells treated according to protocol shown in A.
Then, cells were lysed and RNA was extracted. Expression levels were first normalized to beta actin and Rpl0,
then to the expression values of the non-treated sample at time point 2 h. (left) replicate 1 (mean± SD, n=3),
(right) replicate 2 (mean± SD, n=3).
119
CHAPTER 7. APPENDIX
7.4 Abbreviations
ATM ataxia-telangiectasiamutated protein
ATR Ataxia telangiectasia and Rad3 related
Bak Bcl-2 homologous antagonist killer
Bax Bcl-2-associated X protein
Bcl2 B-cell lymphoma 2
Bcl-xL 2 B-cell lymphoma-extra large
BLUB blue-light sensors utilizing flavin adenine dinucleotide
CLaP cell labelling via photobleaching
CRM1 Chromosome regionmaintenance 1 or exportin 1
CMV cytomegalovirus
DBD DNA-binding domain
DSB double strand brake
EGF epidermal growth factor
Erk extracellular signal-regulated kinase
HAT histone acetyltransferases
IEG immediate-early gene
iLID improved light-induced dimer
LINuS Light-inducible nuclear localization signals
LOV Light oxygen voltage
MAPK mitogen-activated protein kinase
Mcl1 inducedmyeloid leukemia cell differentiation protein
MDM2 murine doubleminute 2
MIP MDM2 inhibitory peptide
NCS neocarzinostatin
NES nuclear export sequence
Nfat nuclear factor of activated T cells
NGF nerve growth factor
NLS nuclear localization sequence
p14ARF alternate reading frame protein product of the CDKN2A locus
p300/CBP protein 300/CREB binding protein
pDI peptide dual inhibitor
PAS Period-ARNT-Singleminded
PCB Phycocyanobilin
PCR polymerase chain reaction
PhyB/PIF Pythochon B/Pythochrome interacting factor
PRD Proline rich domain
PTM posttranslationalmodification
PYP Photoactive yellow proteins
qPCR quantitative polymerase chain reaction
Rap1 Ras-proximate-1
SD Standarad deviation
SNP single nucleotide polymorphism
SOS Son of Sevenless
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SSB single stand break
TAD transactivationDomain
tet0 tet operator sequences
TetR tet repressor proteins
TNF-α tumour necrosis factor-α
TP53 tumor protein p53
TrpR trp repressor
TULIPs light-controlled interacting protein tags
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